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abstract	  
Kindlin-­‐1	  (Kin1)	  is	  an	  epithelial	  focal	  adhesion	  protein	  that	  plays	  a	  key	  role	  in	  
integrin-­‐mediated	   anchorage	   of	   cells	   to	   the	   extracellular	   matrix.	   Congenital	  
loss	   of	   Kin1	   leads	   to	   Kindler	   Syndrome	   (KS),	   whose	   symptoms	   include	  
progressive	   epidermal	   atrophy,	   reduced	   keratinocyte	   proliferation,	   skin	  
blistering	   and	   increased	   incidence	   of	   aggressive	   Squamous	   Cell	   Carcinoma	  
(SCC).	   Objectives	   of	   this	   study	   were	   to	   examine	   the	   role	   of	   Kin1	   in	   skin	  
homeostasis	  and	  in	  the	  development	  of	  aggressive	  SCC	  in	  KS,	  as	  the	  molecular	  
aetiologies	  for	  these	  pathologies	  are	  yet	  to	  be	  clearly	  understood.	  	  
	  
We	   first	   examined	   whether	   the	   recently	   discovered	   role	   of	   Kin1	   in	   mitosis	  
contributes	   to	   reduced	   keratinocyte	   proliferation	   observed	   in	   KS	   epidermis.	  
We	  discovered	  that	  short-­‐term	  loss	  of	  Kin1	  in	  adult	  mouse	  epidermis	  reduced	  
keratinocyte	   proliferation.	   We	   also	   found	   that	   Kin1	   loss	   increased	   mitotic	  
spindle	   misorientation	   that,	   according	   to	   the	   model	   of	   cell	   division	   in	   skin	  
homeostasis,	  decreases	  cell	  proliferative	  potential,	  and,	  thus,	  may	  account	  for	  
the	   reduced	   proliferation	   in	   our	  model.	   As	   spindle	  misorientation	   can	   stem	  
from	  microtubule	   instability,	   we	   believe	   that	   the	   reduction	   in	   acetylated	   α-­‐
tubulin	   (ac-­‐tub),	   a	   known	   marker	   of	   stable	   microtubules,	   that	   we	   also	  
observed	   in	   mouse	   epidermis	   following	   Kin1	   loss	   could	   account	   for	   the	  
defective	  spindle	  orientation	  phenotype.	  	  
	  
The	  role	  of	  Kin1	  in	  spindle	  orientation	  was	  also	  evident	  in	  vitro.	  Moreover,	  data	  
from	   our	   lab	   revealed	   showed	   reduction	   in	   spindle	   ac-­‐tub	   following	   Kin1	  
depletion,	   mirroring	   our	   in	   vivo	   observation.	   Additionally	   to	   orientation	  
defects,	   in	   vitro	   depletion	   of	   Kin1	   led	   to	   enhanced	   chromosome	  
missegregation,	   which	   is	   likely	   to	   result	   from	   reduced	   microtubule	   stability	  
due	  to	  low	  levels	  of	  ac-­‐tub.	  We	  showed	  that	  role	  of	  Kin1	  in	  spindle	  orientation	  
and	  chromosome	  segregation	   is	  dependent	  on	  HDAC6,	  a	  known	   inhibitor	  of	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ac-­‐tub.	   Overall,	   our	   results	   uncover	   an	   in	   vitro	   and	   in	   vivo	   role	   of	   Kin1	   in	  
mitotic	   spindle	   fidelity	   that	   could	  be	   crucial	   to	   skin	  homeostasis,	   and,	  when	  
disturbed,	  may	  lead	  to	  reduced	  keratinocyte	  proliferation.	  Interestingly,	  our	  in	  
vitro	   studies	   also	   revealed	   that	   in	   mitosis	   Kin1	   and	   Kindlin-­‐2	   (Kin2)	   had	  
overlapping,	  but	  also	  distinct	  roles,	  which	   is	   in	   line	  with	  various	  reports	   that	  
show	  different	  biological	  functions	  for	  the	  two	  protein	  isoforms.	  	  
	  
Our	  next	  and	  final	  aim	  was	  to	  explore	  the	  roles	  of	  Kin1	  in	  the	  development	  and	  
progression	  of	  SCC,	  which	  would	  help	  us	  comprehend	  the	  reason	  behind	  the	  
cancer’s	  aggressive	  nature	  in	  KS.	  By	  employing	  in	  vitro	  and	  in	  vivo	  SCC	  growth	  
assays	   and	   tumour	   immunohistochemical	   staining	  we	   found	   that	   absence	   of	  
Kin1	   in	   SCC	   cells	   and	   tumours	   enhanced	   proliferation	   and	   growth,	   and	  
enhanced	   tumour	   vascularisation.	   RNA	   sequencing	   of	   tumour	   material	  
revealed	   that	   lack	   of	   Kin1	   increased	   expression	   of	  matrix	  metalloproteinases	  
and	   chemokines,	   which	   have	   been	   implicated	   in	   tumour	   progression	   via	  
promotion	  of	  angiogenesis	  and	  invasion	  in	  a	  plethora	  of	  studies,	  and	  of	  various	  
angiogenesis	  markers.	  Together	  this	  provides	  an	  insight	  into	  the	  mechanisms	  
via	   which	   Kin1	   controls	   tumour	   microenvironment	   and,	   ultimately,	   SCC	  
tumour	  growth	  and	  development.	  
Overall,	   we	   report	   an	   in	   vitro	   and	   in	   vivo	   role	   for	   Kin1	   in	   mitotic	   spindle	  
stability,	   which	   affects	   a	   variety	   of	   mitotic	   processes	   and	   may	   be	   linked	   to	  
reduced	  keratinocyte	  proliferation	  observed	  in	  epidermis	  of	  KS	  patients,	  thus	  
contributing	   to	   skin	   homeostasis.	   Moreover,	   we	   describe	   a	   role	   for	   Kin1	   in	  
regulation	  of	  SCC	  tumour	  growth	  and	  progression,	  which	  may	  ultimately	  offer	  
an	  explanation	  for	  the	  aggressive	  and	  life-­‐threatening	  nature	  of	  SCC	  developed	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lay	  reader	  summary	  
Kindler	   Syndrome	   (KS)	   is	   a	   rare	   genetic	   disease.	   Most	   of	   its	   symptoms	  
manifest	   at	   birth	   and	   include	   very	   thin	   and	   fragile	   skin	   (atrophy)	   prone	   to	  
blistering,	   photosensitivity	   as	  well	   as	   a	   propensity	   to	   develop	   a	   form	  of	   skin	  
cancer	  known	  as	  Squamous	  Cell	  Carcinoma	  (SCC).	  The	  disorder	  results	   from	  
the	  lack	  of	  a	  protein	  called	  Kindlin-­‐1	  (Kin1)	  whose	  most	  studied	  role	  is	  enabling	  
cells	  to	  adhere	  to	  their	  surroundings.	  Currently,	  there	  is	  no	  cure	  for	  KS,	  nor	  a	  
comprehensive	  understanding	  of	  how	  Kin1	  contributes	  to	  the	  maintenance	  of	  a	  
healthy	  skin.	  We,	  therefore,	  sought	  to	  explore	  the	  cellular	  roles	  of	  Kin1,	  which	  
will	  enhance	  our	  understanding	  on	  how	  the	  KS	  pathologies	  develop	  and	  can	  be	  
treated.	  Our	   interest	  was	  examining	  the	  role	  of	  Kin1	   in	  mouse	  epidermis	  cell	  
proliferation,	   which	   is	   the	   ability	   of	   cells	   to	   multiply,	   as	   well	   as	   in	   the	  
development	  of	  aggressive	  SCC,	  due	  to	  its	  life-­‐threatening	  nature.	  
	  
To	  study	  the	  pathology	  of	  reduced	  cell	  proliferation,	  which	  has	  been	  observed	  
in	  the	  atrophic	  skin	  of	  KS	  patients,	  we	  deleted	  Kin1	  from	  mouse	  epidermis	  and	  
compared	  it	  to	  that	  of	  healthy	  mice.	  We	  observed	  that	   lack	  of	  Kin1	   in	  mouse	  
epidermis	  reduced	  the	  number	  of	  mouse	  cells	  that	  are	  able	  to	  multiply,	  which	  
is	   a	   feature	   of	   the	   epidermis	   of	   KS	   patients.	   Further	   investigation	   into	   the	  
process	   of	   cell	   division	   revealed	   that	   the	   molecular	   structure	   that	   captures	  
DNA	   during	   mitosis	   -­‐	   the	   mitotic	   spindle	   -­‐	   had	   a	   higher	   chance	   of	   being	  
unstable	   and	   abnormally	   formed	   in	   cells	   lacking	   Kin1.	   We	   confirmed	   our	  
findings	  by	  performing	  live	  cell	  imaging,	  which	  allowed	  us	  to	  track	  cells	  during	  
cell	   division	   and	   showed	   a	   variety	   of	   mitotic	   spindle	   abnormalities	   in	   cells	  
without	  Kin1.	  Our	   findings	   therefore	  offer	   an	   insight	   into	   the	   role	  of	  Kin1	   in	  
maintaining	   a	   healthy	  mitotic	   spindle	   during	   cell	   division,	   thus	   indicating	   a	  
potential	  mechanism	  through	  which	  skin	  atrophy	  may	  arise	  in	  KS.	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To	  assess	  the	  role	  of	  Kin1	  in	  SCC,	  we	  compared	  the	  growth	  and	  morphology	  of	  
mouse	   SCC	   tumours	   that	   had	   or	   lacked	   Kin1.	   We	   discovered	   that	   when	  
compared	   to	   tumours	   that	  had	  Kin1,	  SCC	  tumours	  without	  Kin1	  were	  bigger,	  
had	   a	   greater	   number	   of	   multiplying	   cells,	   and	   a	   greater	   number	   of	   blood	  
vessels	   that	   are	   known	   positively	   influence	   tumour	   growth	   by	   transporting	  
oxygen	  and	  nutrients.	  Moreover,	  we	  discovered	  that	  tumours	  without	  Kin1	  had	  
higher	  levels	  of	  various	  MMPs	  (Matrix	  Metalloproteinases),	  which	  are	  proteins	  
that	  degrade	  the	  matrix	  surrounding	  the	  cells	  (extracellular	  matrix)	  and,	  thus,	  
allow	   cells	   to	   multiply	   and	   invade	   other	   tissues	   in	   many	   types	   of	   cancer.	  
Finally,	   SCC	   tumours	  without	  Kin1	   revealed	  higher	   levels	   of	   various	   immune	  
system	   molecules	   known	   as	   chemokines,	   which	   have	   also	   previously	   been	  
shown	   to	   support	   tumour	   growth	   and	   progression	   via	   various	  ways,	   such	   as	  
promoting	  growth	  of	  new	  blood	  vessels.	  Thus,	  our	  findings	  show	  that	  presence	  
of	  Kin1	  is	  inhibitory	  to	  the	  expression	  of	  tumour-­‐promoting	  factors,	  providing	  
a	  mechanistic	  explanation	  for	  why	  loss	  of	  Kin1	  in	  KS	  leads	  to	  the	  development	  
of	  aggressive	  SCC.	  	  
	  
Overall,	  we	  offer	  an	  insight	  into	  a	  novel	  role	  of	  Kin1	  in	  ensuring	  that	  cells	  have	  
normal	  mitotic	   spindles,	  which	   could,	  ultimately,	   contribute	   to	  maintenance	  
of	   healthy	   skin,	   and	   a	   role	   of	   Kin1	   in	   protecting	   cells	   against	   growth	   and	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Chapter	  1:	  introduction	  
1.1.	  Overview	  of	  Kindler	  Syndrome	  
Kindler	   Syndrome	   (KS)	   is	   a	   rare,	   autosomal	   recessive	   genodermatosis	   first	  
described	  in	  1954	  by	  dermatologist	  Dr	  Theresa	  Kindler.	  Symptoms	  first	  appear	  
in	  infancy	  and	  include	  acral	  blistering,	  which	  develops	  spontaneously	  or	  after	  
mechanical	   trauma,	   severe	   epidermal	   atrophy,	   photosensitivity,	   hyper-­‐	   or	  
hypo-­‐	   pigmentation	   and	   poikiloderma	   [1]–[4].	   According	   to	   various	   case	  
reports,	  some	  of	  the	  pathologies,	  such	  as	  blistering	  and	  photosensitivity,	  tend	  
to	   subside	   after	   the	   first	   few	   years	   of	   age,	   in	   contrast	   to	   epidermal	   atrophy	  
which	  is	  often	  progressive	  and,	  therefore,	  one	  of	  the	  major	  clinical	  features	  of	  
the	  disease	  [5]–[7].	  As	  a	  result,	  the	  skin	  of	  KS	  patients	  tears	  easily	  and	  presents	  
a	  characteristic	  cigarette	  paper-­‐like	  wrinkling	  [7][8].	  	  
	  
KS	   patients	   also	   present	   a	   predisposition	   to	   aggressive	   Squamous	   Cell	  
Carcinoma	   (SCC),	   with	   the	   risk	   of	   malignancy	   being	   reported	   to	   70%	   for	  
subjects	  older	  than	  45	  years	  old	  [9].	  According	  to	  KS	  case	  studies,	  cancer	  often	  
develops	  on	  the	  hand,	  leg	  and	  lip,	  and	  less	  frequently	  on	  the	  oral	  mucosa	  and	  
the	   larynx	   of	   individuals	   [2][10]–[12].	   The	   nature	   of	   SCC	   developed	   in	   KS	  
patients,	   particularly	   in	   limbs,	   is	   extremely	   aggressive	   and	  metastatic,	   often	  
requires	  amputation	  and	  lymph	  node	  excision	  [13][14].	  Development	  of	  SCC	  is	  
sometimes	   fatal	   for	   various	   KS	   patients	   [2][15],	   making	   it	   a	   main	   cause	   of	  
morbidity	  and	  mortality	  in	  KS	  amongst	  the	  disease’s	  pathologies.	  	  
	  
Manifestations	   of	   the	   disease	   are	   not	   restricted	   in	   the	   epidermis.	   Clinical	  
intraoral	   findings,	   such	   as	   gingivitis,	   gum	   haemorrhage,	   and	   early-­‐onset	  
aggressive	   periodontitis,	   have	   been	   recorded	   in	   a	   great	   number	   of	   patients	  
[16]–[19].	   Incidence	  of	   other	   features	   such	   as	  ulcerative	  haemorrhagic	   colitis,	  
syndactyly	  and	  nail	  dystrophy	  varies	  between	  cases	  [1][20]–[22].	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The	  disease	   is	   extremely	   rare.	  More	   than	   120	   cases	  have	  been	   reported	   since	  
1954,	  with	  the	  largest	  series	  being	  a	  group	  of	  26	  KS	  patients	  identified	  within	  a	  
tribe	   on	   the	   Northwestern	   Carribean	   coast	   of	   Panama	   [6].	   KS	   shows	   an	  
autosomal	  pattern	  of	   transmission	   [4][23],	   but	   sporadic	   cases	  have	   also	  been	  
recorded	  [1][6][22].	  A	  variety	  of	  patients	  of	  consanguineous	  descent	  have	  been	  
documented	  [7][24].	  
	  
1.2.	  Overview	  of	  Epidermolysis	  Bullosa	  	  
Kindler	   Syndrome	   is	   part	   of	   a	   heterogeneous	   simplex	   of	   inherited	  
genodermatoses	   known	   as	   Epidermolysis	   Bullosa	   (EB),	   which	   affects	  
approximately	  half	  million	  people	  worldwide.	  All	  variants	  of	  EB	  are	  generally	  
characterised	  by	  similar	  symptoms,	  including	  spontaneous	  or	  trauma-­‐induced	  
blistering	  of	  inherently	  atrophic	  skin,	  predisposition	  to	  aggressive	  SCC,	  which	  
can	   be	   fatal,	   and	   a	   variety	   of	   extracutaneous	   manifestations	   including	  
periodontitis	   and	   gastrointestinal	   complications	   [25]–[28].	   Besides	  
development	   of	   SCC,	   mortality	   for	   severe	   EB	   cases	   can	   often	   result	   from	  
mucosal	  strictures	  in	  sites	  such	  as	  in	  the	  gastrointestinal	  tract	  and	  deleterious	  
consequences	  of	  infections	  in	  affected	  skin.	  
	  
As	   there	   is	   currently	   no	   single	   optimal	   therapy	   option	   for	   EB	   patients,	  
treatment	   is	   mainly	   symptomatic	   and	   includes	   wound	   maintenance	   and	  
healing,	   which	   can	   be	   aided	   by	   use	   of	   glucocorticoids,	   photoprotection,	  
avoidance	   of	   physical	   trauma	   and	   good	   oral	   hygiene.	  As	   it	  will	   be	   discussed	  
extensively	   in	  Chapter	   6,	   various	   therapeutic	   avenues	   have	   been	   proposed,	  
which	  hold	  potential	  for	  disease	  modification	  and	  cure.	  	  
	  
According	   to	   the	   first	   classification	   scheme,	   proposed	   in	   1962,	   EB	   was	  
categorised	   in	   three	   major	   types,	   Epidermolysis	   Bullosa	   Symplex	   (EBS),	   JEB	  
Junctional	  Epidermolysis	  Bullosa	   (JEB)	  and	  Dystrophic	  Epidermolysis	  Bullosa	  
(DEB),	  based	  on	   the	   constellations	  of	   structural	  differences	  on	  patients’	   skin	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[29].	   Gaining	   a	   greater	   insight	   on	   clinical,	   molecular,	   histopathological	   and	  
mutational	   features	   of	   EB	   genodermatoses	   led	   to	   the	   addition	   of	   KS	   as	   the	  
fourth	   major	   type	   of	   EB	   a	   decade	   ago,	   as	   decided	   during	   the	   “Third	  
International	  Consensus	  Meeting	  on	  diagnosis	  and	  classification	  of	  EB”	  [29].	  
	  
Intriguingly,	  whereas,	   similarly	   to	  KS,	   JEB	   is	   inherited	   in	   a	   recessive	   fashion	  
[30],	  EBS	  and	  DEB	  have	  a	  dominant	  or	  recessive	  pattern	  of	  inheritance	  [31][32].	  
Moreover,	  in	  contrast	  to	  KS,	  EBS,	  JEB	  and	  DEB	  are	  further	  classified	  into	  more	  
subtypes,	   based	   on	   the	   ultrastructural	   site	   of	   skin	   findings	   and	   gene	  
mutational	   analysis.	  For	  example,	   localised	  EBS	  affects	   the	  basal	   cell	   layer	  of	  
the	  epidermis	  and	  presents	  mutations	   in	  genes	   that	  encode	  keratins,	   such	  as	  
KRT5	   and	   KRT14,	   whereas	   EBS	   with	   plakophilin-­‐1	   deficiency	   affects	  
desmosomes	   of	   suprabasal	   layer	   of	   skin,	   and	   its	   patients	   have	  mutations	   in	  
PKP1	  (Plakophilin-­‐1)	  and	  DSP	  (Desmoplakin)	  [29].	  	  
	  
Mutational	  analysis	  has	  revealed	  that	  EB	  arises	  from	  nonsense,	  missense,	  indel	  
or	  splice	  variant	  mutations	  that	  overall	  affect	  skin	  homeostasis.	   In	  particular,	  
EB	  variants	  present	  abnormalities	  at	  the	  cutaneous	  basement	  membrane	  zone,	  
also	   known	   as	   the	   dermoepidermal	   junction,	   which	   provides	   structural	  
adhesion	  between	   the	  epidermis	   and	   the	  underlying	  dermis,	  preserves	   tissue	  
architecture	  and	  grants	  skin	  resistance	  against	  shearing	  forces	  [33]	  (Fig.1.).	  	  
	  
Mutations	   in	   EBS	  mainly	   target	   genes	   that	   encode	   cytoplasmic	   intermediate	  
filaments	   (IFs)	   keratin	   5	   and	   14,	   forming	   the	   cytoskeletal	   network	   of	   basal	  
epithelial	  cells	  [34].	  EBS	  also	  affects	  Plakophilin-­‐1	  and	  Desmoplakin,	  required	  
for	   normal	   assembly	   of	   desmosomes	   intercellular	   junctions	   that	   tether	   the	  
aforementioned	  keratin	  IFs	  to	  the	  plasma	  membrane	  [35],	  and	  plectin,	  which	  
links	  keratin	  IFs	  to	  transmembrane	  receptor	  integrin	  α6β4	  at	  cell-­‐Extracellular	  
Matrix	   (ECM)	   adhesion	   contacts	   [29][36].	   The	   genetic	   basis	   of	   KS	   is	   loss-­‐of-­‐
functin	  mutations	  in	  FERMT1	  (Fermitin	  family	  member	  1)	  gene,	  which	  target	  an	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adaptor	   protein	   known	   as	   Kindlin-­‐1	   (Kin1),	   a	   member	   of	   cell	   adhesion	  
macromolecular	  complexes	  that	  mediate	  anchorage	  between	  cell	  cytoskeleton	  
and	   ECM	   through	   interactions	   with	   β	   integrins	   [24][37].	   JEB	   results	   from	  
mutations	  in	  genes	  that	  encode	  protein	  anchors	  between	  cell	  and	  ECM,	  such	  
as	  laminin-­‐332,	  collagen	  XVII	  and	  integrin	  α6β4	  [38]–[40].	  Interestingly,	  α6β4	  
integrin	   mutations	   also	   appear	   in	   one	   subtype	   of	   EBS	   [29].	   Finally,	   DEB	  
mutations	  affect	  collagen	  VII,	  the	  major	  component	  of	  the	  anchoring	  fibrils	  at	  
the	  dermoepidermal	  junction,	  providing	  a	  connection	  between	  lamina	  densa,	  a	  
layer	   of	   the	   basement	   membrane,	   and	   the	   underlying	   dermis	   [32].	   Detailed	  
schematic	  representation	  of	  the	  aforementioned	  proteins	  targeted	  in	  the	  four	  



















Figure	  1:	   Schematic	   representation	  of	   the	  proteins	   affected	   in	   the	  4	  different	   types	  of	   inherited	  
Epidermolysis	  Bullosa:	  EBS,	  KS,	  JEB	  and	  DEB.	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1.3.	  Kindlins	  and	  talins	  in	  FERM	  adhesion	  	  
Nomenclature	  of	  FERMT1	  gene	  indicates	  that	  Kin1	  is	  a	  FERM	  (Four-­‐point-­‐one,	  
ezrin,	  radixin,	  moesin)	  domain-­‐containing	  protein.	  FERM	  domain	  is	  found	  in	  
various	   other	   mammalian	   proteins	   that	   function	   towards	   sustaining	   an	  
adhesive	   link	   between	   cells	   and	   ECM,	   such	   as	   Focal	  Adhesion	  Kinase	   (FAK)	  
and	  talin	  [41].	  
	  
FERM	  domains	  consist	  of	  3	  globular	  subdomains	  F1,	  F2	  an	  F3,	  which	  compose	  
the	  domain	  core	  preceded	  by	  a	  less	  well-­‐defined	  F0	  subdomain.	  In	  the	  human	  
genome	  there	  are	  approximately	  50	  distinct	  types	  of	  FERM	  domains,	  encoded	  
by	   over	   30	   genes	   [42].	   Aminoacid	   sequence	   similarity	   of	   FERM	   domain	   is	  
highly	  conserved	  amongst	  Kin1,	  Kindlin-­‐2	  (Kin2)	  and	  Kindlin-­‐3	  (Kin3),	  which	  
together	  compose	  kindlin	  protein	  family.	  FERM	  domain	  sequence	  of	  kindlins	  
resembles	   FERM	   domain	   sequence	   of	   talins	   cell	   adhesion	   proteins	   that	   also	  
share	  have	   functional	   similarities	   to	  kindlins.	   In	  particular,	  kindlin	  F0,	  F1,	  F2	  
and	   F3	   subdomains	   are	   36-­‐55%	   similar	   to	   the	   equivalent	   talin	   subdomains,	  
with	  the	  highest	  similarity	  being	  found	  within	  F1,	  F2	  and	  F3	  subdomains	  [43].	  	  
	  
The	  structure	  of	  talin-­‐1	  and	  talin-­‐2,	  which	  compose	  the	  vertebrate	  talin	  protein	  
family,	   contains	   the	   talin	   head,	   which	   is	   located	   in	   the	   N-­‐terminus	   and	   is	  	  
composed	   of	   the	   F1,	   F2	   and	   F3	   subdomains	   that	   are	   preceded	   by	   the	   F0	  
subdomain,	  and	  a	  flexible	  C-­‐terminal	  rod	  [44][45]	  (Fig.2.).	  Kindlins	  lack	  a	  C-­‐
terminal	  rod,	  but	  also	  contain	  F0,	  F1,	  F2	  and	  F3	  subdomains	  (Fig.2.).	  	  
	  
Through	  their	  FERM	  subdomains,	  kindlins	  and	  talins	  can	  interact	  with	  the	  cell	  
membrane	  as	  well	  as	  with	  integrins	  transmembrane	  αβ	  heterodimer	  receptors.	  
Integrin	  family	  contains	  18α	  and	  8β	  subunits,	  which	  assemble	  into	  24	  distinct	  
heterodimer	  combinations,	  and	  they	  all	  span	  the	  cell	  membrane	  and	  establish	  
a	   connection	   between	   the	   actin	   cytoskeleton	   and	   ECM	  [46].	   Talins/kindlins	  
and	  integrins	  interactions	  foster	  conformational	  alterations	  in	  integrins,	  from	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a	  bent	  and	  clasped	  inactive	  conformation	  to	  an	  extended,	  active	  integrin	  form	  
with	  high	  affinity	  for	  ECM	  ligands	  [47]	  (Fig.2.).	  	  
	  
F3	   subdomain	  contains	  a	   structurally	  conserved	  mechanism	  that	  allows	  both	  
talins	   and	  kindlins	   to	  bind	  β-­‐integrin	   tails	   and	  potentiate	   integrin	   activation	  
that	   is	   critical	   for	   cell	   adhesion	   and	   numerous	   other	   cellular	   functions.	   In	  
particular,	   the	   F3	   subdomain	   of	   talins	   and	   kindlins	   harbours	   a	  
Phosphotyrosine-­‐binding	   (PTB)	  domain	   that	   potentiates	   interaction	  of	   talins	  
and	   kindlins	   to	  NpxY	  membrane-­‐proximal	   and	  NxxY	  membrane-­‐distal	  NxxY	  
motifs	   in	   β-­‐integrin	   subunits,	   respectively	   [48]–[51].	   Mutational	   analysis	  
showed	  that	  disruption	  of	  NPxY	  and	  NxxY	  motifs	  inhibits	  binding	  of	  talins	  or	  
kindlins	   to	   integrin	   tails	   and	   talin/kindlin-­‐mediated	   integrin	   activation	  
[48][49][52].	  	  
	  
F3	   subdomain	   of	  Kin1,	   Kin2	   and	  Kin3	   is	   able	   to	   bind	   and	   activate	   β1	   and	   β3	  
integrin	  tails,	  whilst	  Kin1	  can	  also	  bind	  β6	  integrin,	  and	  Kin3	  is	  also	  capable	  of	  
β2	   integrin	   interaction.	   It	   was	   also	   found	   that	   in	   Chinese	   Hamster	   Ovary	  
(CHO)	  cells,	  W612,	  K610	  and	  I651,	  as	  well	  as	  W615	  are	  key	  F3	  sites	  on	  Kin1	  and	  
Kin2,	   respectively,	   for	   binding	   to	   β1	   integrin	   tails	   [49].	   Similarly,	   the	  
importance	  of	  Kin1	  W612	   site	  on	  β1	   and	  β3	   integrin	   activation	  was	   shown	   in	  
MDA-­‐MB-­‐231	   breast	   cancer	   cells	   and	   keratinoctes,	   as	   well	   as	   in	   CHO	   cells,	  
respectively	  [53]–[55].	  
	  
Integrins	  consist	  of	  an	  ectodomain	  embedded	  into	  the	  ECM,	  a	  transmembrane	  
domain,	  and	  a	  tail	  projecting	  to	  the	  intracellular	  space.	  Interestingly,	  integrins	  
are	  locked	  to	  an	  inactive	  state	  through	  a	  variety	  of	  interactions,	  including	  salt	  
bridges	   formed	  between	  the	  cytoplasmic	  tails	  and	  transmembrane	  domain	  of	  
integrins,	  and	  electrostatic	   interactions	  between	  the	  head	  and	  tail	  of	   integrin	  
subunits	  [56][57].	  It	  was	  shown	  that	  talin	  F3	  subdomain	  forms	  salt	  bridge	  with	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β	   integrin	   tail,	   thus	   disrupting	   the	   salt	   bridges	   between	   α	   and	   β	   subunits	  
[57][58].	  	  
	  
Integrin	  activation	  also	  depends	  on	  binding	  of	  kindlins	  and	   talins	   to	   the	  cell	  
membrane.	  Namely,	  a	  patch	  of	  positively	  charged	  aminoacid	  residues,	  termed	  
“membrane	  orientation	  patch”,	  was	  identified	  on	  talin	  F2	  subdomain,	  allowing	  
talin	   to	   interact	   with	   negatively	   charged	   membrane	   phospholipids	   such	   as	  
Phosphatidylinositol	  4,5-­‐bisphosphate	  (PIP2)	  [58][59].	  This	  orientates	  talin	  to	  
disrupt	  the	  salt	  bridge	  between	  the	  αβ	  heterodimeric	  integrin	  transmembrane	  
complex,	   promoting	   integrins	   to	   adopt	   their	   extended	   form.	   Furthermore,	   it	  
was	   found	   that	   binding	   of	   talin	   F2	   and	   F3	   subdomains	   to	   a	   membrane-­‐
embedded	  dimer	   fragment	  of	  α2β3	   integrin	   induces	   integrin	  orientation	   in	  a	  
fashion	   that	   dissociates	   the	   salt	   transmembrane	   contact	   between	   α	   and	   β	  
subunits	  [60].	  
	  
Besides	   enabling	   integrin	   activation,	   PIP2	   interaction	   is	   critical	   for	   talin	  
activation.	  NMR	  spectroscopy	  revealed	  that	  binding	  of	  talin	  rod	  to	  talin	  head	  
restrains	  talin	  in	  a	  closed	  conformation	  and	  masks	  an	  integrin-­‐binding	  region	  
in	   the	   talin	   PTB	   domain	   [61].	   Talin	   PTB	   domain-­‐PIP2	   interaction	   displaces	  
inhibitory	   talin	   rod,	   thus	   preventing	   talin	   structural	   autoinhibition,	   and	  
exposes	  the	  talin	  β-­‐integrin	  binding	  site	  [61].	  	  
	  
Talin	   can	   also	  bind	  PIP2	   via	   a	   loop	   in	   its	   F1	   subdomain,	   a	   feature	   shared	  by	  
Kin1,	   and	   disruption	   of	   talin/kindlin	   F1-­‐PIP2	   bond	   impairs	   activation	   of	  
integrins	  [62][63].	  Interactions	  between	  kindlin	  and	  anionic	  phospholipids	  are	  
also	   feasible	  through	  basic	  residues	  on	  F0	  subdomain	  [64][43]	  and	  through	  a	  
Pleckstrin	  Homology	   (PH)	   domain	   that	   interrupts	   F2	   subdomain	   of	   kindlins	  
[51][65][66],	   a	   feature	   not	   shared	   by	   talins.	   F0	   and	   PH	   domains	   are	   key	   for	  
integrin	   activation.	   This	   is	   evident	   by	   impairment	   of	   integrin	   activation	   in	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CHO	   cells	   that	   lack	   Kin1	   F0	   subdomain	   [43]	   or	   have	   disrupted	   membrane	  
binding	  due	  to	  mutated	  Kin2	  F0	  or	  PH	  domains	  [64][65].	  	  
	  
A	  number	  of	  the	  most	  important	  domains	  and	  active	  sites	  of	  FERMT1	  that	  are	  
subjected	  to	  mutations	  is	  displayed	  in	  Figure	  3.	  The	  mutational	  range	  includes	  
nonsense	   mutations	   such	   as	   S114X	   in	   F0	   subdomain,	   where	   Serine	   114	   is	  
replaced	   by	   a	   premature	   stop	   codon,	   thus,	   resulting	   in	   a	   truncated	   protein,	  
insertions	  such	  as	   1714insA	   in	  F2	  subdomain,	  where	  an	  Alanine	   is	   inserted	   in	  
position	  1714,	  and	  deletions	  such	  as	  1909delA	  in	  F3	  subdomain,	  where	  Alanine	  










Figure	   2:	   Talin	   and	   kindlin-­‐mediated	   integrin	   activation.	   Interaction	   of	   talins	   and	   kindlins	   to	   β-­‐
integrin	   tails	   leads	   to	   conformation	   changes	   that	   transform	   the	   bent,	   inactive	   integrin	   state	   to	   an	  








Figure	   3:	   The	   spectrum	   of	   mutations	   of	   FERMT1.	   Schematic	   representation	   of	   FERMT1,	   which	  
encodes	  Kin1	  protein,	  and	   the	  most	  well-­‐documented	  mutations	   that	   the	  various	  subdomains	  and	  
active	  FERMT1	  sites	  are	  subjected	  to.	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1.4.	  Kindlins	  and	  talins	  cooperate	  to	  induce	  integrin	  activation	  
The	   landmark	   discovery	   of	   talin-­‐mediated	   integrin	   activation	   occurred	   from	  
talin	  knockdown	  studies	  in	  CHO	  cells	  [67],	  prior	  to	  detecting	  the	  importance	  
of	   kindlins	   in	   integrin	   activation.	   Talins	   are	   required	   for	   integrin	   activation,	  
with	   block	   of	   talin-­‐integrin	   interactions	   resulting	   in	   complete	   abolition	   of	  
talin-­‐	   and	   kindlin-­‐mediated	   integrin	   activation	   [68].	   Nevertheless,	   kindlin	  
knockdown	   experiments	   along	   with	   expression	   of	   integrin-­‐binding	   mutants	  
implicate	  kindlins	  in	  integrin	  activation	  as	  well.	  	  
	  
The	  first	  study	  to	  highlight	  the	  importance	  of	  kindlins	  in	  integrin	  function	  was	  
performed	   in	   Caenorhabditis	   elegans	   (C.	   elegans)	   and	   published	   in	   2000.	   It	  
demonstrated	   that	  homozygous	  null	  mutations	   in	   unc-­‐112,	   a	  gene	  encoding	  a	  
membrane-­‐linked,	   intracellular	   protein,	   resulted	   in	   similarly	   severe	  
abnormalities	   to	   those	   caused	  by	  mutations	   in	   genes	   that	   encode	  C.	   elegans	  
orthologs	   of	   β-­‐integrin	   and	   ECM	   component	   perlecan	   [69].	   All	   mutations	  
resulted	   in	   a	   paralysed	   phenotype	   characterised	   by	   a	   defective	   formation	   of	  
embryonic	   body-­‐wall	   muscle	   [69].	   UNC-­‐112	   showed	   colocalisation	   with	   β-­‐
integrin	  ortholog	  Paralysed	  Arrest	  at	  two-­‐fold-­‐3	  (PAT-­‐3)	  and	  was	  required	  for	  
PAT-­‐3’s	  localisation	  in	  the	  muscle	  cell	  membrane	  of	  C.	  elegans	  [69].	  In	  2003	  it	  
was	  shown	  that	  loss-­‐of-­‐function	  mutations	  in	  KS	  patients	  mapped	  in	  FERMT1,	  
a	  gene	  encoding	  the	  human	  homolog	  of	  unc-­‐112	  that	  was	  named	  Kin1	  [24][70].	  
	  
However,	  it	  wasn’t	  until	  2008	  that	  kindlins	  were	  shown	  to	  be	  key	  for	  integrin	  
activation	   induction,	   when	   FERMT3	   null	   mutations	   reduced	   integrin	  
activation	   in	   platelets,	   despite	   normal	   expression	   of	   talin	   [52].	   Similarly,	  
despite	   expression	   of	   normal	   levels	   of	   talin,	   overexpression	   and	  depletion	   of	  
Kin2	   increased	   and	   impaired	   β	   integrin	   activation	   in	   podocytes,	   respectively	  
[71].	  Additionally,	  as	  explained	  in	  Section	  1.3.,	  individual	  disruption	  of	  kindlin	  
F0,	   F3	   and	   PH	   subdomains	   perturbs	   integrin	   activation,	   despite	   talin	  
expression,	   showing	   the	   importance	   of	   kindlins	   towards	   integrin	   activation.	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However,	  kindlin	  depletion,	  or	  expression	  of	  integrin-­‐binding	  kindlin	  mutants	  
significantly	   reduces,	   but	   does	   not	   completely	   abrogate	   integrin	   activation,	  
suggesting	  a	  synergistic	  effect	  of	  kindlins	  and	  talins	  towards	  maximal	  integrin	  
activation.	  In	  line	  with	  this	  theory,	  whilst	  overexpression	  of	  Kin2	  alone	  showed	  
a	   mild	   effect,	   and	   expression	   of	   talin	   alone	   had	   a	   moderate	   effect	   on	   β3	  
integrin	   activation,	   co-­‐expression	   of	   Kin2	   and	   talin	   dramatically	   enhanced	  
integrin	  activation	  compared	  to	  the	   individual	  effect	  of	  Kin2	  or	  talin	   in	  CHO	  
cells	  [50].	  	  
	  
In	  CHO	  cells,	  Kin1	  and	  Kin2	  overexpression	  was	  surprisingly	  shown	  to	  inhibit	  
activation	  of	  β3	  integrins	  [49].	  Although	  the	  molecular	  explanation	  behind	  this	  
is	   not	   clear	   yet,	   it	   may	   result	   from	   the	   fact	   that	   kindlin	   overexpression	  
uncouples	   potential	   kindlin-­‐induced	   recruitment	   of	   kindlin-­‐binding	   adaptor	  
proteins	   that	   cooperate	   with	   talin	   towards	   integrin	   activation.	   Nevertheless,	  
co-­‐expression	  of	  Kin1	  and	  Kin2	  with	  talin	  head	  strongly	  stimulated	  activation	  
of	  β3	  integrins	  in	  CHO	  cells	  [49].	  	  
	  
It	  is,	  thus,	  clear,	  that	  whereas	  talin	  is	  necessary	  for	  integrin	  activation,	  inability	  
of	  kindlins	  to	  bind	  and	  activate	   integrins	  reduces	  an	  activation	  enhancement	  
effect	   and	   prevents	   maximal	   integrin	   activation,	   which	   showcases	   the	  
cooperation	  between	  talins	  and	  kindlins	  in	  this	  biological	  process.	  	  	  	  
	  
1.5.	  Models	  of	  talin/kindlin-­‐mediated	  integrin	  activation	  
Whilst	  synergy	  between	  talins	  and	  kindlins	  in	  integrin	  activation	  is	  clear,	  the	  
exact	   nature	   of	   integrin	   activation	   remains	   controversial.	  Moreover,	  whereas	  
we	  have	  a	  considerable	  understanding	  on	  how	  talin	  activates	  integrins,	  steps	  of	  
kindlin-­‐mediated	   integrin	   activation	   are	   yet	   to	   be	   determined.	   It	   is	   possible	  
that	   binding	   of	   kindlin	   to	   β-­‐integrin	   tail	   and	   cell	   membrane	   exposes	   talin-­‐
binding	   sites	   on	   β-­‐integrin	   tail,	   thus,	   directly	   promoting	   talin-­‐mediated	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integrin	   activation	   (Fig.4.A.).	   Nevertheless,	   alternative	   models	   of	   synergy	  
between	  talin	  and	  kindlin	  towards	  integrin	  activation	  have	  also	  been	  proposed.	  	  
	  
Integrin	   inhibitor	   filamin	  competes	  with	  talin	   for	  β-­‐integrin	  binding,	  as	  both	  
proteins	   were	   shown	   to	   occupy	   overlapping	   sites	   on	   β-­‐integrins	   tails,	   and	  
filamin	   loss	   stimulated	   integrin	   activation	   [72].	   Filamin	   shares	   the	   same	  
integrin-­‐binding	   site	   as	  Migfilin,	   a	   kindlin-­‐binding	   protein	   recruited	   at	   cell-­‐
ECM	   adhesion	   sites	   by	   kindlin	   [73].	   Expression	   of	   migfilin	   has	   shown	   to	  
enhance	   integrin	  activation	  [74][75],	  potentially	  due	  to	  the	  fact	  that	  migfilin-­‐
integrin	   binding	   disconnects	   filamin	   from	   β	   integrin	   tail,	   resulting	   in	  
talin/integrin	   interaction	   and	   integrin	   activation	   [76].	   Finally,	   kindlins	   and	  
filamins	  also	  share	  overlapping	  β-­‐integrin	  sites	  [77].	  Likewise,	  there	  is	  overlap	  
of	   integrin	   binding	   sites	   between	   kindlins	   and	   other	   inhibitors	   of	   integrin	  
activation,	  such	  as	  Integrin	  Cytoplasmic	  domain-­‐Associated	  Protein-­‐1	  (ICAP-­‐1)	  
[78][79].	  These	  findings	  suggest	  that	  kindlins	  alone	  or	  through	  recruitment	  of	  
other	  integrin-­‐activating	  proteins,	  such	  as	  migfilin,	  could	  displace	  inhibitors	  of	  
integrin	  activation,	  thus	  exposing	  talin-­‐binding	  integrin	  domains	  and	  facilitate	  
talin-­‐mediated	  integrin	  activation	  (Fig.4.B.).	  	  
	  
It	   is	  possible	   that	  kindlins	   also	   influence	   integrin	   clustering,	   thus	  promoting	  
integrin	  interaction	  with	  multiple	  ECM	  ligands	  rather	  than	  with	  a	  monovalent	  
ligand	   (Fig.4.C.).	  Multiplicity	  of	   integrin-­‐binding	  motifs	  on	   filamin	  sequence	  
could	   permit	   filamin	   to	   provoke	   integrin	   clustering,	   and	   migfilin,	   a	   protein	  
with	  multiple	  filamin	  binding	  sites,	  would	  allow	  clusters	  of	  integrin	  to	  undergo	  
activation	  following	  filamin	  displacement	  [80].	  	  
	  
In	   an	   alternative	   model,	   it	   is	   thought	   that	   kindlin	   influences	   integrin	  
activation	   events	   following	   the	   recruitment	   of	   talin	   to	   the	   integrin	   tail.	   This	  
hypothesis	   developed	   from	   the	   observation	   that	   Kin2	   depletion	   or	  
overexpression	  did	  not	   disturb	   recruitment	   of	   talin	   to	   cell	  membrane	   or	   the	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talin-­‐β3-­‐integrin	  interaction	  in	  CHO	  cells	  [81].	   In	  agreement,	  binding	  of	  Kin2	  
to	  integrin	  did	  not	  enhance	  talin-­‐β3-­‐integrin	  interaction,	  or	  vice	  versa,	  and	  no	  
interaction	   has	   been	   reported	   between	   talin	   and	   kindlin	   [82].	   It	   has	   been	  
shown	   that	   recruitment	   of	   talin	   in	   neutrophils	  was	   sufficient	   to	   induce	   low-­‐
affinity	   β2-­‐integrins	   to	   change	   into	   an	   intermediate-­‐affinity	   form,	   whilst	  
synergy	   between	   talin	   and	   Kin3	   was	   required	   for	   high-­‐affinity	   integrin	  
conformation	   (Fig.4.D.).	   Finally,	   Kin2	   was	   found	   unable	   to	   unclasp	   the	  
complex	   formed	   between	   α	   and	   β	   integrin	   cytoplasmic	   tails,	   whereas,	   as	  
mentioned	  in	  Section	  1.3.,	  talin	  is	  capable	  of	  breaking	  the	  low-­‐affinity	  integrin	  
conformation	   [82],	   indicating	   that	   talin-­‐integrin	   interactions	   may	   precede	  


















Figure	  4:	  Models	   for	   synergy	  between	   talin	  and	  kindlin	   to	  achieve	   integrin	  activation.	  A:	  Kindlin-­‐
integrin	  and	  kindlin-­‐membrane	   interactions	  could	  directly	  enable	  talin-­‐mediated	   integrin	  activation	  
by	  exposing	  talin-­‐binding	  sites	  on	  β-­‐integrin	  tail.	  B:	  Kindlin	  alone	  or	  via	  recruitment	  of	  other	  integrin-­‐
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activating	   proteins	   could	   displace	   inhibitor	   that	   occupies	   talin	   binding	   sites	   on	   β-­‐integrin	   tail,	  
facilitating	  talin	  binding	  and	  integrin	  activation.	  C:	  Kindlin	  alone	  or	  via	  recruitment	  of	  other	  integrin-­‐
activating	   proteins	   could	   displace	   inhibitors	   that	   occupy	   talin	   binding	   sites	   on	  multiple	   β-­‐integrin	  
tails,	   thus	   facilitating	   talin	   binding	   and	   activation	   of	   integrin	   clusters.	   D:	   Finally,	   kindlin	   could	   be	  
recruited	   to	   integrin	   sites	   following	   initial	   talin-­‐integrin	  binding,	   and	  alter	  an	   intermediate	   integrin	  
conformation	  to	  a	  fully	  extended,	  high-­‐affinity	  integrin	  conformation.	  (Figure	  adapted	  from	  [83]).	  	  
	  
	  
1.6.	  Kindlins	  and	  talins	  control	  bidirectional	  integrin	  signalling	  	  
Talin-­‐kindlin-­‐mediated	   integrin	   activation	   enhances	   affinity	   of	   individual	  
integrins	  or	  small	  integrin	  clusters	  for	  ECM	  adhesive	  ligands	  and	  is	  known	  as	  
inside-­‐out	  signalling.	  Signal	  transduction	  is	  a	  key	  role	  of	  integrins,	  which	  can	  
transmit	  signals	  bidirectionally.	  	  
Upon	   interaction	   of	   extracellular	   integrin	   head	   with	   ECM	   ligands,	   such	   as	  
fibronectin,	  integrins	  undergo	  conformational	  changes	  that	  initiate	  outside-­‐in	  
signalling,	   which	   transduces	   signals	   to	   the	   cell’s	   interior	   and	   regulates	  
biological	  processes	  such	  as	  cell	  proliferation,	  spreading,	  survival	  and	  assembly	  
of	  cell	  adhesion	  macromolecular	  complexes	  termed	  focal	  adhesions	  [84].	  	  
	  
Thus,	   the	   valence	   of	   talin/kindlin-­‐integrins	   binding	   regulates	   the	   extend	   of	  
inside-­‐out	   and	   outside-­‐in	   signalling.	   Reciprocally,	   ligand-­‐integrin	   head	  
interactions	   may	   also	   influence	   inside-­‐out	   signalling,	   as	   binding	   to	   ECM	  
ligands	   was	   suggested	   to	   separate	   α	   and	   β	   integrin	   transmembrane	   and	  
cytoplasmic	   domains,	   enhancing	   talin/kindlin	   access	   to	   β-­‐integrin	   tail	   [85].	  
The	   necessity	   of	   integrin	   subunit	   separation	   for	   outside-­‐in	   signalling	   was	  
emphasised	  after	  block	  of	  dissociation	  of	  α	  and	  β	  transmembrnae	  domains	  led	  
to	  defective	  cell	  spreading	  and	  focal	  adhesion	  formation	  [86].	  
	  
Focal	  adhesion	  assembly	   is	   triggered	  by	   integrin	  clustering,	  an	  event	   that,	  as	  
described	   earlier,	   is	   influenced	   by	   inside-­‐out	   clustering.	   As	   principle	  
components	   of	   inside-­‐out	   signalling,	   kindlins	   and	   talin	   are	   also	   key	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components	  of	  focal	  adhesions	  and	  can	  also	  regulate	  focal	  adhesion	  formation.	  
Specifically,	  it	  was	  shown	  that	  talin-­‐deleted	  embryonic	  stem	  cells	  	  were	  unable	  
to	   form	  paxilin-­‐	  or	  vinculin-­‐containing	   focal	  adhesions	   [87],	  and	   loss	  of	  Kin2	  
affected	   the	   formation	   of	   talin-­‐containing	   focal	   adhesions	   in	   immortalised	  
keratinocytes	   [88].	   Intriguingly,	   ECM	   ligand-­‐integrin	   binding	   further	  
augments	  clustering	  of	  activated	   integrins,	  which	  result	   in	   formation	  of	   focal	  
adhesions	  enriched	  in	  proteins	  such	  as	  FAK,	  talin	  and	  kindlin	  [89][90].	  	  
	  
1.7.	  Functional	  roles	  of	  kindlins	  in	  biological	  processes	  such	  as	  
cell	  adhesion,	  spreading	  and	  migration	  
Kin1	  and	  Kin2	  share	  a	  62%	  amino	  acid	   identity	  between	  them,	  and	  a	  49-­‐53%	  
homology	   with	   Kin3,	   from	   which	   they	   evolutionary	   diverged.	   Kindlins	   have	  
differences	   in	   tissue	   expression,	   as	   expression	   of	   Kin1	   is	   epithelium-­‐specific	  
and	   expression	   of	   Kin2	   is	   ubiquitous	   with	   the	   exception	   of	   haematopoietic	  
cells	   in	   which	   Kin3	   is	   mainly	   recorded	   [91].	   It	   was	   shown	   that	   Kin3	   is	   also	  
expressed	   in	   non-­‐haematopoietic	   cells,	   such	   as	   breast,	   skin	   and	   lung	   [92].	  
Nevertheless,	   when	   compared	   to	   haematopoietic	   cells	   expression	   of	   Kin3	   in	  
endothelial	   cells	   was	   significantly	   lower,	   and	   Kin2	   levels	   were	   higher	   in	  
endothelial	   cells	   but	   lower	   in	   haematopoietic	   cells,	   when	   compared	   to	   Kin3	  
[93].	  
	  
As	   described	   earlier,	   kindlins	   play	   a	   key	   role	   as	   integrin	   co-­‐activators	   and	  
influence	   important	   cellular	   processes	   through	   control	   of	   inside-­‐out	   or	  
outside-­‐in	   signalling.	   Specific	   kindlin	   cellular	   roles	   can	   be	   appreciated	   from	  
the	   profound	   in	   in	   vivo	   and	   in	   vitro	   defects	   observed	   following	   kindlin	  
depletion	  or	  mutations	  that	  impair	  kindlin	  function.	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1.7.1.	  Cellular	  roles	  of	  Kin1	  	  
Besides	   reduced	   integrin	   activation	   in	   vitro,	   as	   described	   earlier,	   loss	   of	  Kin1	  
results	  in	  decreased	  β1	  integrin	  activation	  in	  vivo,	  as	  observed	  in	  KS	  skin	  [37],	  
and	  in	  intestinal	  epithelium	  of	  mice	  with	  genetic	  loss	  of	  Kin1	  [54].	  Intriguingly,	  
Kin1	   was	   also	   shown	   to	   regulate	   β1	   integrin	   expression	   and	   trafficking	   in	  
keratinocytes,	   as	   a	   great	   proportion	  of	   immortalised	  KS	   cells	  were	  unable	   to	  
redistribute	   internalised	   integrins	   to	   the	   plasma	   membrane,	   a	   process	   that	  
depended	  on	  Kin1	  F3	  subdomain	  [94].	  	  	  
	  
Cultivated	   KS	   keratinocytes	   present	   reduced	   adhesion	   to	   fibronectin	   and	  
laminin	   322,	   which	   are	   well-­‐characterised	   integrin	   ligands	   [8][37][94].	  
Perturbed	   adhesion	   is	   likely	   to	   aggravate	   skin	   atrophy	   and	   fragility	   in	   KS	  
patients,	   as	   KS	   skin	   is	   characterised	   by	   tissue	   separation,	   either	   within	   or	  
below	   the	   basal	   keratinocyte	   layer	   [8].	   Severe	   adhesion	   defect	   was	   also	  
observed	   in	   Kin1-­‐null	   mouse	   intestine,	   where	   intestinal	   epithelial	   cells	  
detacheded	   from	   the	   underlying	   basement	  membrane,	   triggered	   by	   reduced	  
integrin	   activation	   [54].	   This	   led	   to	   loss	   of	   intestinal	   epithelial	   barrier	   and	  
mouse	  post-­‐natal	  lethality,	  and	  is	  likely	  to	  provide	  a	  molecular	  explanation	  for	  
ulcerative	  colitis	  in	  KS	  patients.	  Parallels	  between	  KS	  epidermis	  and	  β1	  integrin	  
mouse	   deficient	   skin,	   which	   present	   disorganised	   basement	   membrane	   and	  
discontinuous	   pattern	   of	   proteins	   such	   as	   collagen	   IV	   and	   laminin	   322	  
[8][37][95][96],	  suggest	  a	  functional	  relation	  between	  β1	  integrin	  and	  Kin1	  that	  
could	  explain	  skin	  blistering	  in	  KS.	  KS	  keratinocytes	  also	  show	  abnormal	  cell	  
shape,	  demonstrated	  in	  keratinocytes	  of	  deficient	  β1	  integrin	  mouse	  epidermis	  
as	   well,	   and	   undirected	  migration	   and	   polarisation	   [8][37][94][96].	   Kin1	   was	  
also	  important	  in	  cell	  spreading,	  as	  observed	  in	  cultured	  KS	  keratinocytes	  and	  
after	  Kin1	  knockdown	  in	  HaCat	  immortalised	  keratinocytes	  [97][94].	  
	  
Kin1	  loss	  was	  also	  shown	  to	  impair	  proliferation	  in	  vitro	  and	  in	  vivo	  [8],	  as	  well	  
as	  reduce	  stem	  cell	  markers	  in	  KS	  skin	  and	  lower	  the	  colony-­‐forming	  ability	  of	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KS	  keratinocytes	   in	   vitro	   [37],	  highlighting	  a	   role	   for	  Kin1	   in	   these	  processes.	  
Complementing	   these	   findings	   is	   the	   observation	   of	   early	   stem	   cell	   marker	  
depletion	  and	  precocious	  senescence	   in	  primary	  cultured	  KS	  keratinocytes	   in	  
contrast	   to	   healthy	   counterparts	   [98].	   Induction	   of	   premature	   senescence	   in	  
keratinocytes	   in	   the	   absence	   of	   Kin1	   could	   be	   a	   potential	   cause	   for	   KS	   skin	  
atrophy.	  
	  
Finally,	  a	  novel	  role	  for	  Kin1	  in	  mitosis	  was	  discovered	  a	  few	  years	  ago	  in	  vitro.	  
Kin1	   localisation	   was	   observed	   in	   centrosomes	   of	   mitotic	   cells	   where	   it	   was	  
shown	  to	  be	  phosphorylated	  by	  Plk-­‐1	  (polo-­‐like	  kinase-­‐1),	  a	  function	  required	  
for	  correct	  mitotic	  spindle	  formation	  and	  orientation	  [53].	  	  
 
1.7.2.	  Cellular	  roles	  of	  Kin2	  and	  Kin3	  	  
Similarly	   to	   Kin1,	   Kin2	   and	   Kin3	   play	   a	   pivotal	   role	   in	   integrin	   activation	   in	  
vivo,	   but	   since	   kindlins	   are	   expressed	   in	   distinct	   tissues,	   their	   loss	   leads	   to	  
different	  phenotypes.	  	  
	  
Disruption	   of	   Fermt2	   gene	   during	  mouse	   embryonic	   development	   results	   in	  
peri-­‐implantation	   lethality	   due	   to	   diminished	   integrin	   activation	   and	  
detachment	  of	   epiblast	   and	   endoderm	   from	  embryonic	  basement	  membrane	  
[99].	   On	   the	   other	   hand,	   human	   subjects	   with	   Kin3	   mutations	   leading	   to	  
protein	   loss	   suffer	   from	  LAD-­‐III	   (type	   III	   Leukocyte	  Adhesion	  Deficiency),	   a	  
haematopoietic	   disorder	   with	   symptoms	   of	   severe	   bleeding	   tendency	   and	  
recurrent	   infections	   [100][101].	   Symptoms	   are	   derived	   from	   inability	   of	  
leukocytes	   and	   platelets	   to	   adhere	   and	   aggregate,	   respectively,	   and	   from	  
compromised	  activation	  of	  β1,	  β2	  and	  β3	   integrins,	  as	  observed	  by	  studies	  on	  
cells	  isolated	  from	  LAD-­‐III	  patients.	  Mice	  that	  lack	  Kin3	  expression	  died	  within	  
a	   week	   of	   birth	   due	   to	   severe	   haemorrhages	   in	   gastrointestinal	   tract,	   brain,	  
bladder	  and	  skin	  that	  derived	  from	  platelet	  adherence	  dysfunction	  and	  lower	  
β3	  integrin	  activation	  [52].	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Besides	   integrin	   activation,	  Kin2	   and	  Kin3	   play	   a	   role	   in	   integrin	   trafficking,	  
which	  is	  in	  line	  with	  the	  role	  of	  Kin1	  in	  this	  process	  [52][102][103].	  Intriguingly,	  
in	  vitro	  Kin2	  loss	  not	  only	  reduced	  surface	  expression	  of	  β1	  integrins,	  but	  also	  
resulted	   in	   β1	   integrin	   accumulation	   in	   lysosomes	   and	   enhanced	   β1	   integrin	  
degradation	  [102].	  	  
	  
Finally,	  Kin2	  and	  Kin3	  also	  play	  a	   role	   in	  Kin1-­‐regulated	  cell	   features	   such	  as	  
spreading,	   cell	  migration	  and	  proliferation.	  Due	   to	   its	  ubiquitous	  expression,	  
Kin2	   regulates	   these	   processes	   in	   a	   variety	   of	   cell	   types.	   For	   example,	   Kin2	  
demonstrated	   a	   role	   in	   cell	   spreading	   in	   mouse	   embryonic	   stem	   cells	   and	  
mouse	   osteoblasts,	   and	   in	   migration	   in	   vascular	   smooth	   muscle	   cells	  
[99][104][105].	   Moreover,	   Kin2-­‐null	   mice	   showed	   reduced	   chondrocyte	  
proliferation,	  and	  Kin2	  depletion	  decreased	  mouse	  osteoblast	  proliferation	   in	  
vitro,	   highlighting	   the	   role	   of	   Kin2	   in	   proliferation	   [104][106].	   In	   a	   similar	  
manner,	  Kin3	  controls	  cell	  spreading	  in	  haematopoietic	  cells,	  such	  as	  platelets	  
and	   neutrophils,	   is	   required	   to	   retain	   proliferation	   of	   haematopoietic	   stem	  
cells,	   and	   demonstrates	   a	   role	   in	   regulation	   of	   cell	   migration	   in	   leukocytes	  
isolated	  from	  LAD-­‐III	  patients	  [52][101][107][108].	  	  
	  
1.7.3.	  Overlapping	  and	  distinct	  cellular	  roles	  of	  Kin1	  and	  Kin2	  	  
Due	  to	  similarities	  in	  various	  Kin1	  and	  Kin2	  functions,	  and	  expression	  of	  Kin1	  
and	  Kin2	  in	  epithelial	  cells,	  studies	  have	  scrutinised	  whether	  the	  two	  proteins	  
also	  share	  overlapping	  functions	  in	  tissues	  where	  they	  are	  co-­‐expressed,	  and	  if	  
they	   can	   compensate	   for	   each	   other’s	   loss.	   Kin1	   and	   Kin2	   show	   functional	  
redundancy	   in	   cell	   adhesion,	   survival	   and	   β1	  integrin	   activation	   [88][94].	  
Nonetheless,	  presence	  of	  endogenous	  Kin2	  is	  unable	  to	  compensate	  the	  loss	  of	  
Kin1	   in	  KS	  and	  mouse	  models	  of	  Kin1	   loss,	   suggesting	   that	  distinct	   functions	  
may	  exist	  between	  the	  two	  protein	  isoforms.	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Indeed,	  whereas	  cell-­‐cell	  contacts	  and	  talin-­‐containing	  focal	  adhesions	  in	  Kin1-­‐
depleted	  keratinocytes	  resembled	  the	  ones	   formed	  by	  control	  cells	   to	  a	  great	  
extend,	   they	   were	   severely	   malformed	   in	   Kin2-­‐depleted	   cells	   [88].	   Likewise,	  
migration	  of	  keratinocytes	  was	  particularly	  impacted	  by	  lack	  of	  Kin2	  compared	  
to	   Kin1,	   highlighting	   important	   distinct	   functions	   between	   the	   two	   protein	  
isoforms	   [88].	   Additionally,	   despite	   its	   normal	   expression	   and	   effective	   focal	  
adhesion	   localisation,	   Kin1	   was	   unable	   to	   rescue	   impaired	   keratinocyte	  
spreading	   in	   Kin2-­‐depleted	   keratinocytes,	   further	   emphasising	   functional	  
differences	   between	   Kin1	   and	   Kin2	   [109].	   Interestingly,	   Kin2,	   but	   not	   Kin1,	  
showed	   localisation	   at	   cell-­‐cell	   contacts	   in	   vitro	   and	   in	   vivo,	   indicating	   that	  
differential	   subcellular	   compartment	   localisation	   of	   the	   two	   proteins,	   and	  
could	   justify	   why	   Kin1	   and	   Kin2	   cannot	   compensate	   for	   each	   other’s	   loss	   in	  
vitro	  or	  in	  vivo	  [54][91]	  .	  	  	  	  
 
1.8.	  Kindlins	  in	  cancer	  	  
1.8.1.	  Roles	  of	  kindlins	  in	  tumour	  promotion	  	  
Kindlin	  overexpression	  has	  been	  reported	  in	  a	  variety	  of	  primary	  tumours	  and	  
cancer	  cell	  lines.	  Particularly,	  enhanced	  expression	  levels	  of	  Kin1	  were	  found	  in	  
lung,	  colon	  and	  hepatocellular	  carcinoma	  as	  well	  as	  pancreatic	  cancer	  cell	  lines	  
[110]–[112],	   of	  Kin2	   in	  malignant	  mesothelioma	   cell	   lines	   [113],	   and	  of	  Kin3	   in	  
breast	  cancer	  [114].	  	  
	  
A	   plethora	   of	   studies	   has	   implicated	   kindlins	   in	   cancer	   progression	   via	   the	  
employment	   of	   various	   signalling	  pathways.	  Kin1	   expression	   showed	  positive	  
correlation	   with	   breast	   cancer	   lung	   metastasis,	   and	   orthotopic	   injection	   of	  
Kin1-­‐depleted	  breast	  cancer	  cells	  reduced	  tumour	  growth	  and	  inhibited	  breast	  
cancer-­‐lung	  metastasis	  [115].	  In	  vitro,	  Kin1	  overexpression	  in	  poorly	  metastatic	  
breast	   cancer	   cell	   line	   enhanced	   proliferation	   and	   migration,	   and	   induced	  
transforming	   growth	   factor-­‐β	   (TGF-­‐β)	   dependent	   epithelial	   to	  mesenchymal	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transition	  (EMT)	  [115].	  Notably,	  Kin1	  expression	  levels	  are	  also	  higher	  in	  other	  
types	  of	  epithelial	  tumours	  that	  spread	  to	  the	  lungs	  such	  as	  colon	  and	  bladder,	  
compared	   to	   cancers	   that	   do	   not	   show	   lung	  metastasis	   such	   as	   ovarian	   and	  
prostate	  [115].	  Moreover,	  Kin1	  expression	  correlated	  positively	  with	  metastatic	  
status	   and	   tumour	   size	   and	   aggressiveness	   in	   hepatocellular	   carcinoma,	   and	  
inhibition	   of	   Kin1	   supressed	   pancreatic	   cancer	   cell	   migration	   and	   invasion	  
although	   no	   underlying	   molecular	   mechanism	   has	   been	   proposed	   for	   these	  
observations	  [111][112].	  	  
	  
Concurrent	   enhanced	   expression	   of	   Kin2	   and	   ILK	   at	   the	   invasion	   front	   of	  
malignant	  mesothelioma	  tumours	   suggested	  a	  putative	   link	  between	   the	   two	  
proteins	   in	   tumour	   progression,	   although	   this	   is	   yet	   to	   be	   examined	   [113].	  
Interestingly,	   in	   vitro	   expression	   of	   ILK	   in	  malignant	  mesothelioma	   rescued	  
impaired	   cell	   migration	   caused	   by	   Kin2	   depletion,	   which	   strengthened	   the	  
hypothesis	   for	   potential	   association	   between	   Kin2	   and	   ILK	   in	   tumour	  
progression	   [113].	   Furthermore,	  Kin2	   promoted	   breast	   cancer	   cell	   invasion	   in	  
vitro	  and	  tumour	  growth	  in	  vivo,	  which	  was	  achieved	  via	  epigenetic	  repression	  
of	  micro	  RNA	  miR-­‐200b	  [116].	  In	  particular	  Kin2	  formed	  a	  complex	  with	  DNA	  
methyltransferase	   3A,	  which	  occupied	  miR-­‐200b	  promoter	   and	   induced	  CpG	  
island	   hypermethylation	   of	   miR-­‐200b	   [116].	   An	   alternative	   mechanism	   for	  
Kin2-­‐induced	  tumour	  progression	  in	  breast	  cancer	  has	  also	  been	  proposed,	  as	  
Kin2	   was	   shown	   to	   interact	   with	   EGFR,	   and	   stabilise	   EGFR	   expression	   by	  
inhibiting	   its	   degradation,	   ultimately	   promoting	   EGF-­‐induced	   breast	   cancer	  
cell	   migration	   [117].	   Finally,	   Kin2	   demonstrated	   a	   pivotal	   role	   in	   prostate	  
angiogenesis	   and	   normal	   vessel	   formation	   and	  maturation	   in	   vivo,	  which,	   in	  
turn,	   regulated	   tumour	   growth	   and	   was	   dependent	   on	   Kin2-­‐mediated	   β3	  
integrin	  activation	  [118].	  	  
	  
Kin3	   also	   demonstrated	   a	   role	   in	   tumour	   progression	   via	   regulation	   of	  
angiogenesis.	   In	   vivo,	   expression	   of	   Kin3	   was	   significantly	   higher	   in	   breast	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tumours	  compared	  to	  normal	  tissue,	  and	  breast	  tumours	  with	  higher	  levels	  of	  
Kin3	  had	  increased	  vascularisation	  and	  lung	  metastasis	  [114].	  Mechanistically,	  
Kin3	   overexpression	   in	   breast	   cancer	   cells	  was	   accompanied	   by	   enhanced	   β1	  
integrin	  activation	  and	  increased	  production	  of	  Twist,	  a	  tumour	  angiogenesis-­‐
promoting	  transcription	  factor,	  and	  vascular	  endothelial	  growth	  factor	  (VEGF)	  
[114].	   It	  was	   established	   that	  Kin3	  maintains	   a	   crosstalk	  between	  β1	   integrins	  
and	   Twist	   to	   promote	   VEGF	   production	   and	   enhance	   tumour	   angiogenesis,	  
which	  is	  likely	  to	  contribute	  to	  the	  metastasis	  observed	  in	  this	  model.	  
	  
1.8.2.	  Roles	  of	  kindlins	  in	  tumour	  suppression	  	  	  
Nonetheless,	   kindlin	   expression	   was	   also	   demonstrated	   to	   hinder	   tumour	  
progression,	   and	   tumour-­‐suppressor	   mechanisms	   for	   kindlins	   have	   been	  
identified	  over	  the	  years.	  
	  
As	   aforementioned	   in	  Section	   1.1.,	   one	  of	   the	  main	  pathologies	   of	  KS	   is	   the	  
predisposition	   to	   aggressive	   SCC	   that	   often	   results	   in	   patient	   mortality.	   A	  
single	   study	   has	   addressed	   the	   mechanism	   for	   SCC	   predisposition,	   by	  
concluding	  that	  Kin1	  sustains	  an	  equilibrium	  between	  Wnt	  tumour-­‐promoting	  
signals	  and	  TGF-­‐β	  tumour-­‐supressing	  signals,	  which	  is	  disturbed	  following	  loss	  
of	  Kin1,	  resulting	  in	  cutaneous	  stem	  cell	  hyperactivation	  and	  enhanced	  growth	  
of	   skin	   tumours	   [119].	  Despite	   the	  pathology’s	   severity,	   the	  molecular	   reason	  
underlying	  aggressiveness	  of	  SCC	  developed	  KS	  is	  yet	  to	  be	  addressed.	  	  
	  
Expression	  of	  Kin1	   in	  non-­‐small-­‐cell	   lung	  cancer	  was	  also	  shown	  to	  inhibit	   in	  
vitro	   cell	  migration	   and	   in	   vivo	   tumour	   growth	   via	   inhibition	   of	   EMT	   [120].	  
Notably,	  Kin1	  and	  Kin2	  presented	  counteracting	  functional	  roles	  in	  this	  model,	  
as	   Kin2	   expression	   in	   non-­‐small-­‐cell	   lung	   cancer	   promoted	   EMT,	   cell	  
migration	  and	  tumour	  growth.	  In	  sharp	  contrast,	  Kin2	  expression	  was	  reduced	  
in	   serous	   epithelial	   ovarian	   cancer	   where	   Kin2	   induced	   mesenchymal-­‐to-­‐
epithelial	  transition	  and	  inhibited	  cell	  peritoneal	  dissemination,	  a	  process	  that	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can	   normally	   lead	   to	   metastasis	   [121].	   Clinically,	   low	   Kin2	   levels	   showed	  
positive	  correlation	  with	  tumour	  grade	  and	  longer	  survival	  [121].	  	  
	  	  
Finally,	  Kin3	  expression	  in	  melanoma,	  lung	  and	  breast	  cancer	  was	  significantly	  
reduced	  when	  compared	  to	  normal	  tissue,	  which,	  as	  suggested,	  was	  achieved	  
by	  the	  significantly	  higher	  levels	  of	  FERMT3	  promoter	  hypermethylation	  found	  
in	   tumours	   samples	   [92].	   Kin3	   downregulation	   enhanced	   lung	  metastasis	   in	  
melanoma	   and	   breast	   cancer	   cell	   lines,	   led	   to	   in	   vitro	   impairment	   of	   talin-­‐
integrin	   interaction	   and	   reduction	   of	   β3	   integrin	   activation,	   and	   promoted	  
internalisation	  of	  active	  β3	   integrins	   [92].	  Consequences	  of	   impaired	   integrin	  
function	   after	   Kin3	   depletion	   decreased	   cell	   adhesion	   and	   enhanced	   cell	  
invasion,	  which	  can	  justify	  in	  vivo	  enhancement	  of	  metastasis	  [92].	  	  	  
	  
1.9.	  project	  aims	  
Skin	  atrophy,	  which	  has	  been	   linked	   to	   reduced	  keratinocyte	  proliferation	   in	  
KS	   epidermis,	   and	   development	   of	   aggressive	   SCC	   are	   two	   of	   the	   most	  
prominent	   pathologies	   of	   KS.	   In	   particular,	   the	   progressive	   nature	   of	  
epidermal	  atrophy	  leads	  to	  a	  lifetime	  of	  cutaneous	  fragility	  that,	  in	  turn,	  causes	  
skin	   tears,	   wounds	   and	   bleeding,	   whilst	   the	   aggressive	   behaviour	   of	   SCC	  
increases	   morbidity	   and	   risk	   of	   fatality	   in	   KS	   patients.	   As	   molecular	  
mechanisms	   that	   underline	   reduced	   keratinocyte	   proliferation,	   which	   could	  
contribute	  to	  skin	  atrophy,	  and	  development	  of	  SCC	  in	  KS	  are	  undefined,	  this	  
thesis	   has	   focused	   in	   establishing	   a	   role	   of	   Kin1	   in	   skin	   homeostasis	   and	  
development	  of	  SCC.	  	  
	  
The	  aims	  of	  this	  study	  were:	  
1.	  Develop	  and	  characterise	  the	  epidermis	  of	  a	  mouse	  model	  of	  Kin1	  loss.	  
2.	  Use	  mouse	  model	   of	  Kin1	   loss	   in	   order	   to	   explore	   the	   recently	   discovered	  
role	  of	  Kin1	  in	  mitosis,	  in	  the	  context	  of	  skin	  homeostasis.	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3.	  Use	  live	  cell	  imaging	  and	  characterise	  in	  detail	  the	  role	  of	  Kin1	  and	  Kin2	  in	  
mitosis	  in	  epithelial	  cells.	  
4.	  Examine	  if	  Kin1	  and	  Kin2	  have	  overlapping	  or	  distinct	  functions	  in	  mitosis	  in	  
epithelial	  cells.	  	  
5.	  Generate	  and	  characterise	  growth	  kinetics	  of	  mouse	  SCC	  cell	  lines	  that	  lack	  
Kin1,	  express	  Kin1	  or	  express	  integrin-­‐binding	  mutant	  of	  Kin1.	  
6.	  Generate	  mouse	  SCC	  tumours	  that	  lack	  Kin1	  or	  express	  Kin1.	  	  
7.	  Explore	  roles	  of	  Kin1	  in	  SCC	  tumour	  development	  and	  progression.	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Chapter	  2:	  materials	  and	  methods	  
2.1.	  Cell	  culture	  	  
2.1.1.	  Cell	  line	  maintenance	  
Unless	   stated	   otherwise,	   all	   cell	   lines	   were	   cultured	   in	   DMEM	   (Dulbecco's	  
modified	   eagle’s	   medium)	   (Invitrogen)	   with	   10%	   FBS	   (Fetal	   Bovine	   Serum)	  
(Invitrogen),	  supplemented	  with	  2mM	  L-­‐glutamine	  (Gibco),	  and	  incubated	  at	  
370C	  and	  5%	  CO2.	  Cell	   lines	  were	   routinely	   tested	   for	  mycoplasma	  and	  were	  
negative.	  Routine	  subculture	  was	  performed	  twice	  a	  week	  when	  cells	  reached	  
70-­‐80%	  confluency.	  	  
	  
2.1.2.	  Generation	  of	  MDA-­‐MB-­‐231H2B:DsRed	  cell	  line	  
MDA-­‐MB-­‐231	   cells	   (American	   Type	   Culture	   Collection)	   were	   transfected	  
using	  1μg	  of	  Histone	  H2B:DsRed	  plasmid	  DNA	  and	  Lipofectamine	  RNAiMAX	  
(Invitrogen)	  according	  to	  manufacturer’s	  instructions.	  The	  plasmid	  used	  was	  
based	  on	  pcDNA2.1	  backbone	  and	  was	  kindly	  given	  to	  us	  by	  Dr	  Viji	  Draviam.	  
Prior	   to	   transfection,	   One	   Shot	   TOP10	   chemically	   competent	   bacteria	  
(ThermoFischer	  Scientific)	  were	  transformed	  using	  heat-­‐shock	  protocol	  and	  
selected	   with	   Ampicillin,	   and	   plasmid	   isolation	   was	   performed	   with	  
Miniprep	  kit.	  	  
	  
Transfected	   cells	  were	   subsequently	   incubated	   for	   72	   hours	   in	  DMEM+10%	  
FBS,	   at	   370C	   and	   5%	  CO2.	   Subsequently,	   5x107	  cells	   at	   concentration	   of	   1x107	  
cells/ml	  were	  subjected	  to	  fluorescence-­‐activated	  cell	  sorting	  (FACS)	  with	  the	  
use	  of	  594nm	  laser	   for	  DsRed	  excitation.	  Resulting	  MDA-­‐MB-­‐231H2B:DsRed	  cells	  
were	   maintained	   in	   DMEM+10%	   FBS	   supplemented	   with	   1:100	   ampicillin	  
(ThermoFischer	   Scientific),	   in	   order	   to	   sustain	   selection	   of	   H2B:DsRed-­‐
expressing	  cells,	  at	  370C	  and	  5%	  CO2.	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HeLaH2B:GFP/β-­‐tub:DsRed	  cells,	  which	  were	  kindly	  given	  to	  us	  by	  Dr	  Viji	  Draviam,	  
were	  maintained	   in	   DMEM+10%	   FBS	   supplemented	   with	   1:100	   geneticin	   (G-­‐
418)	   (ThermoFischer	   Scientific),	   in	   order	   to	   sustain	   selection	   of	  H2B:DsRed-­‐
expressing	  cells,	  at	  370C	  and	  5%	  CO2.	  
	  	  	  
2.1.3.	  RNA	  interference,	  live	  cell	  imaging	  and	  cell	  viability	  assay	  	  
2.1.3.1.	  RNA	  interference	  in	  MDA-­‐MB-­‐231	  and	  HeLa	  cell	  lines	  
Small	   interfering	   RNA	   (siRNA)	   treatments	   in	   MDA-­‐MB-­‐231H2B:DsRed	   and	  
HeLaH2B:GFP/β-­‐tub:DsRed	   cells	   were	   performed	   with	   the	   use	   of	   Lipofectamine	  
RNAiMAX	   (Life	   Technologies),	   according	   to	  manufacturer’s	   instructions.	   All	  
siRNA	  oligos	  were	  purchased	   from	  Dharmacon	  RNAi	  Technologies	  and	  were	  
used	  at	  a	  final	  concentration	  of	  60nM	  for	  MDA-­‐MB-­‐231H2B:DsRed	  cells	  and	  90nM	  
for	   HeLaH2B:GFP/β-­‐tub:DsRed	   cells.	   For	   Kin1+Kin2	   co-­‐depletion	   in	   HeLaH2B:GFP/β-­‐
tub:DsRed	   cells,	   combination	  of	  Kin1UTR1,	  Kin1UTR2,	  Kin2ORF1	   and	  Kin2ORF2.	   siRNA	  
oligos	   were	   used	   at	   a	   final	   concentration	   of	   90nM.	   Media	   was	   changed	   24	  
hours	  post-­‐transfection,	  with	  the	  addition	  of	   fresh	  DMEM+10%FBS.	  Duration	  
of	  siRNA	  treatment	  lasted	  48	  hours	  for	  MDA-­‐MB-­‐231H2B:DsRed	  cells	  and	  72	  hours	  
for	  HeLaH2B:GFP/β-­‐tub:DsRed	   cells,	   after	  which	   cells	  were	   either	   lysed	   or	   used	   for	  
live	  cell	  imaging.	  siRNA	  was	  performed	  in	  dishes	  if	  cells	  were	  destined	  for	  lysis,	  
and	   in	   chambered	   glass	   coverslips	   (Cover	   glass	   Lab-­‐tek	   Chambers,	   FISHER)	  
covered	  with	  collagen	  I	  diluted	  in	  acetic	  acid	  (3.33μl/ml)	  if	  cells	  were	  destined	  
for	  live	  cell	  imaging.	  	  
	  
2.1.3.2.	  Live	  cell	  imaging	  of	  MDA-­‐MB-­‐231	  and	  HeLa	  cell	  lines	  
Prior	   to	   live	   cell	   imaging,	   cell	   media	   was	   replaced	   with	   Leibovitz’s	   L-­‐15	  
Medium	   (ThermoFischer	   Scientific),	   which	   supports	   cell	   growth	   in	  
environments	   that	   lack	   CO	   equilibrium.	   Cells	   were	   imaged	   at	   37°C.	   Images	  
were	  captured	  every	  10	  minutes	  for	  a	  total	  of	  8	  hours	  with	  a	  40x0.85	  NA	  Plan-­‐
Apochromat	   objective	   lens	   (CarlZeiss	   UK,	   Cambridge,	   UK)	   on	   a	   Zeiss	   Axio-­‐
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Observer	   Z1	   inverted	   microscope	   equipped	   with	   a	   Lumencor	   Spectra	   XLED	  
light	   source	   (Lumencor	   Inc,	   Beaverton,	   OR)	   and	   a	   Photometrics	   Coolsmap	  
HQ2	  CCD	  camera	  (Photometrics,	  Tucson,	  AZ).	  Exposures	  of	  0.1	  seconds	  were	  
applied	  for	  GFP	  channel	  and	  of	  0.3	  seconds	  for	  RFP	  channel.	  Every	  image	  was	  
captured	  on	  five	  Z	  planes	  separated	  by	  1μm.	  Mitosis	  images	  were	  combined	  in	  
an	   8	   hour-­‐long	   video	   automatically	   by	   Micro-­‐Manager	   software	   [122]	   and	  
phenotype	  assessment	  and	  quantification	  was	  performed	  manually,	  in	  a	  blind	  
fashion.	  	  
	  
2.1.3.3.	  Alamar	  blue	  cell	  viability	  assay	  in	  HeLa	  cell	  lines	  
72	  hours	  following	  siRNA	  treatment,	  alamar	  blue	  assay	  was	  used	  to	  assess	  cell	  
viability	   in	  HeLa	   cells.	   To	   achieve	   this,	   cell	   culture	  media	  was	   removed	   and	  
was	   implemented	  with	   10%	  alamar	  blue	   (Thermo	  Fisher	  Scientific),	   and	  cells	  
were	  incubated	  with	  the	  mix	  for	  3h	  at	  37oC.	  Fluorescence	  was	  then	  measured	  
as	  indicator	  of	  cellular	  activity	  at	  590nm	  emission	  wavelength.	  The	  assays	  were	  
performed	  in	  96-­‐well	  plates,	  48h	  post-­‐siRNA	  treatments	  in	  triplicates.	  	  
	  
	  
2.1.4.	  Incucyte	  cell	  count	  proliferation	  assay	  	  
We	  used	  Incucyte	  real-­‐time	  live-­‐cell	  analysis	  system	  (Essen	  Instruments,	  Ann	  
Arbor,	   MI,	   USA)	   to	   assess	   cell	   proliferation	   in	   two-­‐dimensional	   cell	   culture	  
conditions,	   according	   to	  manufacturer’s	   instructions.	   Cells	   were	   seeded	   at	   a	  
density	  of	   1500	  cells/well	   in	  96	  well	  plates,	  and	  were	  immediately	  transferred	  
in	  Incucyte	  system,	  which	  was	  kept	  within	  a	  370C+5%	  CO2	  incubator.	  Phase-­‐
contrast	   images	   were	   captured	   directly	   after	   plates	   were	   placed	   within	  
Incucyte,	  which	  determined	  the	  exact	  cell	  density	  at	  0	  hours,	  and	  every	  3	  hours	  
after	  that.	  Images	  were,	  eventually,	  combined	  by	  Incucyte	  to	  form	  time-­‐lapse	  
microscopy	  movies.	  Cell	  density	  quantification	  of	  every	  phase-­‐contrast	   image	  
was	  performed	  automatically	  by	  Incucyte	  control	  software.	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2.1.5.	  Methylcellulose-­‐over-­‐agarose	  proliferation	  assay	  	  
We	   used	   methylcellulose-­‐over-­‐agarose	   assay	   to	   assess	   cell	   proliferation	   in	  
three-­‐dimensional	  cell	  culture	  conditions.	  For	  this	  assay,	  we	  transformed	  cell	  
culture	   plastic	   dishes	   into	   low-­‐adherent	   dishes	   by	   plating	   a	   combination	   of	  
1.8%	   UltraPure	   agarose	   (Invitrogen)	   and	   DMEM+10%FBS	   to	   a	   1:1	   ratio,	   and	  
subsequently	   stored	  at	  40C	  overnight.	  On	  the	  day	  of	   the	  experiment,	  desired	  
amount	  of	  cells	  were	  counted,	  pelleted	  and	  resuspended	   in	  DMEM+20%FBS.	  
Resuspended	   cells	   were	   then	   passed	   through	   a	   single	   cell	   filter	   (Stem	   Cell	  
Technologies)	   to	   ensure	   single-­‐cell	   suspension,	   and	   cells	   were	   added	   to	   3%	  
methylcellulose	  (StemCell)	  to	  a	  1:1	  ratio.	  Cells	  were	  subsequently	  plated	  on	  the	  
pre-­‐prepared	   agarose	   dishes,	   and	   immediately	   phase	   contrast	   images	   were	  
captured.	   For	   every	   cell	   line	   there	   were	   3	   repeats	   of	   methylcellulose-­‐over-­‐
agarose	   dishes,	   and	   for	   every	   plate	   5	   low-­‐power	   field	   images	  were	   captured.	  
Phase	  contrast	  images	  were	  captured	  on	  Day0,	  Day1,	  Day3	  and	  Day6	  and	  were	  
used	  to	  manually	  determine	  the	  area	  of	  every	  spheroid	  formed	  with	  the	  use	  of	  
ImageJ	  software.	  
	  
2.2.	  Animal	  models	  and	  cell	  culture	  
2.2.1.	  Generation	  of	  mouse	  model	  of	  Kin1	  loss	  	  
Kin1	   loss	   in	  adult	  mouse	  epidermis	  was	  performed	  as	   illustrated	   in	  Figure	   6.	  
Kin1fl/fl	  transgenic	  mice,	  in	  which	  exons	  4	  and	  5	  of	  FERMT1	  gene	  were	  floxed	  by	  
loxP	  sites,	  was	  crossed	  with	  a	  K14-­‐Cre-­‐ERT2	  (K14-­‐Cre)	  mouse	  [123]	   to	  generate	  
K14-­‐Cre-­‐ERT2-­‐Kin1fl/fl	   (K14-­‐Cre-­‐Kin1fl/fl)	   conditional	  knockout	  mouse	   line.	  Cre-­‐
ERT2	   represents	   the	   fusion	   between	   mouse	   epidermis	   Cre-­‐recombinase	   and	  
estrogen	   receptor	   (ER),	   and	  was	   expressed	  under	   the	   control	   of	  K14	   (keratin	  
14)	  promoter	  [124].	  Adult	  (28-­‐day	  old)	  K14-­‐Cre-­‐Kin1fl/fl	  and	  K14-­‐Cre	  mice,	  were	  
subjected	   to	   daily	   subcutaneous	   injections	   of	   100μg	   4OHT	   (4-­‐
hydroxytamoxifen)	   (Sigma-­‐Aldrich),	   resulting	   in	   the	   translocation	   of	  
cytoplasmic	   Cre-­‐ERT2	   to	   the	   nucleus	   [123][124].	   In	   K14-­‐Cre-­‐Kin1fl/fl	   mice	   this	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resulted	  in	  Cre	  recombination	  at	  loxP	  sites	  [125],	  deletion	  of	  exons	  4	  and	  5	  and	  
knockout	  of	  Fermt1.	  Duration	  of	  4OHT	  treatment	  lasted	  5	  days.	  From	  the	  end	  
of	   the	  4OHT	   treatment	  until	  mouse	   scarification,	   animals	  were	   checked	  and	  
weighed	  regularly.	  	  
	  
Mice	  were	  sacrificed	  using	  cervical	  dislocation,	  and	  tails	  and	  dorsal	  skin	  were	  
collected	  5	  days,	   10	  days	  or	   1	   year	   following	   the	  end	  of	   the	  4OHT	  treatment.	  
Dorsal	   skin	   was	   fixed	   overnight	   in	   neutral-­‐buffered	   10%	   formaldehyde	  
(Surgipath	   Europe)	   for	   later	   immunohistochemical	   analysis.	   Dorsal	   skin	   of	  
mice	   that	  were	  kept	   for	   1	   year	   after	   the	   termination	  of	  4OHT	   treatment	  was	  
shaved	   8	   months	   following	   the	   end	   of	   4OHT	   treatment	   and,	   subsequently	  
photographed	   on	   a	   regular	   basis	   to	   monitor	   hair	   growth	   and	   overall	   skin	  
appearance.	  	  
	  
All	  mice	  were	   bred	   and	  maintained	   on	   an	   FVB	   genetic	   background.	   Animal	  
husbandry	   and	   breeding	   were	   carried	   out	   by	   the	   staff	   of	   the	   Institute	   of	  
Genetics	   and	  Molecular	  Medicine,	   University	   of	   Edinburgh.	   Genotyping	  was	  
performed	  by	  Transnetyx	  with	  the	  use	  of	  ear	  notch	  tissue	  from	  at	  least	  14-­‐day	  
old	  mice.	  All	  animal	  experiments	  (Sections	  2.2.1.,	  2.2.3.	  and	  2.4.)	  were	  carried	  
out	   in	   compliance	   with	   UK	   Home	   Office	   guidelines	   and	   with	   the	   help	   of	  
Morwenna	  Muir.	  
	  
2.2.2.	  Isolation	  of	  mouse	  primary	  keratinocytes	  	  
Following	   mouse	   sacrifice,	   skin	   was	   removed	   from	   tails	   of	   mice	   and	   was	  
incubated	   in	   4mg/ml	   dispase	   (Gibco)	   diluted	   in	   PBS	   for	   3	   hours	   at	   37°C.	  
Subsequently,	   tail	   epidermis	   was	   separated	   from	   dermis	   and	   dissected	   into	  
minor	  pieces	  that	  were	  then	  incubated	  in	  trypsin	  diluted	  in	  PBS-­‐EDTA	  for	  10	  
minutes	   at	   37oC.	   To	   aid	   cell	   disaggregation,	   solution	   was	   subjected	   to	   brief	  
vortex.	   Addition	   of	   DMEM	   supplemented	   with	   20%	   FBS	   (Invitrogen)	  
neutralised	  trypsin,	  and	  the	  solution	  was	  sieved	  through	  a	  70μm	  cell	  strainer	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(Becton	   Dickinson).	   Centrifugation	   collected	   cells	   into	   a	   pellet	   that	   was	  
washed	  with	  PBS,	  and	  this	  was	  repeated	  two	  times.	  Cells	  were	  then	  plated	  on	  
tissue	  culture	  dishes	  (Greiner	  bio-­‐one)	  coated	  with	  collagen	  I	  diluted	  in	  acetic	  
acid	  (3.33μl/ml)	  and	  maintained	  in	  keratinocyte	  basal	  medium	  supplemented	  
with	  SingleQuotes	  kit	  (Clonetics)	  in	  37oC	  and	  5%	  CO2.	  Tail	  keratinocytes	  were	  
incubated	   for	   4	   days,	   after	   which	   they	   were	   collected	   for	   generation	   of	   cell	  
lysate.	  	  
2.2.3.	  Generation	  of	  mouse	  SCC	  tumour	  cell	  lines:	  117	  SCC	  cells,	  130	  
SCC	  cells	  and	  145	  SCC	  cells	  	  
Two-­‐stage	   chemical	   carcinogenesis	   protocol	   [126][127]	   had	   been	   previously	  
applied	  by	  Dr	  Hitesh	  Patel,	  as	   follows,	   to	  generate	  mouse	  SCC	  tumours	   in	  K14-­‐
Cre-­‐Kin1fl/fl	   mice,	   as	   depicted	   in	   Figure	   30.	   A	   single	   application	   of	   7,12-­‐
dimethylbenz[a]anthracene	  (DMBA)	  was	  followed	  by	  repeated	  applications	  of	  
phorbol	   ester	   12-­‐O-­‐tetradecanoylphorbol	   13-­‐acetate	   (TPA).	   This	   led	   to	   the	  
formation	  of	  benign	  cutaneous	  papillomas,	  some	  of	  which	  progressed	  to	  form	  
cutaneous	  SCC	  tumours	  in	  3	  different	  mice	  (mouse	  no.117,	  no.130	  and	  no.145).	  
Mouse	   SCC	   tumours	   were	   then	   removed,	   dissected	   into	   minor	   pieces	   and	  
incubated	  in	  trypsin	  diluted	  in	  PBS-­‐EDTA	  for	  10	  minutes	  at	  room	  temperature.	  
Trypsin	   was	   neutralised	   with	   addition	   of	   DMEM+10%FBS.	   Cells	   were	  
subsequently	   plated	   and	   allowed	   to	   grow	   in	  DMEM+10%	   FBS	   supplemented	  
with	  100	  units	  penicillin	  and	  streptomycin	  per	  ml	  (Sigma-­‐Aldrich)	  in	  37oC	  and	  
5%	  CO2.	  
	  
2.3.	  Cloning,	  cell	  infections	  and	  generation	  of	  Kin1null,	  Kin1wt	  
and	  Kin1AA	  mouse	  SCC	  cell	  lines	  	  
This	  protocol	  had	  been	  previously	  performed	  by	  Dr	  Hitesh	  Patel	   to	  generate	  
Kin1null,	   Kin1wt	   and	   Kin1AA	   mouse	   SCC	   cell	   lines.	   RNA	   was	   extracted	   from	  
mouse	   mammary	   mammary	   epithelial	   cells	   with	   RNeasy	   kit	   (Qiagen)	  
according	  to	  manufacturer’s	  instructions.	  SuperScript	  II	  Reverse	  Transcriptase	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and	   random	   hexameres	   (SuperScript	   First-­‐Strand	   cDNA	   synthesis	   kit,	  
Invitrogen)	   catalysed	   the	   conversion	   of	   RNA	   to	   cDNA.	   Following	   DNA	  
synthesis,	   coding	   sequence	   for	   wild-­‐type	   and	   QW611/612AA	   mutant	   Fermt1	  
(primer	   sequences	   at	   Table	   1)	   were	   amplified	   by	   PCR	   using	   the	   PfuUltra	  
Hotstart	  PCR	  master	  mix	  (Agilent	  Technologies)	  and	  run	  on	  a	  1%	  agarose	  gel.	  
DNA	  was	   isolated	   from	   the	   corresponding	   gel	   bands	  with	   the	  QIAquick	   gel	  
extraction	  kit	   (Qiagen),	   and	  cloned	   into	  pWZL-­‐Hygro	   retroviral	   vectors	  with	  
the	   use	   of	   a	   standard	   DNA	   ligation	   kit	   protocol	   (Roche),	   according	   to	  
manufacturer’s	  instructions.	  One	  Shot	  TOP10	  chemically	  competent	  bacteria	  
(ThermoFischer	  Scientific)	  were	  then	  transformed	  using	  heat-­‐shock	  protocol	  
and	   selected	   with	   Hygromycin	   (Calbiochem)	   antibiotic,	   and	   plasmid	  
isolation	  was	  performed	  with	  Maxiprep	  kit	  (Qiagen).	  	  
	  
Finally,	  pEco	  packaging	  retrovirus	  producing	  cells	  were	  transfected	  with	  5μgr	  
of	   pWZL	   plasmids	   of	   Lipofectamine	   2000	   (Invitrogen)	   according	   to	  
manufacturer’s	  instructions.	  Supernatant	  containing	  the	  produced	  retroviruses	  
was	   subsequently	   collected,	   filtered	   through	   0.45μm	   filters	   (Millipore)	   and	  
implemented	  with	   10%	  FBS	   and	   1:1000	   polybrene	   (Millipore).	   Finally,	   Kin1null	  
mouse	   SCC	   clonal	   cell	   line	   was	   infected	   with	   the	   retrovirus-­‐contaning	  
supernatant	  under	  1:100	  Hygromycin	  selection	  (Calbiochem).	  	  
	  





forward	   cgccaatatgaagcagtgg	  
	  
reverse	   gtcaaactcgattgccacct	  
	  
	  
Fermt1	  WQ611/612AA	  	  
forward	   ccagttgacattcgccgccttcatattg	  
	  
reverse	   ccagttgacattcgccgccttcatattg	  
	  
	  
Table	  1:	  List	  of	  primers	  for	  wild-­‐type	  Fermt1	  gene	  and	  Fermt1	  gene	  with	  QW611/612AA	  mutation	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2.4.	  Development	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  tumours	  	  
Kin1null,	  Kin1wt	  and	  Kin1AA	  mouse	  SCC	  cells	  were	  grown	  in	  T150	  culture	  flasks	  to	  
a	   confluency	   of	   80%	   before	   being	   harvested.	   Following	   cell	   counting,	   the	  
appropriate	  amount	  of	  cells	  was	  pelleted,	  washed	   in	  PBS	  and	  resuspended	   in	  
Hank’s	   balanced	   salt	   solution	   (Gibco)	   to	   final	   concentrations	   of	   0.25x106	   or	  
0.50x106	  or	   1.00x106	  cells/ml.	  Cell	   suspension	  was	  passed	   through	  a	   single	  cell	  
filter	  (Stem	  Cell	  Technologies)	  to	  ensure	  single-­‐cell	  suspension.	  
	  
5-­‐week	  old	  female	  athymic	  mice	  received	  bilateral	  subcutaneous	  injections	  of	  
100μl	  of	  Kin1null,	  Kin1wt	  or	  Kin1AA	  mouse	  SCC	  cells.	  Animals	  were	  monitored	  for	  
signs	  of	  growth,	  and	  tumour	  growth	  was	  measured	  twice	  a	  week	  with	  the	  use	  
of	   a	   calliper	   by	   recording	   the	   longest	   and	   shorter	   tumour	   dimensions.	   First	  
measurements	  were	  performed	  3	  days	  after	  tumour	  cell	  implantation.	  Animals	  
were	  all	  culled	  by	  cervical	  dislocation	  once	  the	  first	  ulcerated	  tumours	  began	  
to	  appear	  in	  the	  study	  or	  if	  tumours	  reached	  their	  maximum	  permitted	  size.	  	  
	  
On	   cull,	   tumours	  were	   removed	  and	   fixed	  overnight	   in	  neutral-­‐buffered	   10%	  
formaldehyde	  10%	  (Surgipath	  Europe)	  for	  later	  immunohistochemical	  analysis,	  
and	   half	   were	   snap	   frozen	   in	   liquid	   N2	   and	   stored	   at	   -­‐80oC	   for	   later	   RNA	  
extraction.	  	  
	  
2.5.	  Immunoblotting,	  Immunohistochemistry	  and	  
Immunofluorescence	  	  
2.5.1.	  Cell	  lysis,	  protein	  quantification	  and	  Immunoblotting	  	  
Cells	   to	   be	   analysed	   by	   western	   blotting	   were	   cultured	   until	   reaching	   the	  
desired	   confluency	   and	   placed	   on	   ice.	   Following	   removal	   of	   cell	  media,	   ice-­‐
cold	   PBS	  was	   used	   to	  wash	   any	   residual	  media.	   Cell	   lysis	  was	   performed	   by	  
adding	   cold	   RIPA	   cell	   lysis	   buffer	   (10	  mM	  Tris-­‐HCl	   pH	   8.0	   (Sigma-­‐Aldirch),	  
140mM	   NaCl	   (Sigma-­‐Aldrich),	   1	   mM	   EDTA	   (Sigma-­‐Aldirch),	   0.5%	   sodium	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deoxycholate	   (Thermo	   Fisher	   Scientific),	   0.1%	   SDS	   (Sigma-­‐Aldrich)	   and	   1%	  
Triton	   X100	   (Sigma-­‐Aldrich))	   supplemented	   with	   1	   proteinase	   inhibitor	  
(complete	   ULTRA	   tablet,	   Roche)	   and	   1	   phosphatase	   inhibitors	   (phosSTOP	  
tablet,	  Roche),	  for	  15	  minutes	  on	  ice.	  Cells	  were	  collected	  in	  an	  Eppendorf,	  and	  
cell	  lysis	  was	  completed	  by	  high-­‐speed	  centrifugation	  at	  13200rpm	  for	  15min	  at	  
4oC.	  	  	  	  	  
	  
Protein	   concentration	  was	   then	  defined	  using	  a	  Micro	  BCA	  protein	  assay	  kit	  
(Thermo	   Scientific)	   according	   to	  manufacturer’s	   instructions.	   Quantification	  
of	  protein	  concentration	  was	  defined	  by	  measuring	  solution	  absorbance	  using	  
a	  plate	   reader	   set	  at	  570nm.	  Unless	  otherwise	   stated,	   15μg	  of	  cell	   lysate	  were	  
used	   for	   gel	   electrophoresis	   by	   combining	   with	   6x	   Laemmli	   sample	   buffer	  
(292.5mM	  Tris	  pH6.8	  with	  HCL	  (Sigma-­‐Aldrich),	  9.36%	  SDS	  (Sigma-­‐Aldrich),	  
0.027%	   bromophenol	   blue	   (BioRad),	   glycerol	   (ThermoFisher	   Scientific),	  
0.027%	   bromophenol	   blue	   (BioRad)	   and	   10%	   β-­‐mercaptoethanol	   (Sigma-­‐
Aldrich)	   and	   10%	  β-­‐mercaptoethanol	   (Sigma-­‐Aldrich)),	   and	   incubating	   for	   10	  
minutes	   at	   95oC.	   Protein	   separation	  was	   achieved	  with	   SDS-­‐PAGE	   on	   4-­‐15%	  
mini	   protean	  TGX	   stain-­‐free	  precast	   gels	   (Biorad	  Life	   Science),	   facilitated	  by	  
addition	   of	   running	   buffer	   (10x	   Tris-­‐Glycine-­‐SDS	   running	   buffer	   in	   distilled	  
water).	  Gels	  were	  run	  at	  180V	  for	  40	  minutes.	  5μl	  of	  precision	  plus	  protein	  dual	  
colour	  standard	  marker	  (Biorad)	  was	  used,	  which	  enabled	  identification	  of	  the	  
desired	  band.	  Gels	  were	   then	   transferred	  on	  a	  nitrocellulose	   trans-­‐blot	   turbo	  
nitrocellulose	   transfer	   packs	   (BioRad)	   using	   the	   trans-­‐blot	   turbo	   transfer	  
system	   (Biorad),	   and	   incubated	   in	   5%	   bovine	   serum	   albumin	   (BSA)	  
(Calbiochem)	   diluted	   in	   TBST	   (0.15%	   Tween-­‐20	   (Thermo	   Fisher	   Scientific))	  
(5%	  TBST-­‐BSA)	  for	  1	  hour	  at	  room	  whilst	  being	  constantly	  agitated.	  	  
	  
Blots	   were	   incubated	   with	   primary	   antibody	   of	   interest	   in	   5%	   TBST-­‐BSA	  
overnight	   at	   4oC	   whilst	   being	   constantly	   agitated.	   Following,	   blots	   were	  
washed	   three	   times	   in	   TBST	   and	   incubated	   with	   the	   appropriate	   secondary	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antibodies	   for	   1	   hour	   at	   room	   temperature,	   before	   being	   washed	   further	   3	  
times	   and	   visualised.	   Visualisation	   with	   LI-­‐COR	   Odyssey	   infrared	   imaging	  
system	   required	   use	   of	   680	   and	   800	   IRDye	   fluorescent	   secondary	   antibodies	  
(Li-­‐COR)	   at	   concentrations	   recommended	   by	   the	   manufacturer.	   HRP	   anti-­‐
mouse	   and	   anti-­‐rabbit	   antibodies	   were	   used	   for	   blot	   visualisation	   with	  
enhanced	  chemiluminescence	  detection	  at	  the	  Biorad	  Chemi	  Doc	  MP	  imaging	  
system.	  	  
	  
List	  of	  primary	  antibodies	  used	  can	  be	  found	  on	  Table	  2.	  
	  
2.5.2.	  Immunohistochemistry	  	  
Formaldehyde-­‐fixed	   dorsal	   skin	   and	   tumour	   specimens	   were	   embedded	   in	  
paraffin	  and	  cut	  into	  5μm	  sections	  for	  hematoxylin	  and	  eosin	  (H&E)	  staining,	  
performed	   by	   the	   University	   of	   Edinburgh	   Histology	   Service,	   or	   antibody	  
staining	  performed	  as	  follows.	  	  
	  
Paraffin	   sections	  were	   dewaxed	  with	   2	   x	   5	  minute	  washes	   of	   xylene	   (Fischer	  
Scientific),	   followed	   by	   rehydration	   with	   5	   minute	   washes	   in	   decreasing	  
concentrations	   of	   ethanol	   (100%,	   100%,	   80%	   and	   50%).	   Sections	   were	   then	  
rinsed	   with	   water	   and	   were	   subjected	   to	   antigen	   retrieval	   by	   microwaving	  
sections	   under	   pressure	   for	   10	   minutes	   in	   10mM	   pre-­‐heated	   sodium	   citrate	  
buffer	  (pH	  6.0)	  (Fisher	  Scientific).	  Once	  cool,	  sections	  were	  briefly	  washed	  in	  
tap	  water	  and	  twice	  with	  0.0025%	  Tween20	  (Thermo	  Fisher	  Scientific)	  in	  TBS,	  
and	  outlined	  with	  an	  ImmEdge	  Hydrophobic	  barrier	  pen	  (Vector	  laboratories).	  
Subsequently,	   sections	  were	   incubated	  with	   peroxidase	   block	   (DAKO)	   for	   15	  
minutes	   at	   room	   temperature,	   which	   was	   then	   removed	   and	   sections	   were	  
washed	   briefly	   with	   water.	   Sections	   were	   then	   incubated	   with	   serum	   free	  
protein	  block	  (DAKO)	  for	  1	  hour	  at	  room	  temperature.	  
	  
Primary	   antibody,	   which	   was	   diluted	   in	   antibody	   diluent	   buffer,	   was	   then	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added	   to	   sections,	   followed	   by	   an	   overnight	   incubation	   at	   4oC.	   A	   negative	  
control	  was	   included	   in	   all	   experiments,	  which	   consistent	  of	   a	   tissue	   section	  
incubated	   with	   serum	   free	   protein	   block	   (DAKO)	   overnight.	   Following	   day,	  
sections	  were	  washed	  2	  times	  in	  0.0025%	  Tween20	  in	  TBS	  and	  incubated	  with	  
mouse	  or	  rabbit	  Envision	  (DAKO)	  secondary	  antibody	  for	  45	  minutes	  at	  room	  
temperature.	   Sections	  were	   then	  washed	   3	   times	  with	   TBS	   and	   treated	  with	  
DAB/DAB	   chromogen	   	   (DAKO)	   for	   10	  minutes	   at	   room	   temperature,	   rinsed	  
briefly	  with	  water,	  and	  counterstained	  for	  2	  minutes	  in	  haematoxylin	  (Pioneer	  
Research	   Chemicals).	   Following,	   sections	   were	   briefly	   washed	   with	   water,	  
treated	   for	   2	   minutes	   at	   room	   temperature	   with	   Scott’s	   tap	   water	   solution	  
(0.35%	   sodium	   bicarbonate	   (Sigma-­‐Aldrich)	   and	   2%	   magnesium	   sulphate	  
(Sigma-­‐Aldrich)	   in	   distilled	   water)	   and	   briefly	   washed	   with	   water	   again.	  
Finally,	  sections	  were	  dehydrated	  in	  a	  series	  of	  solutions	  of	  increasing	  ethanol	  
concentrations	   (50%,	   80%	   100%	   and	   100%),	   with	   5	   minute	   wash	   in	   each	  
solution.	   Finally,	   sections	   were	   washed	   twice	   for	   5	   minute	   in	   xylene	   before	  
being	  mounted	  DPX	  mounting	  medium	  (Fisher).	  	  
	  
Sections	   were	   scanned	   using	   NanoZoomer-­‐XR	  Digital	   slide	   scanner	  
(Hamamatsu)	   and	   visualised	   using	   NDP	   view2	  Viewing	   software	  
(Hamamatsu),	   or	   visualised	   using	   BX-­‐51	   microscope	   (Olympus)	   and	   images	  
were	   captured	   using	   CellR	   software.	   Image	   analysis	   was	   performed	   blind,	   as	  
specified	   in	   each	   figure	   legend,	   either	   manually,	   with	   the	   use	   of	   ImageJ	  
software,	   or	   with	   the	   use	   of	   ImmunoRatio	   plugin	   of	   ImageJ	   software	   [128].	  
Analysis	  and	  interpretation	  of	  histological	  staining	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
tumours	  was	  carried	  out	  with	  assistance	  of	  pathologist	  Dr	  Mark	  Arends.	  
	  
List	  of	  primary	  antibodies	  used	  can	  be	  found	  on	  Table	  2.	  
	  
2.5.3.	  Immunofluorescence	  	  
For	   tissue	   immunofluorescence,	   formaldehyde-­‐fixed	   dorsal	   skin	   and	   tumour	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specimens	   were	   embedded	   in	   paraffin	   and	   cut	   into	   5μm	   sections,	   and,	  
subsequently,	   subjected	   to	   the	   same	   treatment	   received	  by	   sections	  analysed	  
by	   Immunohistochemistry	   (Section	   2.5.2.).	   Variation	   from	  
Immunohistochemistry	   protocol	   was	   that	   instead	   of	   using	   mouse/rabbit	  
Envision	  (DAKO)	  secondary	  antibodies,	  sections	  were	  incubated	  in	  the	  dark	  at	  
room	  temperature	  with	   fluorescent	  secondary	  antibodies	   (488	  and	  594	  Alexa	  
Fluor,	  Invitrogen)	  that	  were	  diluted	  in	  antibody	  diluent	  (Dako).	  Subsequently,	  
secondary	   antibody	  was	   washed	   3	   times	   with	   TBS	   in	   the	   dark,	   and	   sections	  
were	  mounted	  with	  DAPI-­‐containing	  Vectashield	  mounting	  medium	   (Vector	  
Laboratories).	   Sections	   were	   scanned	   using	   NanoZoomer-­‐XR	  Digital	   slide	  
scanner	   (Hamamatsu)	   and	   visualised	   using	   NDP.view2	  Viewing	   software	  
(Hamamatsu).	  Image	  analysis	  was	  performed	  blind,	  as	  specified	  in	  each	  figure	  
legend,	   either	  manually,	  with	   the	  use	   of	   ImageJ	   software,	   or	  with	   the	  use	   of	  
ImmunoRatio	  plugin	  of	  ImageJ	  software	  [128].	  	  
	  
For	   cell	   immunofluorescence,	   cells	   were	   plated	   on	   sterile	   19mm	   glass	  
coverslips	  (VWR	  collection)	  and	  fixed	  and	  permeabilised	  on	  ice	  for	  10	  minutes	  
in	   cold	   fixation	   solution	   (3.7%	   formaldehyde	   (Thermo	   Fisher	   Scientific),	  
100mM	   PIPES	   (Sigma-­‐Aldrich),	   1mM	   MgCl2	   (Sigma-­‐Aldrich),	   10mM	   EGTA	  
(Sigma-­‐Aldrich)	  and	  0.2%	  Triton	  X100	  (Sigma-­‐Aldrich)).	  Following,	  cells	  were	  
washed	  3	  times	  on	  ice	  with	  0.1%	  Triton	  X100	  in	  TBS	  and	  blocked	  for	  1	  hour	  on	  
ice	  with	  2%	  BSA	  (Calbiochem)	  in	  TBST.	  Coverslips	  were	  overnight	  at	  4oC	  with	  
the	   appropriate	   primary	   antibodies	   in	   2%	  BSA	   in	   TBST,	   followed	   by	   3	   TBST	  
washes	  on	   ice	  the	   following	  day.	  Subsequently,	  coverslips	  were	   incubated	   for	  
45	  minutes	  on	  ice	  in	  the	  dark	  with	  secondary	  fluorescent	  antibodies	  (488,	  594	  
Alexa	  Fluor,	  Invitrogen).	  Finally,	  coverslips	  were	  washed	  3	  times	  on	  ice	  in	  the	  
dark	   with	   TBST,	   before	   being	   mounted	   with	   DAPI-­‐containing	   Vectashield	  
mounting	  medium	  (Vector	  Laboratories).	  	  
	  
Visualisation	   of	   immunofluorescent	   staning	   was	   performed	   in	   Olympus	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FV1000	   confocal	   microscope	   with	   the	   use	   of	   60x1.35	   NA	   UPLANSAPO	   oil	  
immersion	  objective,	  and	  Olympus	  FluoView	  FV1000	  software.	  	  
	  
List	  of	  primary	  antibodies	  used	  can	  be	  found	  on	  Table	  2.	  
	  
	  




Kin1	   Abcam	   WB	  1:2000	  
IF	  1:100	  	  
Rabbit	  
	  





CST	   WB	  1:5000	   Mouse	  
Ki-­‐67	  
	  
Vector	   IHC	  1:800	   Mouse	  
pHH3	  
	  
CST	   IHC	  1:700	   Rabbit	  
α-­‐tub	  
	  
CST	   IF	  1:4000	   Mouse	  
ac-­‐tub	  
	  
CST	   IF	  1:6000	   Rabbit	  
casp-­‐3	  
	  
CST	   IHC	  1:100	   Rabbit	  
E-­‐cadherin	  
	  
CST	   WB	  1:1000	   Rabbit	  
FAK	  
	  
CST	   IF	  1:200	   Mouse,	  Rabbit	  
CD31	  
	  
Abcam	   IHC,	  IF	  1:400	   Rabbit	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2.6.	  Second	  harmonic	  imaging	  microscopy	  
Second	   harmonic	   imaging	   microscopy	   was	   performed	   with	   the	   help	   of	   Dr	  
Martin	   Lee	   and	   enabled	   visualisation	   of	   collagen-­‐I	   in	   paraffin-­‐embedded	  
Kin1null	   and	  Kin1wt	  mouse	  SCC	   tumours.	  A	  picoEmerald	   (APE)	   laser	  provided	  
both	  a	   tunable	  pump	   laser	   (720–990  nm,	  7  ps,	  80  MHz	  repetition	   rate)	   and	  a	  
spatially	   overlapped	   second	   beam	   termed	   the	   Stokes	   laser	   (1064,	   nm,	   5–6  ps	  
and	  80  MHz	  repetition	  rate).	  The	  laser	  was	  inserted	  into	  an	  Olympus	  FV1000	  
microscope	   coupled	   to	   an	   Olympus	   XLPL25XWMP	   N.A.	   1.05	   objective	   lens	  
using	   a	   short-­‐pass	   690	   nm	   dichroic	   mirror	   (Olympus).	   Second	   harmonic	  
generation	   signals	   were	   filtered	   using	   the	   following	   series	   of	   filters:	   FF552-­‐
Di02,	   FF483/639-­‐Di01	   and	  FF420/40.	  The	  pump	   laser	  was	   tuned	   to	  816.8	  nm	  
and	  used	  50	  mW	  power	  as	  measured	  at	  the	  objective,	  whilst	   the	  Stokes	   laser	  
used	  20	  mW	  power	  as	  measured	  at	  the	  objective.	  
	  
2.7.	  Tumour	  and	  cell	  RNA	  extraction,	  RNA	  Sequencing	  and	  
quantitative	  real-­‐time	  PCR	  	  
2.7.1.	  RNA	  extraction	  	  
RNA	  was	   extracted	   from	   snapped-­‐frozen	   tumours	   that	   had	   been	   stored	   in	   -­‐
80oC	  for	  RNA	  preservation.	  Tumours	  were	  disrupted	  using	  pestle	  and	  mortar	  
that	  were	  coated	  with	  dry	  ice	  for	  1	  minute	  and	  cleaned	  with	  70%	  ethanol	  prior	  
to	  every	  tumour	  disruption.	  RNA	  was	  subsequently	  extracted	  using	  the	  RNeasy	  
kit	  (Qiagen)	  according	  to	  manufacturer’s	  instructions.	  RNA	  concentration	  was	  
determined	   with	   the	   use	   of	   NanoDrop	   Spectrophotometr	   (ThermoFischer	  
Scientific).	  	  RNA	  was	  also	  extracted	  from	  Kin1null,	  Kin1wt	  and	  Kin1AA	  cells	  grown	  
on	  two-­‐dimensional	  cell	  monolayers,	  and	  from	  Kin1null,	  Kin1wt	  and	  Kin1AA	  cells	  
grown	   on	   low-­‐adherent	   plates	   (Fischer	   Scientific),	   in	   DMEM+10%FBS.	   Cells	  
were	  plated	  at	  the	  same	  number	  (500	  000	  cells	  )	  and	  grown	  for	  48	  hours	  before	  
RNA	  extraction	  was	  performed	  using	  the	  RNeasy	  kit	  (Qiagen)	  according	  to	  the	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manufacturer’s	  instructions.	  RNA	  concentration	  was	  determined	  with	  the	  use	  
of	  NanoDrop	  Spectrophotometr	  (ThermoFischer	  Scientific).	  
	  
2.7.2.	  RNA-­‐Sequencing	  and	  analysis	  	  	  
RNA-­‐Sequencing	  (RNA-­‐Seq)	  was	  performed	  on	  tumour	  RNA	  material	  isolated	  
as	   aforementioned,	   using	   single	   read	   sequencing	   on	   the	   Illumina	   Next-­‐
Generation	  Sequencing	  platform	  by	  the	  services	  of	  GATC	  Biotech	  (Constance,	  
Germany).	   The	   average	   number	   of	   reads	   obtained	   in	  Kin1null	   samples	  was	   55	  
million,	  and	  31	  million	  in	  Kin1wt	  samples.	  	  
	  
Bioinformatics	  analysis	  was	  performed	  with	  assistance	  of	  Dr	  Stuart	  Aitken.	  48	  
million	  Kin1null	   reads	  and	  26	  million	  Kin1wt	   reads	  were	  mapped	   to	   the	  mouse	  
mm9	  reference	  genome	  using	  Tophat2	  [129]	  that	  aligns	  the	  reads	  across	  splice	  
junctions	   independently	   of	   gene	   annotations.	   Overall	   alignment	   rates	   were	  
~30%	  due	   to	   variable	  mapping	   rates	   across	   the	   replicates	   in	   each	   condition.	  
Differential	   expression	  was	  analysed	  by	  Cuffdiff	   [129]	  and	  by	  DESeq2	   [130]	   to	  
obtain	   lists	   of	   differentially	   expressed	   genes	   by	   two	   alternative	   statistical	  
techniques.	   Finally,	   reads	   were	   used	   to	   construct	   a	   Principal	   Component	  
Analysis	   (PCA),	   revealing	   variance	   in	   gene	   expression	   between	   different	  
tumour	  samples.	  	  
	  
2.7.3.	  Quantitative	  real-­‐time	  PCR	  
Tumour	   RNA	   was	   converted	   into	   cDNA	   with	   the	   use	   of	   SuperScript	   first-­‐
strand	   cDNA	   synthesis	   kit	   and	   random	   hexamer	   primers	   (Invitrogen),	  
according	  to	  manufacturer’s	  instructions.	  Quantitative	  real-­‐time	  PCR	  reactions	  
were	  performed	  with	  the	  use	  of	  SensiFAST	  Hi-­‐ROX	  kit	  (Bioline),	  as	  instructed	  
by	  the	  manufacturer.	  Primers	  (Table	   3)	  were	  used	  at	  a	  final	  concentration	  of	  
400nM,	  and	  10-­‐20ng	  of	  cDNA	  were	  used	  per	  20μl	  reaction.	  Gapdh	  expression	  
was	  used	  as	  internal	  control.	  Reactions	  were	  run	  on	  a	  StepOnePlus	  Real	  Time	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PCR	   system	   (Thermo	   Fisher	   Scientific)	   and	   quantification	   of	   relative	   gene	  









forward	   cgccaatatgaagcagtgg	  
	  




forward	   ccaagtctaactctctggaacctg	  
	  





forward	   gccagaacttcccaaccat	  
	  





forward	   ctaaagacgccgaagtgtacg	  
	  




forward	   agctcatattactgcaaataccaatc	  
	  





forward	   ccttgtggagaatggcaagt	  
	  





forward	   cactgaatgtggagcagacaa	  
	  














forward	   aaaaacgaaagcgcaagaaa	  
	  




forward	   gcctacctcaccgtgcaa	  
	  




forward	   cagtggtactggcagctagaag	  
	  




forward	   ccccaaccttcccaactc	  
	  





forward	   gactccagccacactccaac	  
	  





forward	   catccacgtgttggctca	  
	  





forward	   ttctgtgcctgctgctcata	  
	  
reverse	   ttgacatagcagcatgtggat	  
	  
	   	   	  
	  
Table	  3:	  List	  of	  primers	  used	  for	  q-­‐PCR.	  	  
	  
	  
2.8.	  Data	  statistical	  analysis	  	  
Assessment	  of	  normality	  for	  all	  data	  sets	  was	  performed	  in	  GraphPad	  Prism	  7	  
by	   the	   recommended	   D’Agostino	   &	   Pearson’s	   normality	   test.	   Statistical	  
significance	   was	   assessed	   by	   using	   unpaired	   student’s	   t-­‐test	   or	   one-­‐way	  
ANOVA	   (one-­‐way	   analysis	   of	   variance)	  with	  Tukey’s	  multiple	   comparison	   in	  
data	   that	   were	   normally	   distributed.	   Statistical	   significance	   was	   assessed	   by	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using	  Mann-­‐Whitney’s	   test	   or	   Kruskal-­‐Wallis	   one-­‐way	   ANOVA	  with	   Dunn’s	  
multiple	   comparison	   in	   non-­‐normally	   distributed	   data.	   Pearson’s	   correlation	  
coefficient	   was	   calculated	   via	   GraphPad	   Prism	   7,	   and	   compared	   correlation	  
between	   gene	   expression	   and	   tumour	   volume	   according	   to	   correlation	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  3:	  	  
development	  and	  characterisation	  of	  a	  mouse	  
model	  of	  Kin1	  loss	  
	  
Part	  of	  the	  findings	  presented	  in	  this	  chapter	  have	  been	  published	  in	  the	  following	  article:	  Patel,	  
H.,	  Stavrou,	  I.,	  Shrestha,	  R.L.,	  Draviam,	  V.,	  Frame,	  M.C.,	  Brunton,	  V.G.	  (2016).	  Kindlin1	  regulates	  
microtubule	  function	  to	  ensure	  normal	  mitosis.	  Journal	  of	  Molecular	  and	  Cell	  Biology	  8,	  338-­‐348	  
	  
Skin	  atrophy	  is	  one	  of	  the	  main	  clinical	  pathologies	  of	  KS,	  which	  in	  contrast	  to	  
other	   KS	   symptoms	   that	   tend	   to	   improve	   by	   age,	   such	   as	   skin	   blistering,	   it	  
becomes	   progressively	   worse	   [5]–[7].	   Skin	   atrophy	   has	   been	   linked	   to	  
proliferation	   defects	   that	   are	   present	   in	   keratinocytes	   of	   KS	   patients	   and	   of	  
Kin1-­‐null	   mice	   with	   KS-­‐like	   features	   [8][54].	   However,	   the	   molecular	  
mechanisms	   via	   which	   Kin1	   controls	   keratinocyte	   proliferation	   and,	   hence,	  
skin	  homeostasis	  have	  not	  been	  fully	  elucidated.	  	  
	  
Recent	  data	  on	  MDA-­‐MB-­‐231	  breast	  cancer	  epithelial	  cells	  demonstrated	  that	  
Kin1	  regulates	  mitotic	  spindle	  formation	  in	  vitro	  [53].	  Consequently,	  we	  wanted	  
to	   generate	   a	   mouse	   model	   of	   Kin1	   loss	   to	   assess	   whether	   and	   how	   Kin1	  
regulates	  mitosis	   in	   vivo,	   and	   whether	   this	   role	   of	   Kin1	   is	   implicated	   in	   the	  
reduced	  keratinocyte	  proliferation	   and,	   potentially,	   skin	   atrophy	  observed	   in	  
the	  epidermis	  of	  KS	  patients.	  	  	  
	  
Specific	  aims	  of	  this	  section	  of	  the	  chapter	  are:	  
1. Development	  of	  a	  mouse	  model	  of	  Kin1	  loss	  by	  performing	  conditional	  
knockout	  of	  Fermt1	  gene	  in	  mouse	  epidermis.	  
2. Examination	   and	   characterisation	   of	   potential	   morphological,	  
proliferation	   and	  mitotic	   defects	   in	   epidermal	   keratinocytes	   following	  
loss	  of	  Kin1	  in	  mouse	  epidermis.	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3.1.	  Use	  of	  Cre-­‐Lox	  recombination	  system	  to	  achieve	  
conditional	  knockout	  of	  Fermt1	  in	  the	  epidermis	  of	  adult	  mice	  
A	   number	   of	   KS	   patients	   suffer	   from	   ulcerative	   colitis	   that	   first	   develops	  
during	   infancy	   [20][21][133].	  Whereas	   this	  pathology	   is	  not	   lethal	   in	  humans,	  
deletion	  of	  Fermt1	  in	  mice	  leads	  to	  lethal	  neonatal	  gastrointestinal	  dysfunction	  
[54].	   To	   circumvent	   the	   lethality	   of	   a	   constitutive	   Fermt1	   ablation,	   we	  
established	  a	  unique	  model	  of	  Kin1	  loss	  in	  which	  deletion	  of	  Fermt1	  gene	  was	  
performed	   only	   in	   the	   epidermis	   of	   adult	   mice	   in	   a	   temporally	   controlled	  
manner.	  	  
	  
To	  achieve	   this,	  we	  engineered	  a	  Kin1fl/fl	   transgenic	  mouse,	   in	  which	  exons	  4	  
and	  5	  of	  Fermt1	  gene	  were	  floxed,	  and	  crossed	  it	  with	  a	  K14-­‐Cre-­‐ERT2	  (K14-­‐Cre)	  
mouse	   to	   generate	   K14-­‐Cre-­‐ERT2-­‐Kin1fl/fl	   (K14-­‐Cre-­‐Kin1fl/fl)	   double	   transgenic	  
progeny,	   in	   which	   Cre-­‐ERT2	   was	   under	   the	   control	   of	   K14	   skin	   promoter	  
[123][124]	  (Fig.5.1.).	  Adult	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  and	  adult	  K14-­‐Cre	  mice,	  which	  
were	   used	   as	   control,	   were	   treated	  with	   4OHT	   (Fig.5.2.).	   In	   K14-­‐Cre-­‐Kin1fl/fl	  
mice	   this	   resulted	   in	   Cre	   recombination	   at	   loxP	   sites	   [125],	   thus	   inducing	  
deletion	   of	   exons	   4	   and	   5	   and,	   therefore,	   deletion	   of	   Fermt1	   (Fig.5.3.).	   Any	  
subsequent	  mention	  of	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  refers	  to	  K14-­‐Cre	  and	  










































Figure	  5:	  Conditional	  knockout	  of	  Fermt1	  gene	  in	  the	  epidermis	  of	  adult	  mice.	  1:	  Mice	  with	  floxed	  
Fermt1	  exons	  4	  and	  5	  (Kin1fl/fl)	  were	  crossed	  with	  K14-­‐Cre-­‐ERT2	  (K14-­‐Cre)	  mice	  to	  generate	  K14-­‐Cre-­‐
ERT2-­‐Kin1fl/fl	   (K14-­‐Cre-­‐Kin1fl/fl)	   double	   transgenic	   mice.	   2:	   Subsequently,	   adult	   K14-­‐Cre-­‐Kin1fl/fl	   mice	  
and	  adult	  K14-­‐Cre	  mice,	  which	  were	  used	  as	  controls,	  were	  treated	  with	  4OHT.	  3:	  This	  induced	  Cre-­‐
mediated	  recombination	  at	  loxP	  sites,	  deletion	  of	  the	  above	  exons	  and,	  thus,	  knockout	  of	  Fermt1	  in	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Our	   initial	   aim	  was	   to	   confirm	   the	   loss	   of	  Kin1	   in	   the	   epidermis	   of	  K14-­‐Cre-­‐
Kin1fl/fl	  mice.	   Thus,	   lysates	   from	   tail	   epidermal	   keratinocytes	   of	   K14-­‐Cre	   and	  
K14-­‐CreKin1fl/fl	  mice	  were	  analysed	  by	  western	  blot,	  which	  confirmed	  the	   loss	  















Figure	  6:	  Loss	  of	  Kin1	  in	  the	  epidermis	  of	  adult	  K14-­‐Cre-­‐Kin1fl/fl	  adult	  mice.	  Tail	  keratinocytes	  were	  
isolated	   from	  the	  epidermis	  of	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  10	  days	   following	   the	  end	  of	   the	  
4OHT	  treatment.	  Western	  blot	  analysis	  of	  Kin1	  expression	  in	  the	  epidermis	  of	  K14-­‐Cre	  and	  K14-­‐Cre-­‐
Kin1fl/fl	  mice.	  β-­‐actin	  was	  used	  as	   loading	   control.	  Due	   to	   the	   low	  yield	  of	   keratinocytes	   from	  each	  
tail,	   it	   was	   necessary	   to	   pool	   keratinocytes	   from	   multiple	   tails	   together	   [K14-­‐Cre	   (n=3),	   K14-­‐Cre-­‐
Kin1fl/fl	  (n=6)]	  .	  The	  difference	  in	  the	  amount	  of	  β-­‐actin	  reflects	  the	  variability	  in	  the	  number	  and	  size	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3.2.	  Phenotypic	  analysis	  and	  histological	  examination	  of	  	  	  	  	  	  	  	  
K14-­‐Cre-­‐Kin1fl/fl	  mouse	  epidermis	  	  
We	   first	   performed	   a	   visual	   inspection	   of	   K14Cre-­‐Kin1fl/fl	   epidermis,	   but	  
detected	  no	  signs	  of	  skin	  atrophy	  or	  other	  KS	  symptoms	  (Fig.7.A.).	  Moreover,	  
we	  assessed	  hair	  coat	  development	  in	  K14Cre-­‐Kin1fl/fl	  mice	  over	  the	  course	  of	  2	  
months,	  as	  mice	  with	  congenital	  loss	  of	  Kin1	  were	  previously	  shown	  to	  develop	  
irregular	  hair	  coat	  with	  alternating	  patches	  of	  dense	  hair	  and	  areas	  of	  alopecia	  
[119].	  To	  achieve	  this	  we	  shaved	  the	  back	  of	  K14Cre-­‐Kin1fl/fl	  and	  K14-­‐Cre	  mice	  
(Fig.7.B.)	   and	   observed	   hair	   re-­‐growth	   over	   time.	  We	   detected	   normal	   hair	  
coat	  development,	  both	   in	  K14Cre-­‐Kin1fl/fl	   and	  K14-­‐Cre	  mice	  and	  normal	   skin	  
pigmentation	  (Fig.7.C,D).	  
	  
Following,	   we	   examined	   whether	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   mice	  
presented	   any	   morphologic	   aberrations	   in	   comparison	   to	   K14-­‐Cre	   mouse	  
epidermis.	   In	   order	   to	   determine	   the	   effects	   of	   short-­‐term	   and	   long-­‐term	  
epidermal	  loss	  of	  Kin1	  on	  skin	  morphology,	  dorsal	  skin	  from	  K14-­‐Cre	  and	  K14-­‐
Cre-­‐Kin1fl/fl	  mice	  was	  collected	  5	  days	   (Fig.8.A.),	   10	  days	   (Fig.8.B.)	   and	   1	  year	  
(Fig.8.C.)	  after	  the	  end	  of	  the	  4OHT	  treatment.	  Histological	  H&E	  examination	  
revealed	  no	  epidermal	  structural	  changes	  between	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  

















































Figure	  7:	  Loss	  of	  Kin1	  in	  the	  epidermis	  of	  K14-­‐Cre-­‐Kin1fl/fl	  adult	  mice	  did	  not	  alter	  skin	  phenotype	  
or	  hair	  growth.	  Representative	  photographs	  of	  mice	  A:	  before	  shaving,	  B:	  the	  day	  of	  shaving	  and	  C:	  





































Figure	   8:	   Loss	   of	   Kin1	   in	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   adult	   mice	   did	   not	   alter	   epidermal	  
morphology.	  Representative	   images	  of	  H&E	  staining	  that	  was	  performed	  on	  sections	  of	  dorsal	  skin	  
isolated	  from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  A:	  5	  days,	  B:	  10	  days	  and	  C:	  1	  year	  following	  the	  end	  
of	  the	  4OHT	  treatment.	  E=	  epidermis,	  D=	  dermis,	  AT=	  adipose	  tissue,	  M=	  muscle.	  Mag	  x40.	  The	  scale	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3.3.	  Characterisation	  of	  the	  proliferative	  and	  mitotic	  capacity	  in	  
keratinocytes	  of	  K14-­‐Cre-­‐Kin1fl/fl	  mouse	  epidermis	  	  
KS	   keratinocytes	   exhibit	   minimal	   proliferation	   in	   comparison	   to	   healthy	  
counterparts,	   both	   in	   vitro	   and	   in	   vivo	   [8][54][98],	   which	   led	   us	   to	   explore	  
whether	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   mice	   presented	   any	   proliferation	  
defects	  when	  compared	  to	  K14-­‐Cre	  epidermis.	  
	  
Proliferative	   capacity	   of	   cells	   was	   determined	   via	   immunolabeling	   of	   dorsal	  
skin	   from	   K14-­‐Cre	   and	   K14-­‐Cre-­‐Kin1fl/fl	  mice	   with	   Ki-­‐67	   proliferation	  marker	  
(Fig.9.A).	  We	  observed	  that	  ~50%	  of	  K14-­‐Cre	  nuclei	  scored	  positive	  for	  Ki-­‐67,	  
which	  was	  significantly	  reduced	  by	  ~16%	  in	  nuclei	  of	  K14-­‐Cre-­‐Kin1fl/fl	  epidermis	  
(Fig.9.B).	  	  
	  
Recent	   findings	   uncovered	   a	   novel	   role	   for	   Kin1	   in	   the	   regulation	   of	  mitotic	  
spindle	  formation,	  as	  depletion	  of	  Kin1	  in	  MDA-­‐MB-­‐231	  breast	  cancer	  epithelial	  
cells	  significantly	   increased	  the	  presence	  of	  abnormal	  spindles	  and	  decreased	  
cell	   survival	   [53].	  We,	  therefore,	   assessed	  whether	   epidermal	   keratinocytes	   of	  
K14-­‐Cre-­‐Kin1fl/fl	   mice	   displayed	   mitotic	   defects	   compared	   to	   K14-­‐Cre	  
keratinocytes.	  
	  
We	   determined	   the	   mitotic	   index	   of	   basal	   keratinocytes	   by	   scoring	   the	  
percentage	   of	   epidermal	   nuclei	   that	   were	   positive	   for	   phospho-­‐histone	   H3	  
(pHH3),	   a	   mitotic	   marker	   expressed	   during	   late	   G2	   and	  M	   phases	   [134],	  on	  
dorsal	  skin	  from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  (Fig.10.A.).	  We	  detected	  a	  
statistically	  significant	  reduction	  in	  keratinocyte	  mitosis	  following	  loss	  of	  Kin1,	  
as	  only	  ~6%	  of	  K14-­‐Cre-­‐Kin1fl/fl	  cells	  were	  undergoing	  mitosis	  compared	  to	  ~11%	  





























Figure	   9:	   Short-­‐term	   loss	   of	   Kin1	   in	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   adult	   mice	   significantly	  
decreased	  the	  number	  of	  proliferating	  cells.	  IHC	  was	  performed	  with	  a	  Ki-­‐67	  antibody	  on	  sections	  of	  
dorsal	   skin	   isolated	   from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  10	  days	   following	  the	  end	  of	   the	  4OHT	  
treatment.	  A:	   Representative	   IHC	   images	   of	   Ki-­‐67	   staining.	   The	   basement	  membrane	   is	   indicated	  
with	   a	   dotted	   black	   line.	   E=	   epidermis,	   D=	   dermis.	   Mag	   x80.	   Scale	   bar	   represents	   50μm.	   B:	  
Quantification	   of	   the	   percentage	   of	   Ki-­‐67-­‐positive	   nuclei	   was	   performed	  manually	   by	   scoring	   the	  
selected	  epidermis.	  Cells	   from	  10	  or	  more	  representative	   low-­‐power	  fields	  were	  analysed	  per	  K14-­‐
Cre	  (n=4)	  and	  K14-­‐Cre-­‐Kin1
fl/fl	  mouse	  (n=4).	  Results	  presented	  as	  mean	  ±	  SEM.	  Unpaired	  t-­‐test;	  *	  p-­‐





































Figure	   10:	   Short-­‐term	   loss	   of	   Kin1	   in	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   adult	   mice	   significantly	  
decreased	   the	   number	   of	  mitotic	   cells.	   IHC	  was	   performed	  with	   a	   pHH3	   antibody	   on	   sections	   of	  
dorsal	   skin	   isolated	   from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  10	  days	   following	  the	  end	  of	   the	  4OHT	  
treatment.	  A:	   Representative	   IHC	   images	   of	   pHH3	   staining.	   Arrows	   indicate	   pHH3-­‐positive	   nuclei.	  
Magnified	  cells	  are	  undergoing	  anaphase.	  The	  basement	  membrane	  is	  indicated	  with	  a	  dotted	  black	  
line.	   E=	   epidermis,	   D=	   dermis.	   Mag	   x100.	   Scale	   bar	   represents	   50μm.	   B:	   Quantification	   of	   the	  
percentage	  of	  pHH3-­‐positive	  nuclei	  was	  performed	  manually	  by	  scoring	  the	  selected	  epidermis.	  Cells	  
from	   6	   or	   more	   representative	   low-­‐power	   fields	   were	   analysed	   per	   K14-­‐Cre	   (n=4)	   and	   K14-­‐Cre-­‐
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3.4.	  Characterisation	  of	  mitosis	  in	  keratinocytes	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
K14-­‐Cre-­‐Kin1fl/fl	  mouse	  epidermis	  	  
Epidermal	   progenitors	   must	   maintain	   a	   theoretical	   balance	   between	   self-­‐
division	   and	   generation	   of	   differentiated	   progeny,	   in	   order	   to	  maintain	   skin	  
homeostasis.	   To	   accomplish	   this,	   basal	   keratinocytes	   divide	   symmetrically,	  
which	  yields	  two	  basal,	  proliferative	  daughter	  cells	  and,	  thus,	  increases	  surface	  
area,	   and	   asymmetrically,	   which	   results	   in	   one	   basal,	   proliferative	   and	   one	  
suprabasal,	  non-­‐proliferative	  cell	  that	  engages	  in	  terminal	  differentiation,	  thus	  
promoting	  epidermal	  stratification	  [135]	  (Fig.11.A.).	  Symmetrical	  Cell	  Division	  
(SCD)	   is	   achieved	  by	   aligning	   the	  mitotic	   spindles	  parallel	   to	   the	  underlying	  
substrate	   (basement	  membrane),	  whereas	  during	  Asymmetrical	  Cell	  Division	  
(ACD)	   mitotic	   spindles	   are	   misorientated	   and	   form	   perpendicularly	   to	   the	  
substrate	  (Fig.11.A.).	  	  
	  
We,	   thus,	   sought	   to	   determine	   if	   the	   significant	   reduction	   in	   the	  number	   of	  
proliferative	   and	   mitotic	   K14-­‐Cre-­‐Kin1fl/fl	   keratinocytes	   is	   accompanied	   by	   a	  
shift	   in	   the	   SCD/ACD	   balance.	   Using	   α-­‐tubulin	   (α-­‐tub)	   as	   a	  mitotic	   spindle	  
marker,	  we	  scored	  the	  incidence	  of	  SCD	  and	  ACD	  in	  the	  epidermis	  of	  K14-­‐Cre	  
and	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  (Fig.11.B.).	  In	  the	  K14-­‐Cre	  epidermis	  ~29%	  of	  mitotic	  
keratinocytes	   underwent	  ACD,	  whereas	   the	   incidence	   significantly	   increased	  









































Figure	   11:	   Short-­‐term	   loss	   of	   Kin1	   in	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   adult	   mice	   significantly	  
increased	  the	  incidence	  of	  ACD.	  IF	  was	  performed	  with	  an	  α-­‐tub	  antibody	  on	  sections	  of	  dorsal	  skin	  
isolated	  from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1
fl/fl
	  mice	  A:	  Diagram	  of	  SCD	  and	  ACD	  accomplished	  by	  a	  plane	  
of	  division	  which	  is	  parallel	  or	  misorientated/perpendicular	  to	  the	  underlying	  basement	  membrane	  
(gray	   line),	  respectively.	  SCD	  results	   in	  two	  basal,	  proliferative	  daughter	  cells	  (green),	  whereas	  ACD	  
generates	  one	  basal	  (green)	  and	  one	  suprabasal,	  non-­‐proliferative	  daughter	  cell	  (red)	  that	  terminally	  
differentiates	  (Figure	  adapted	  from	  [136]).	  B:	  Representative	   IF	   images	  of	  α-­‐tub	  staining.	  Examples	  
of	  mitotic	  keratinocytes	  undergoing	  SCD	  and	  ASD	  are	  shown.	  The	  dotted	  white	   line	  represents	  the	  
basement	   membrane	   and	   the	   green	   solid	   line	   represents	   the	   axis	   of	   cell	   division.	   Scale	   bar	  
represents	   10μm.	   C:	   Quantification	   of	   the	   percentage	   of	   cells	   undergoing	   ACD	   was	   performed	  
manually	  by	  scoring	  the	  epidermis,	  which	   is	  separated	  from	  the	  dermis	  by	  the	   indicated	  basement	  
membrane.	  Overall,	   41	   cells	   from	  K14-­‐Cre	  (n=4)	  and	  45	  cells	   from	  K14-­‐Cre-­‐Kin1
fl/fl
	  mice	   (n=4)	  were	  
analysed.	  Results	  presented	  as	  mean	  ±	  SEM.	  Unpaired	  t-­‐test;	  *	  p-­‐value	  <	  0.05.	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Spindle	   orientation	   parallel	   to	   the	   underlying	   substrate	   relies	   on	   a	   stable	  
mitotic	  spindle	   [137][138].	  Spindle	  stability	  can	  be	  assessed	  by	   the	  acetylation	  
status	  of	  microtubules,	  the	  major	  structural	  element	  of	  mitotic	  spindles,	  with	  
acetylated	   microtubules	   representing	   more	   stable	   and	   longer-­‐lived	  
microtubules	  [139]–[142].	  	  
	  
Our	  aim	  was,	  therefore,	  to	  examine	  if	  the	  significant	  increase	  in	  the	  occurrence	  
of	   misorientated	   spindles	   and,	   consequently,	   ACD	   in	   K14-­‐Cre-­‐Kin1fl/fl	  
keratinocytes	  is	  linked	  to	  a	  reduction	  in	  microtubule	  acetylation.	  	  We	  used	  IF	  
to	   stain	   the	   epidermis	   of	   K14-­‐Cre	   and	   K14-­‐Cre-­‐Kin1fl/fl	  mice	   with	   α-­‐tub	   and	  
acetylated-­‐α-­‐tubulin	   (ac-­‐tub)	   (Fig.12.A.)	   and	   subsequently	   evaluated	   the	  
degree	  of	  microtubule	  acetylation	  by	  quantifying	  the	  ac-­‐tub:α-­‐tub	  ratio	  of	  each	  
mitotic	   spindle.	   Our	   results	   revealed	   a	   ~35%	   reduction	   in	   the	   ac-­‐tub:α-­‐tub	  
ratio	   in	   K14-­‐Cre-­‐Kin1fl/fl	   mitotic	   keratinocytes	   compared	   to	   K14-­‐Cre	   mitotic	  































Figure	   12:	   Short-­‐term	   loss	   of	   Kin1	   in	   the	   epidermis	   of	   K14-­‐Cre-­‐Kin1fl/fl	   adult	   mice	   significantly	  
reduced	   levels	   of	  microtubule	   acetylation.	   IF	  was	  performed	  with	  α-­‐tub	  and	  ac-­‐tub	  antibodies	  on	  
sections	  of	  dorsal	  skin	   isolated	  from	  K14-­‐Cre	  and	  K14-­‐Cre-­‐Kin1
fl/fl
	  mice.	  A:	  Representative	   IF	   images	  
of	  α-­‐tub	  and	  ac-­‐tub	  staining	  in	  mitotic	  keratinocytes	  undergoing	  SCD	  and	  ACD.	  The	  dotted	  white	  line	  
represents	   the	   basement	  membrane	   and	   the	   green	   solid	   line	   represents	   the	   axis	   of	   cell	   division.	  
Scale	  bar	  represents	  2.5μm.	  B:	  Quantification	  of	  the	  α-­‐tub:ac-­‐tub	  ratio	  in	  the	  mitotic	  spindles	  of	  cells	  
was	  performed	  with	  ImageJ	  software	  by	  measuring	  the	  Raw	  Integrated	  Density	  (sum	  of	  pixel	  value)	  
of	  every	   image.	  Overall,	   55	  mitotic	   spindles	   from	  K14-­‐Cre	  mice	   (n=4)	  and	  48	  mitotic	   spindles	   from	  
K14-­‐Cre-­‐Kin1fl/fl	  mice	   (n=4)	  were	  analysed.	  Results	  presented	  as	  mean	  ±	  SEM.	  Unpaired	   t-­‐test;	  *	  p-­‐
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3.5.	  Characterisation	  of	  the	  apoptotic	  capacity	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
K14-­‐Cre-­‐Kin1fl/fl	  mouse	  epidermis	  	  
As	  prominent	  epidermal	  apoptosis	  had	  been	  previously	  reported	  in	  the	  skin	  of	  
KS	  patients	  [8][143],	  we	  investigated	  the	  apoptotic	  status	  of	  our	  mouse	  model	  
epidermis	   by	   manually	   scoring	   keratinocytes	   that	   stained	   positive	   for	   the	  
apoptotic	   marker	   cleaved-­‐caspase-­‐3	   (casp-­‐3)	   (Fig.13.A.).	   Subsequent	  
quantification	  revealed	  no	  significant	  difference	  in	  the	  percentage	  of	  apoptotic	  























Figure	  13:	  Short-­‐term	  loss	  of	  Kin1	  in	  the	  epidermis	  of	  K14-­‐Cre-­‐Kin1fl/fl	  adult	  mice	  did	  not	  alter	  the	  
level	   of	   apoptosis.	   IHC	  was	   performed	  with	   a	   casp-­‐3	   antibody	   on	   sections	   of	   dorsal	   skin	   isolated	  
from	   K14-­‐Cre	   and	   K14-­‐Cre-­‐Kin1
fl/fl
	  mice.	   A:	   Representative	   IHC	   images	   of	   casp-­‐3	   staining.	   Arrows	  
indicate	   casp-­‐3-­‐positive	   nuclei.	   The	   basement	  membrane	   is	   indicated	  with	   a	   dotted	   black	   line.	   E=	  
epidermis,	  D=	  dermis.	  Mag	  x100.	  Scale	  bar	  represents	  50μm.	  B:	  Quantification	  of	  the	  percentage	  of	  
casp-­‐3-­‐positive	   nuclei	   was	   performed	   manually.	   Cells	   from	   6	   or	   more	   representative	   low-­‐power	  
fields	  were	  analysed	  per	  K14-­‐Cre	  (n=4)	  and	  K14-­‐Cre-­‐Kin1
fl/fl
	  (n=4)	  mouse.	  Results	  presented	  as	  mean	  
±	  SEM.	  Unpaired	  t-­‐test;	  ns	  (non-­‐significant):	  p-­‐value	  >	  0.05.	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3.6.	  Discussion	  
	  
Kin1	   is	   a	  well-­‐documented	   integrin	   co-­‐activator	   [49][97],	   a	   role	   that	   is	   often	  
associated	  with	  the	  molecular	  mechanism	  underlying	  a	  number	  of	  KS	  features.	  
In	  particular,	   intestinal	  epithelial	  dysfunction,	  as	  well	  as	  reduced	  adhesion	  in	  




3.6.1.	  Kin1	  plays	  a	  role	  in	  regulation	  of	  keratinocyte	  proliferation	  and	  
mitosis	  in	  mouse	  epidermis	  	  
The	   aetiology	   that	   underlies	   reduced	   keratinocyte	   proliferation,	   which	   is	   a	  
characteristic	  of	  KS	  keratinocytes	  and	  a	  KS	  symptom	  linked	  to	  skin	  atrophy,	  is	  
still	  unclear	  [8][54].	  An	   in	  vitro	  study	  that	  emerged	  a	  few	  years	  ago	  defined	  a	  
role	   for	   Kin1	   in	   mitotic	   spindle	   formation	   [53].	   No	   subsequent	   studies	   have	  
addressed	   the	  mitotic	   role	   of	   Kin1	   in	   vivo	   or	   its	   possible	   contribution	   to	   KS	  
features	  such	  as	  reduced	  cell	  proliferation.	  	  
	  
Here	   we	   show	   for	   the	   first	   time	   that	   Kin1	   plays	   a	   role	   in	   mitotic	   spindle	  
stability	   and	   orientation	   in	   vivo,	   which	   we	   believe	   to	   be	   associated	   with	  
proliferation	  defects	  observed	  in	  KS	  epidermis.	  To	  examine	  the	  effects	  of	  Kin1	  
loss	  in	  vivo,	  we	  performed	  short-­‐term	  (10-­‐day)	  epidermis-­‐restricted	  deletion	  of	  
Fermt1	  in	  adult	  mice	  (Fig.5,6),	  and	  employed	  a	  variety	  of	  immunological	  stains	  
on	  their	  dorsal	  skin.	  	  
	  
Consistent	  with	  previous	  observations	  of	  lower	  keratinocyte	  proliferation	  in	  KS	  
skin,	   our	   data	   displayed	   significant	   decrease	   in	   the	   number	   of	   proliferating	  
keratinocytes	   following	   loss	   of	   Kin1	   in	   adult	  mouse	   epidermis	   	   (Fig.9.)	   and,	  
thus,	   indicated	  an	   in	   vivo	   function	   for	  Kin1	   in	  keratinocyte	  proliferation.	  We	  
proceeded	  to	  show	  for	  the	  first	  time	  that	  Kin1	  also	  played	  a	  mitotic	  role	  in	  vivo,	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as	   we	   detected	   a	   significantly	   lower	   mitotic	   capacity	   in	   K14-­‐Cre-­‐Kin1fl/fl	  
keratinocytes	  compared	  to	  K14-­‐Cre	  counterparts	  (Fig.10.).	  	  
	  
As	   proposed	   over	   a	   decade	   ago,	   the	   outcome	   of	   cell	   division	   in	   the	   skin	  
depends	   on	   the	   axis	   of	   cell	   division,	   primarily	   governed	   by	   orientation	   of	  
mitotic	   spindles	   in	   relation	   to	   the	   underlying	   basement	   membrane.	   SCD	  
occurs	   when	  mitotic	   spindles	   are	   parallel	   to	   the	   substratum	   and	   yields	   two	  
basal	   proliferative	   cells,	   whereas	   ACD	   is	   marked	   by	   spindles	   off-­‐
parallel/perpendicular	   to	   the	   substrate	   plane	   and	   produces	   one	   basal	  
proliferative	  and	  one	  suprabasal	  non-­‐proliferative	  keratinocyte	  that	  terminally	  
differentiates	   [135]	   (Fig.11.A.).	   The	   reduction	   in	   proliferative	   and	   mitotic	  
capacity	   in	  K14-­‐Cre-­‐Kin1fl/fl	  keratinocytes	   could	   stem	   from	   the	   significant	   rise	  
in	  the	  percentage	  of	  misorientated	  spindles	  and,	  thus,	  in	  cells	  undergoing	  ACD	  
observed	   in	   K14-­‐Cre-­‐Kin1fl/fl	   epidermis	   (Fig.11.B-­‐C.).	   Our	   data	   parallel	   the	  
findings	  of	  the	  in	  vitro	  study	  on	  mitotic	  role	  of	  Kin1,	  which	  also	  showed	  that	  a	  
significantly	  higher	  percentage	  of	  Kin1-­‐depleted	  epithelial	  cells	  failed	  to	  orient	  
their	  spindles	  parallel	  to	  the	  substrate	  plane	  compared	  to	  control	  cells	  [53].	  	  
Orientation	  of	  mitotic	  spindle	  parallel	  to	  underlying	  substrate	  relies	  on	  stable	  
microtubules	  [137][138].	  The	  degree	  of	  mitotic	  spindle	  stability	  can	  be	  assessed	  
by	   the	   microtubule	   acetylation	   status,	   as	   stable	   microtubules	   are	   known	   to	  
possess	  high	  levels	  of	  ac-­‐tub	  [139]–[142].	  Our	  findings	  showed	  a	  role	  for	  Kin1	  in	  
regulation	   of	   ac-­‐tub	   and,	   therefore,	   spindle	   stability	   in	   K14-­‐Cre-­‐Kin1fl/fl	  
epidermis	  (Fig.12.),	  which	  could	  potentially	  account	  for	  the	  rise	  in	  ACD.	  
	  
Integrin-­‐deficient	  keratinocytes	  also	  present	  proliferation	  defects,	  both	  in	  vitro	  
[145][146]	   and	   in	   vivo	   [96].	   Interestingly,	   inhibition	   of	   β1	   integrin	   function	  
results	   in	   abnormalities	   in	   spindle	   formation	   and	   orientation,	   indicating	   an	  
integral	  role	  for	  integrins	  in	  spindle	  biology	  [53][137][147].	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According	   to	   literature,	   appropriate	   alignment	  of	  mitotic	   spindles	  parallel	   to	  
the	   substratum	   can	   occur	   via	   integrin-­‐dependent	   and	   integrin-­‐independent	  
mechanisms,	  such	  as	  regulation	  of	  cortical	  contractile	  forces	  and	  cell-­‐substrate	  
adhesion.	  In	  vitro,	  β1	  integrin	  promoted	  accumulation	  of	  phosphatidylinositol-­‐
3,4,5-­‐triphosphate	  (PIP3)	  in	  metaphase	  cell	  midcortex	  during	  anaphase,	  which	  
allowed	   dynein-­‐dynactin	   motor	   complex	   to	   exert	   contractile	   forces	   that	  
correctly	   orient	   mitotic	   spindles	   [148].	   Moreover,	   regulation	   of	   dynein-­‐
dynactin	   complex	   by	   β1	   integrin	   was	   also	   essential	   for	   proper	   spindle	  
alignment	   in	   mouse	   epidermis	   [135],	   and	   interaction	   of	   dynactin-­‐1	   and	  
dynactin-­‐2	   subunits	   of	   the	   dynein-­‐dynactin	   complex	   with	   β1	   integrins	   was	  
required	   for	   spindle	   orientation	   in	   HeLa	   cells	   [149].	   Mitotic	   spindles	   were	  
severely	   misorientated	   in	   HeLa	   cells	   plated	   on	   poly-­‐L-­‐lysine,	   an	   artificial	  
substrate	   that	   does	   not	   adhere	   to	   integrins	   [150],	   or	   treated	   with	   anti-­‐β1	  
integrin	   antibody	   or	   RGD	   peptide,	   which	   prevents	   integrin-­‐mediated	  
signalling	   [151],	   highlighting	   the	   importance	   of	   β1	   integrin-­‐mediated	   cell-­‐
substrate	  adhesion	  and	  overall	  function	  in	  spindle	  orientation	  [137].	  Finally,	  β1	  
integrin	   inactivation	   in	   the	   embryonic	   ventricular	   zone	   of	   mouse	   cerebral	  
cortex	   resulted	   in	   ventricular	   zone	   detachment,	   impaired	   proliferation	   of	  
neural	   stem	   cells	   and	   defective	   adhesion	   to	   their	   niche,	   and	   misorientated	  
divisions	  [152].	  
	  
Finally,	   microtubule	   stability,	   which	   is	   another	   key	   factor	   that	   ensures	  
appropriate	   spindle	   alignment,	   also	   occurs	   via	   mechanisms	   dependent	   and	  
independent	   of	   integrins.	   Integrins	   promoted	   microtubule	   stabilisation	   and	  
proper	   orientation	   in	   Drosophila	   eye	   disc	   epithelium	   [141],	   and	   glandular	  
epithelium	   [153].	   Nevertheless,	  microtubule	   stability	   can	   also	   be	   achieved	   in	  
integrin-­‐independent	   manner.	   In	   particular,	   various	   integrin-­‐independent	  
factors	   were	   shown	   to	   promote	   stability	   of	   astral	   microtubules,	   a	   subset	   of	  
microtubules	   that	   attach	   to	   cell	   cortex	   and	   are	   required	   for	   spindle	  
stabilisation	  and	  positioning	  [154].	  Examples	  include	  End	  Binding	  1	  (EB1)	  [137],	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Cylindromatosis	   [138]	   and	   AMP-­‐activated	   Protein	   Kinase	   [155],	   and	   their	  
deficiency	   leads	   to	   short	   and	   unstable	   astral	   microtubules,	   improper	   astral	  
microtubule-­‐cell	  cortex	  interactions	  and,	  ultimately,	  spindle	  misorientation	   in	  
vitro.	  
	  
In	   vitro	   study	  from	  our	   lab	  previously	  showed	  that	  the	  role	  of	  Kin1	   in	  proper	  
mitotic	   spindle	   formation	   occurred	   in	   a	   manner	   both	   dependent	   and	  
independent	   of	   the	   protein’s	   role	   in	   integrin	   interaction	   and	   activation.	   In	  
particular,	   expression	   of	   Kin1-­‐W612A	   mutant,	   which	   is	   unable	   to	   bind	   and	  
activate	  integrins	  [49],	  was	  unable	  to	  rescue	  the	  abnormal	  spindle	  phenotypes,	  
including	  elevated	  misorientation,	   that	  were	  observed	  after	  depletion	  of	  Kin1	  
in	  MDA-­‐MB-­‐231	  epithelial	  cells	  [53].	  However,	  the	  study	  also	  showed	  that	  Kin1	  
is	  phosphorylated	  by	  polo-­‐like	  kinase	  1	  (PLK1)	   in	   vitro,	  which	  is	  what	  renders	  
Kin1	   able	   to	   regulate	   spindle	   orientation	   and	   formation,	   and	   that	   whilst	  
expression	  of	  non-­‐Plk1	  phosphorylatable	  Kin1	  mutant	   failed	  to	  rescue	  mitotic	  
defects,	  it	  did	  not	  affect	  integrin	  activation	  [53].	  	  
Collectively,	   the	   aforementioned	   literature	   findings	   raise	   the	   possibility	   that	  
the	  role	  of	  Kin1	  in	  proliferation	  and	  mitotic	  spindle	  stability	  and	  orientation	  in	  
mouse	  epidermis	  could	  be	  integrin-­‐dependent	  and/or	  -­‐independent.	  One	  way	  
that	   this	  could	  be	  addressed	   is	   to	  examine	  expression	  of	  pKin1T30,	  where	  T30	  
represents	   a	   strong	   PLK1	   phosphorylation	   consensus	   site	   on	   Kin1	   [53],	   in	  
mouse	   epidermis.	   pKin1T30	   was	   previously	   shown	   to	   localise	   across	   spindle	  
microtubules	   [53],	   where	   Kin1	   is	   thought	   to	   be	   phosphorylated	   by	   Plk1	   to	  
employ	  its	  function	  in	  spindle	  stability	  [156].	  
	  
3.6.2.	  Evaluation	  of	  K14-­‐Cre-­‐Kin1fl/fl	  mouse	  model	  of	  Kin1	  loss	  
Defects	  in	  keratinocyte	  proliferation	  were	  shown	  to	  accompany	  the	  pathology	  
of	   skin	   atrophy	   in	   KS	   patients	   and	   Kin1-­‐null	   mice	   with	   KS-­‐like	   phenotypes	  
[8][54].	   However,	   despite	   the	   significant	   reduction	   in	   the	   number	   of	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proliferating	   keratinocytes	   following	   a	   short-­‐term	   (10-­‐day)	   loss	   of	   Kin1	   in	  
K14Cre-­‐Kin1fl/fl	   epidermis	   (Fig.9.),	   no	   indications	   of	   skin	   atrophy	   or	   other	  
morphological	   aberrations	   were	   observed	   (Fig.7.).	   Likewise,	   structural	  
comparison	   between	   K14Cre-­‐Kin1fl/fl	   and	   K14-­‐Cre	   epidermis	   after	   a	   5-­‐day	  
(Fig.8.A.)	   or	   1-­‐year	   (Fig.8.C.)	   Kin1	   loss	  mirrored	   the	   results	   of	   a	   10-­‐day	  Kin1	  
loss	   (Fig.8.B.),	   thus	  excluding	   the	  possibility	  of	   a	   transient	  or	   long-­‐term	  KS-­‐
like	  phenotype	  in	  our	  model.	  	  
	  
C57BL/6	   (C57Black/6)	  mice	   with	   long-­‐term	   (>6	  months)	   loss	   of	   Kin1	   in	   the	  
epidermis,	   which	   occurred	   during	   development,	   developed	   poikiloderma,	  
signs	   of	   skin	   atrophy	   and	   irregular	   hair	   coat	   [119].	   This	   occurred	   due	   to	  
enlarged	   stem	   cell	   compartments	   and	   provoked	   hypeproliferation	   and	  
eventual	   exhaustion	   of	   cutaneous	   stem	   cells	   [119].	   However,	   K14Cre-­‐Kin1fl/fl	  
mice	  with	  1-­‐year	  old	  Fermt1	  deletion	  showed	  no	  histological	  signs	  of	  abnormal	  
epidermis	  (Fig.8.C.),	  developed	  a	  normal	  hair	  coat	  and	  presented	  no	  signs	  of	  
poikiloderma	  (Fig.7.).	  	  
	  
A	   possible	   explanation	   for	   lack	   of	   KS	   phenotypes,	   such	   as	   skin	   atrophy,	   or	  
poikiloderma	   in	   our	   model	   is	   that	   in	   our	   study	   deletion	   of	   Fermt1	   was	  
performed	  in	  adult	  mice.	  Aberrations	  in	  keratinocyte	  stem	  cell	  compartments	  
in	  C57BL/6	  mice,	  which	  occurred	   following	   loss	   of	  Kin1	   during	  development	  
and	   resulted	   in	   KS-­‐like	   phenotypes,	   allow	   us	   to	   hypothesise	   that	   Kin1	   could	  
regulate	   development	   of	   bulge	   stem	   cells	   during	   embryonic	  morphogenesis,	  
but	  exert	  minimal	  effects	  on	  an	  established	  adult	  stem	  cell	  population.	  Indeed,	  
our	   findings	   displayed	   a	   reduction	   of	   only	   ~16%	   in	   adult	   keratinocyte	  
proliferation	   following	   loss	   of	   Kin1	   in	   adult	   mice	   (Fig.9.),	   which	   is	   not	  
substantial	  to	  cause	  skin	  atrophy,	  thus	  supporting	  the	  above	  hypothesis.	  	  
	  
Different	  mouse	  strains,	  including	  FVB	  and	  C56BL/6,	  have	  inherent	  variations	  
in	   various	   features,	   such	   as	   susceptibility	   to	   skin	   carcinogenesis	   [157].	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Therefore,	   lack	   of	   atrophy-­‐like	   abnormalities	   in	   our	  model	   could	   stem	   from	  
the	   fact	   that	   epidermal	   stem	   cell	   population	   of	   C57BL/6	   mice	   is	   more	  
susceptible	   to	   Kin1	   loss	   compared	   to	   that	   in	   FVB	  mice.	   Finally,	   Kin1	   loss	   in	  
C57BL6/6	  mice	  was	  achieved	  via	  the	  K5	  skin	  promoter,	  which	  drives	  a	  4OHT-­‐
independent	   activity	   of	   Cre	   recombinase	   and,	   thus,	   resulted	   in	   spontaneous	  
epidermal	   loss	   of	   Kin1	   during	   embryogenesis	   [119].	   K5	   and	   K14	   promoters	  
target	   slightly	   different	   stem	   cell	   populations	   [158][159],	   which	   could	   also	  
contribute	  to	  the	  differences	  observed	  between	  the	  two	  models.	  	  
	  
We	   believe	   that	   it	   is	   unlikely	   that	   poor	   K14-­‐Cre	   recombination	   efficiency	  
accounts	   for	   the	   lack	  of	  KS	  phenotype	   in	  our	  model.	  Although	  we	  could	  not	  
examine	  Kin1	  loss	  at	  single	  level,	  due	  to	  the	  lack	  of	  efficient	  Kin1	  antibody	  for	  
IHC,	   western	   blot	   analysis	   showed	   complete	   loss	   of	   Kin1	   band	   in	   tail	  
keratinocytes	   (Fig.6),	   indicating	   highly	   efficient	   disruption	   of	   Fermt1	   gene.	  
Moreover,	   other	   studies	   have	   demonstrated	   the	   ability	   of	   K14-­‐Cre	  mouse	   to	  
recombine	   floxed	   sequences	   in	   a	   highly	   efficient	   and	   keratinocyte-­‐specific	  
manner	  [158][160][161].	  
	  
3.6.3.	  Summary	  and	  future	  work	  
In	  summary,	  our	  data	  reveal	  a	  novel	  role	  of	  Kin1	  in	  skin	  homeostasis.	  We	  show	  
that	  Kin1	  regulates	  mitotic	  capacity,	  spindle	  orientation	  and	  α-­‐tub	  acetylation	  
in	   mouse	   epidermis,	   and	   show	   that	   loss	   of	   Kin1	   reduced	   keratinocyte	  
proliferation,	   an	   observation	   that	   was	   previously	   reported	   in	   mouse	   and	  
human	   KS	   epidermis.	   We	   hypothesise	   that	   that	   disturbance	   of	   spindle	  
orientation	   and	   α-­‐tub	   acetylation	   upon	   loss	   of	  Kin1	   could	   produce	   a	   smaller	  
number	  of	  keratinocytes	  that	  bear	  a	  mitotic	  and	  proliferative	  capacity.	  	  
	  
For	   future	   studies	  we	  suggest	  establishment	  of	  K5-­‐Cre/Kin1fl/fl	  mice,	   in	  which	  
spontaneous	   deletion	   of	   Fermt1	   during	   embryogenesis	   will	   recapitulate	   the	  
genetic	   background	   of	   KS	   patients.	  Moreover,	  we	   propose	   a	   shift	   from	  mice	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with	   FVB	   background	   to	   C57BL/6	   mice,	   to	   enhance	   the	   likelihood	   of	  
development	  of	  KS	  features	  and	  examine	  the	  mitotic	  role	  of	  Kin1	  in	  the	  KS-­‐like	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Chapter	  4:	  	  
exploring	  the	  roles	  of	  Kin1	  and	  Kin2	  in	  mitosis	  	  
	  
Part	  of	  the	  findings	  presented	  in	  this	  chapter	  have	  been	  published	  in	  the	  following	  article:	  Patel,	  
H.,	  Stavrou,	  I.,	  Shrestha,	  R.L.,	  Draviam,	  V.,	  Frame,	  M.C.,	  Brunton,	  V.G.	  (2016).	  Kindlin1	  regulates	  
microtubule	  function	  to	  ensure	  normal	  mitosis.	  Journal	  of	  Molecular	  and	  Cell	  Biology	  8,	  338-­‐348	  
	  
In	  Chapter	  3	  we	  showed	  that	  Kin1	  plays	  a	  mitotic	  role	  in	  vivo,	  with	  loss	  of	  Kin1	  
in	   mouse	   epidermis	   enhancing	   the	   presence	   of	   misorientated	   spindles.	  
Increase	   in	   abnormally	   orientated	   spindles	   had	   been	   previously	   shown	  
following	  depletion	  of	  Kin1	  in	  MDA-­‐MB-­‐231	  breast	  cancer	  epithelial	  cells	  [53].	  	  
	  
The	   aforementioned	   in	   vitro	   study	   as	  well	   as	   our	   study	   on	  mouse	   epidermis	  
analysed	   spindle	  defects	  on	   fixed	  mitotic	   cells,	   following	  depletion	  or	   loss	  of	  
Kin1,	  respectively.	  However,	  as	  mitosis	  is	  not	  a	  static	  process,	  we	  next	  sought	  
to	  analyse	  in	  greater	  detail	  the	  temporal	  and	  dynamic	  nature	  of	  mitotic	  spindle	  
abnormalities	  in	  Kin1	  depleted	  cells.	  For	  this,	  we	  employed	  live	  cell	  imaging,	  a	  
time-­‐lapse	   microscopy	   technique	   that	   allows	   surveillance	   of	   mitosis	   in	   real	  
time,	  in	  contrast	  to	  immunostaining	  on	  fixed	  cells	  or	  tissue	  that	  only	  provides	  
a	  snapshot	  of	  a	  single	  time	  point.	  As	  live	  cell	  imaging	  provides	  high-­‐resolution	  
imaging	   of	   chromosomes	   and	   spindles	   throughout	   mitosis	   in	   live	   cells,	   we	  
were	  able	   to	  extensively	  study	  the	  role	  of	  Kin1	  and	  Kin2	   in	  processes	  such	  as	  
chromosomal	   alignment	   at	   the	   metaphase	   plate,	   chromosome	   segregation	  
during	  anaphase,	  as	  well	  as	  mitotic	  spindle	  formation	  and	  orientation.	  
	  
Specific	  aims	  of	  this	  section	  of	  the	  chapter	  are:	  
1. Use	  of	  live	  cell	  imaging	  to	  explore	  the	  roles	  of	  Kin1	  and	  Kin2	  in	  mitosis	  
in	  a	  comprehensive	  manner.	  
2. Explore	  if	  Kin1	  and	  Kin2	  have	  redundant	  or	  distinct	  functions	  in	  mitosis	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4.1.	  Establishment	  4.9.5	  –	  105	  
of	  MDA-­‐MB-­‐231H2B:DsRed	  cell	  line	  
Kin1	  and	  Kin2	  share	  a	  variety	  of	  partially	  redundant	  roles	   in	   vitro	  and	   in	   vivo	  
including	   maintenance	   of	   muscle	   integrity	   in	   Drosophila	   [162],	   and	   cell	  
adhesion,	  survival	  and	  β1	   integrin	  activation	  [88][94].	  As	  a	  result,	  we	  initially	  
set	  out	  to	  examine	  the	  outcome	  of	  Kin1	  depletion	  during	  mitosis	  in	  cells	  that	  
expressed	  no	  other	  member	  of	   the	  kindlin	  protein	   family.	  This	  allowed	  us	   to	  
clearly	   establish	   the	   function	   of	   Kin1	   towards	   mitotic	   fidelity	   without	   any	  
potential	  compensation	  from	  Kin2.	  	  
	  
The	   vast	  majority	  of	   epithelial	   cell	   lines	   express	  Kin1	   and	  Kin2,	   as	  Kin1	   is	   an	  
epithelium-­‐specific	   protein,	   whereas	   Kin2	   is	   expressed	   ubiquitously.	  
Nevertheless,	  MDA-­‐MB-­‐231	  epithelial	  cell	   line,	  which	  is	  the	  cell	   line	  in	  which	  
the	  mitotic	  role	  of	  Kin1	  was	  first	  described,	  expresses	  readily	  detectable	  levels	  

















Figure	   14:	  MDA-­‐MB-­‐231	   cells	   express	   Kin1,	   but	   not	   Kin2.	  Western	  blot	   analysis	  of	  Kin1	  and	  Kin2	  
expression	   in	   MDA-­‐MB-­‐231	   and	   T47D	   breast	   cancer	   epithelial	   cell	   lines.	   γ-­‐tubulin	   was	   used	   as	  
loading	  control.	  Data	  reproduced	  from	  [53]	  with	  permission	  of	  Dr	  Hitesh	  Patel.	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We	  transfected	  MDA-­‐MB-­‐231	  cells	  with	  human	  histone	  H2B	  gene	  fused	  to	  the	  
gene	  encoding	  red	  fluorescent	  protein	  DsRed	  of	  Discosoma	  coral,	  resulting	  in	  
expression	   of	  H2B:DsRed	   fusion	  protein	   by	   a	   number	   of	   cells.	   Subsequently,	  
DsRed-­‐positive	  cells	  were	  selected	  with	  the	  use	  of	  FACS	  and	  pooled	  together	  
to	  generate	  a	  stable	  cell	   line	  constitutively	  expressing	  H2B:DsRed	  (MDA-­‐MB-­‐
231H2B:DsRed	   cell	   line)	   (Fig.15.).	   As	   histones	   are	   principle	   components	   of	  
chromatin	   and,	   thus,	   eukaryotic	   chromosomes,	   this	   allowed	   us	   to	   study	  
chromosomal	   movement	   and	   dynamics	   in	   live	   MDA-­‐MB-­‐231H2B:DsRed	   cells	  
throughout	  mitosis.	  
	  
Our	  initial	  aim	  was	  to	  also	  fluorescently	  tag	  microtubules,	  the	  most	  abundant	  
component	  of	  the	  mitotic	  spindle,	  in	  order	  to	  monitor	  spindle	  formation	  and	  
orientation	  throughout	  mitosis.	  However,	  this	  was	  not	  feasible	  due	  to	  lack	  of	  
appropriate	   fluorescent	   tag	   for	   β-­‐tubulin,	   one	   of	   the	   basic	   structures	   of	  
microtubules.	   Nevertheless,	   we	   were	   able	   to	   deduce	   the	   formation	   and	  
orientation	   of	   mitotic	   spindle	   based	   on	   chromosomal	   positioning	   during	  















Figure	   15:	   Expression	   of	   Histone	   H2B:DsRed	   as	   a	   chromatin	   marker	   in	  MDA-­‐MB-­‐231H2B:DsRed	  cell	  
line.	  Representative	  phase	  contrast	  fluorescent	  image	  showing	  expression	  of	  Histone	  H2B:DsRed	  in	  
MDA-­‐MB-­‐231H2B:DsRed	   cells,	   which	   allowed	   us	   to	   explore	   chromosome	   movement	   throughout	   the	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various	   phases	   of	   mitosis.	   White	   arrow	   indicates	   a	   mitotic	   cell	   undergoing	   anaphase.	   Scale	   bar	  
represents	  20μm.	  	  
4.2.	  Kin1	  depletion	  in	  MDA-­‐MB-­‐231H2B:DsRed	  cell	  line	  
Our	  lab	  has	  previously	  shown	  depletion	  of	  Kin1	  in	  MDA-­‐MB-­‐231	  cells	  with	  the	  
use	  of	  a	  pool	  of	  4	  siRNAs	  oligos	  (si-­‐Kin1pool),	  consisting	  of	  two	  oligos	  directed	  
against	  the	  translated	  and	  two	  against	  the	  untranslated	  region	  of	  FERMT1	  [53].	  
Moreover,	   depletion	   was	   shown	   with	   the	   use	   of	   two	   single	   siRNA	   oligos	  
directed	   against	   the	  untranslated	  FERMT1	   region	   individually	   (si-­‐Kin1UTR1,	   si-­‐
Kin1UTR2)	  and	   in	  combination	   (si-­‐Kin1UTR1+UTR2)	  [53].	  Transfection	  of	  cells	  with	  
si-­‐Kin1pool,	   si-­‐Kin1UTR1	   and	   si-­‐Kin1UTR1+UTR2	   induced	   similar	   level	   of	   Kin1	  
knockdown	   and	   of	   spindle	   abnormalities	  (Fig.16.A,B.	   by	   Dr	   Hitesh	   Patel)	  
[53].	   Re-­‐expression	   of	   si-­‐RNA	   resistant	  Kin1	   concomitantly	   to	   si-­‐Kin1UTR1+UTR2	  
treatment	  achieved	  exogenous	  Kin1	  expression,	  but	   to	   lower	   levels	  compared	  
to	  endogenous	  levels	  of	  Kin1	  in	  cells	  treated	  with	  scrambled	  siRNA	  (si-­‐Scram)	  
(non-­‐targeting	   siRNA)	   [53].	   This	   resulted	   in	   partial	   rescue	   of	   the	   abnormal	  
spindle	  phenotypes,	  indicating	  that	  effects	  of	  Kin1UTR1+UTR2	  on	  mitotic	  spindles	  














Figure	  16:	  Depletion	  of	  Kin1	  in	  MDA-­‐MB-­‐231	  cells.	  (A)	  Western	  blot	  analysis	  of	  Kin1	  expression	  in	  si-­‐
Scram,	   si-­‐Kin1pool,	   si-­‐Kin1UTR1,	   si-­‐Kin1UTR2	   and	   si-­‐Kin1UTR1+UTR2.	   β-­‐actin	   was	   used	   as	   loading	   control.	  
Quantification	  of	  Kin1	  depletion	  (knockdown)	  relative	  to	  treatment	  with	  si-­‐Scram	  is	  also	  shown.	  (B)	  
Quantification	   of	   the	   percentage	   of	   abnormal	   spindles	   following	   transfection	   with	   si-­‐Scram,	   si-­‐
Kin1pool,	  si-­‐Kin1UTR1,	  si-­‐Kin1UTR2	  and	  si-­‐Kin1UTR1+UTR2.	  Data	  reproduced	  from	  [53]	  with	  permission	  of	  Dr	  
Hitesh	  Patel.	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We,	  therefore,	  used	  si-­‐Kin1UTR1+UTR2	  for	  Kin1	  depletion	  in	  MDA-­‐MB-­‐231H2B:DsRed	  
cells	  (Fig.17.)	  and	   for	  subsequent	   live	  cell	   imaging	  experiments	   in	  MDA-­‐MB-­‐
231H2B:DsRed.	  Hereinafter,	  MDA-­‐MB-­‐231H2B:DsRed	  cells	  will	  be	  referred	  to	  as	  MDA-­‐









Figure	  17:	  Depletion	  of	  Kin1	  in	  MDA-­‐MB-­‐231H2B:DsRed	  cells.	  Western	  blot	  analysis	  of	  Kin1	  expression	  
in	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐231H2B:DsRed	  cells.	  MDA-­‐MB-­‐231H2B:DsRed	  cells	  were	  lysed	  48	  hours	  
following	  si-­‐RNA	  transfection.	  β-­‐actin	  was	  used	  as	  loading	  control.	  	  
	  
	  
4.3.	  Morphological	  assessment	  of	  si-­‐NT	  and	  si-­‐Kin1	  treated	  
MDA-­‐MB-­‐231	  cells	  
We	  observed	  that	  48	  hours	  post-­‐transfection,	  cells	  transfected	  with	  si-­‐NT	  had	  
an	   elongated,	   spindle-­‐like	  phenotype,	  whereas	  many	   si-­‐Kin1	   transfected	   cells	  













Figure	  18:	  Morphological	  characterisation	  of	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐231	  cells.	  Phase-­‐
contrast	  images	  of	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐231	  cells	  48	  hours	  post-­‐transfection.	  Scale	  bar	  
represents	  10μm.	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4.4.	  Assessment	  of	  duration	  of	  mitosis	  and	  mitotic	  spindle	  
phenotypes	  in	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐231	  cells	  	  
Mitosis	   is	  a	  dynamic	  process	  divided	   into	  a	  series	  of	  stages,	  which	  ultimately	  
result	  in	  segregation	  of	  duplicated	  chromosomes.	  Live	  cell	  imaging	  allowed	  us	  
to	  monitor	  chromosome	  movement	  during	  all	  different	  stages	  of	  mitosis.	  The	  
initial	   stage	   of	  mitosis	   is	   prophase,	  marked	   by	   nuclear	   envelope	   breakdown,	  
initiation	   of	   chromosome	   condensation	   (Fig.19.i.)	   and	   emergence	   of	   spindle	  
fibres	   from	   centrosomes.	   Subsequently,	   chromosomes	   continue	   to	   condense	  
during	   prometaphase	   (Fig.19.ii.),	   and	   centrosomes	   move	   towards	   opposite	  
poles	  and	  mitotic	   spindle	  microtubules	  attach	   to	  kinetochore.	   In	  metaphase,	  
chromosomes	   align	   at	   the	  metaphase	  plate	   (Fig.19.iii.)	   and	   centrosomes	   are	  
located	  at	  opposite	  poles	  of	   the	  cell.	  Chromosome	  segregation	  occurs	  during	  
anaphase,	   with	   sister	   chromatids	   being	   pulled	   at	   opposite	   poles	   of	   the	   cell	  
(Fig.19.iv.)	  by	  spindle	  microtubules.	  At	   telophase,	  sister	  chromatids	  arrive	  at	  
opposite	  poles	  and	  begin	  to	  decondense	  (Fig.19.v.).	  For	  each	  cell	  we	  assessed	  












Figure	  19:	  Assessment	  of	  mitosis	  in	  MDA-­‐MB-­‐231	  cells	  from	  prophase	  to	  telophase	  with	  the	  use	  of	  
live	  cell	  imaging.	  Representative	  fluorescent	  image	  of	  an	  MDA-­‐MB-­‐231	  cell	  undergoing	  (i):	  prophase,	  
(ii)	  prometaphase,	  (iii)	  metaphase,	  (iv)	  anaphase	  and	  (v)	   telophase.	  Main	  chromosome	  events	  that	  
accompany	   each	   phase	   of	   mitosis	   are	   described	   below	   each	   representative	   image.	   Scale	   bar	  
represents	  5μm.	  For	  visual	  acuity,	  Histone	  H2B:DsRed	  is	  represented	  in	  grey.	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We	  initiated	  live	  cell	  imaging	  48	  hours	  following	  si-­‐RNA	  transfection.	  Initially,	  
we	  measured	  the	  time	  that	  cells	  would	  spend	  in	  mitosis,	  from	  prophase	  until	  
telophase.	   We	   observed	   that	   the	   majority	   of	   si-­‐NT	   treated	   cells	   completed	  
mitosis	   within	   20-­‐40	   minutes,	   which	   we	   considered	   to	   be	   the	   typical	   time	  
MDA-­‐MB-­‐231	  cells	  spend	  to	  undergo	  mitosis	  (Fig.20.).	  Any	  cells	  undertaking	  
longer	   to	   complete	  mitosis	   (40-­‐80	  minutes)	  were	  marked	   as	   having	   “mitotic	  
exit	  delay”.	  No	  difference	  in	  the	  duration	  of	  mitosis	  was	  observed	  between	  si-­‐










Figure	  20:	  Assessment	  of	  duration	  of	  mitosis	   in	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐231	  cells	  with	  
the	  use	  of	   live	  cell	   imaging.	  Live	  cell	  imaging	  was	  performed	  in	  si-­‐NT	  and	  si-­‐Kin1	  treated	  MDA-­‐MB-­‐
231	   cells	   that	   had	   been	   transfected	   with	   Histone	   H2B:DsRed.	   Quantification	   of	   length	   of	  mitosis,	  
from	  prophase	  to	  telophase	  was	  performed	  manually.	  We	  categorised	  cells	  as	  spending	  20-­‐40	  min	  or	  
40-­‐80	  minutes	  in	  mitosis.	  Results	  presented	  as	  mean	  ±	  SEM.	  Unpaired	  t-­‐test;	  ns	  (non-­‐significant):	  p-­‐
value	  >	  0.05.	  n=4.	  	  
	  
We	  also	  assessed	  spindle	  orientation	  relative	  to	  the	  substratum.	  Evaluation	  of	  
chromosome	   alignment	   at	   the	   metaphase	   plate	   and	   segregation	   during	  
anaphase	   enabled	   us	   to	   infer	   whether	   the	   mitotic	   spindle	   had	   a	   normal	  
orientation,	   parallel	   to	   the	   underlying	   substratum,	   or	   was	   misorientated	   by	  
being	   positioned	   in	   a	   manner	   off-­‐parallel/perpendicular	   to	   the	   substratum	  
(Fig.21.A.).	   Moreover,	   we	   were	   able	   to	   assess	   chromosomal	   segregation	  
fidelity,	   by	   observing	   whether	   chromosomes	   segregated	   completely	   or	  
missegregated	   during	   anaphase	   (Fig.21.B.).	   Finally,	   we	   evaluated	   whether	  
spindles	  formed	  in	  a	  bipolar	  or	  multipolar	   fashion,	  by	  assessing	  chromosome	  
alignment	  and	  segregation	  (Fig.21.C.).	  

























Figure	   21:	   Phenotypic	   analysis	   of	   spindle	   orientation,	   chromosome	   segregation	   and	   spindle	  
formation	  in	  MDA-­‐MB-­‐231	  cells.	  A(i):	  Representative	  fluorescent	  images	  of	  anaphase	  chromosomes	  
in	   correctly	   orientated	   spindle	   positioned	   parallel	   to	   the	   underlying	   substratum,	   and	   in	   incorrect,	  
misorientated	  spindle	  positioned	  perpendicularly	  (~90o)	  to	  the	  underlying	  substratum.	  White	  arrow	  
indicates	   set	   of	   chromosomes	   of	   the	   daughter	   cell	   that	   proceeded	   to	   adhere	   to	   substratum	  
immediately	  following	  anaphase.	  Grey	  arrow	  indicates	  set	  of	  chromosomes	  of	  the	  daughter	  cell	  in	  a	  
different	   focal	   plane	   (out	   of	   focus),	   which	   failed	   to	   adhere	   to	   substratum	   immediately	   following	  
anaphase.	   (ii):	   Schematic	   showing	   microtubules,	   chromosome	   positioning	   and	   centrosome	  
positioning	   in	   a	   cell	   with	   normally	   orientated	   spindle	   and	   a	   cell	   with	   misorientated	   spindle.	   B:	  
Representative	   fluorescent	   images	   of	   complete	   chromosome	   segregation	   and	   chromosome	  
missegregation	   during	   anaphase.	   Yellow	   arrow	   indicates	   missegregated	   chromosome.	   C:	  
Representative	  fluorescent	  images	  of	  chromosome	  positioning	  during	  metaphase	  and	  anaphase	  in	  a	  
cell	  with	  bipolar	  spindle	  and	  a	  cell	  with	  multipolar	  spindle.	  A-­‐C:	  Scale	  bar	  represents	  5μm.	  For	  visual	  
acuity,	  Histone	  H2B:DsRed	  is	  represented	  in	  grey.	  	  	  
	  
Chapter	  4:	  exploring	  the	  role	  of	  Kin1	  and	  Kin2	  in	  mitosis	   91	  
We	   considered	   that	   cells	   underwent	   normal	   mitosis,	   when	   bipolar	   mitotic	  
spindles	   orientated	   parallel	   to	   the	   underlying	   substrate	   and	   there	   was	  
complete	   chromosome	   segregation	   during	   anaphase.	   Overall	   ~70%	   of	   si-­‐NT	  
treated	   cells	   underwent	   normal	   mitosis,	   where	   chromosomes	   segregated	  
faultlessly	  during	  anaphase	   in	  a	  bipolar	   fashion	  with	   their	   spindle	  parallel	   to	  
the	  underlying	   substrate.	  However,	   the	   percentage	  was	   significantly	   reduced	  
to	   ~50%	   in	   si-­‐Kin1	   treated	   cells	   (Fig.22.A.).	  We	   detected	   that	   percentage	   of	  
misorientated	  spindles	  was	  significantly	  increased	  in	  si-­‐Kin1	  treated	  cells	  (~30	  
%)	  compared	  to	  si-­‐NT	  treated	  cells	  (~10%)	  (Fig.22.B.).	  We	  also	  observed	  that	  
si-­‐Kin1	   treated	   cells	   had	   a	   significant	   increase	   in	   the	   percentage	   of	   mitotic	  
spindles	  with	  missegregated	   chromosomes	   during	   anaphase	   compared	   to	   si-­‐
NT	  treated	  cells	  (Fig.22.C.).	  Finally,	  we	  found	  no	   significant	  difference	  in	  the	  
incidence	  of	  multipolar	  spindles	  following	  treatment	  with	  si-­‐Kin1	  (Fig.22.D.).	  	  
	  
As	  shown	  in	  Figure	   12,	  in	  vivo	  short-­‐term	  loss	  of	  Kin1	  in	  mouse	  epidermis	  led	  
to	   a	   significant	   reduction	   in	   ac-­‐tub	   levels,	   and	   in	   vitro	   data	   from	   our	   lab	  
showed	  that	  Kin1	  depleted	  MDA-­‐MB-­‐231	  cells	  had	  a	  significant	  reduction	  in	  ac-­‐
tub	   levels,	   compared	   to	   control	   cells	   [156].	   Acetylation	   of	   α-­‐tub	   is	   a	   well-­‐
established	   readout	   of	   microtubule	   stability	   [137]-­‐[140]	   and	   is	   critically	  
regulated	   by	   histone	   deacetylase	   6	   (HDAC6),	   which	   interacts	   with	   and	  
deacetylates	  α-­‐tub	  [163][164].	  We,	  thus,	  next	  examined	  if	  inhibition	  of	  HDAC6	  
with	   tubacin,	   a	   broadly	   used,	   highly	   selective	   inhibitor	   of	  HDAC6	   [165]	   was	  
able	  to	  rescue	  the	  misorientation	  and	  missegregated	  chromosome	  phenotype.	  
Tubacin	   treatment	   resulted	   in	  significant	   reduction,	  but	  partial	   rescue	  of	   the	  
incidence	   of	   misorientated	   spindles,	   as	   the	   resulting	   percentage	   of	  
misorientated	  spindles	  did	  not	  return	  to	  levels	  observed	  in	  si-­‐NT	  treated	  cells	  
(Fig.22.B.).	  We	  saw	   full	   rescue	  of	   spindles	  with	  missegregated	  chromosomes	  
(Fig.22.C.).	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The	  activity	  of	  tubacin	  was	  also	  demonstrated	  in	  recently	  published	  data	  from	  
our	  lab,	  which	  showed	  rescue	  of	  ac-­‐tub	  levels	  in	  tubacin-­‐treated	  Kin1	  depleted	  
MDA-­‐MB-­‐231	   mitotic	   and	   non-­‐mitotic	   cells	   [156].	   Furthermore,	   tubacin	  
treatment	   increased	  microtubule	  stability	   in	  Kin1	  depleted	  MDA-­‐MB-­‐231	  cells	  
as	  well	  as	  in	  cells	  treated	  with	  non-­‐targeting	  siRNA,	  which	  had	  been	  previously	  
























Figure	   22:	   Assessment	   of	   spindle	   orientation,	   chromosome	   segregation	   and	   mitotic	   spindle	  
formation	   in	   si-­‐NT,	   si-­‐Kin1	   and	   si-­‐Kin1+Tub	   treated	   MDA-­‐MB-­‐231	   cells	   with	   the	   use	   of	   live	   cell	  
imaging.	   Live	   cell	   imaging	  was	  performed	   in	   si-­‐NT	  and	   si-­‐Kin1	   treated	  MDA-­‐MB-­‐231	  cells	   that	  had	  
been	   transfected	   with	   Histone	   H2B:DsRed.	   Quantification	   of	   percentage	   of	   A:	   normal	   spindles	  
(bipolar,	   correct	   spindle	   orientation	   during	  metaphase,	   complete	   chromosome	   segregation	   during	  
anaphase),	   B:	   misorientated	   spindles,	   C:	   spindles	   with	   missegregated	   chromosomes	   and	   D:	  
multipolar	   spindles	   was	   performed	   manually.	   A-­‐D:	   Results	   presented	   as	   mean	   ±	   SEM.	   n=4.	   A,C:	  
Unpaired	   t-­‐test;	   p-­‐value	   >	   0.05,	   	   ***	   p-­‐value	   ≤	   0.001.	   B,C:	   one-­‐way	  ANOVA	  with	   Tukey’s	  multiple	  
comparison	  test;	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	  ≤	  0.01.	  si-­‐Kin1+Tub	  marks	  Kin1-­‐depleted	  
cells	  treated	  with	  tubacin,	  3mM.	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4.5.	  Characterisation	  of	  HeLaH2B:GFP/β-­‐tub:DsRed	  cell	  line	  
Due	  to	  the	  redundant	  nature	  of	  some	  functions	  of	  Kin1	  and	  Kin2,	  we	  next	  set	  
out	  to	  determine	  if	  Kin2	  shares	  the	  same	  mitotic	  role	  of	  Kin1,	  and	  whether	  in	  
mitosis,	   the	   two	   proteins	   have	   overlapping	   or	   distinct	   functions	   and	   can	  
compensate	  for	  each	  other’s	  depletion.	  We	  thus	  explored	  cell	  division	  in	  HeLa	  
epithelial	  cells	  that	  express	  both	  Kin1	  and	  Kin2	  isoforms,	  and	  are	  widely	  used	  
in	  studies	  of	  mitosis.	  	  
	  
We	   observed	   mitosis	   in	   HeLaH2B:GFP/β-­‐tub:DsRed	   cells	   (Fig.23.),	   which	   will	   be	  
referred	  to	  as	  HeLa	  cells,	  following	  depletion	  of	  Kin1	  or	  Kin2	  or	  co-­‐depletion	  of	  
Kin1	   and	   Kin2.	   HeLa	   cell	   line	   was	   kindly	   offered	   to	   us	   by	   Dr	   Viji	   Draviam.	  
Histone	  H2B	  chromatin	  marker	  allowed	  us	  to	  examine	  chromosomal	  dynamics	  
and	   movement,	   whereas	   β-­‐tubulin	   microtubule	   marker	   helped	   us	   assess	  
formation	   and	   orientation	   of	   mitotic	   spindles	   in	   live	   HeLa	   cells	   during	   the	  












Figure	   23:	   Expression	   of	   Histone	   H2B:GFP	   as	   a	   chromatin	   marker	   and	   β-­‐tubulin:DsRed	   as	   a	  
microtubule	  marker	  in	  HeLaH2B:GFP/β-­‐tub	  cell	  line.	  Expression	  of	  Histone	  H2B:GFP	  and	  β-­‐tubulin:DsRed	  
allowed	   us	   to	   explore	   chromosome	  movement	   and	   spindle	   formation	   and	   orientation	   throughout	  
the	  various	  stages	  of	  mitosis,	  respectively.	  White	  arrow	  indicates	  a	  mitotic	  cell	  undergoing	  anaphase.	  
Black	  arrow	  indicates	  a	  mitotic	  cell	  undergoing	  metaphase	  Scale	  bar	  represents	  20μm.	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4.6.	  Individual	  depletion	  of	  Kin1	  and	  Kin2,	  and	  co-­‐depletion	  of	  
Kin1	  and	  Kin2	  in	  HeLa	  cells	  	  
Kin1	  depletion	  was	  achieved	  with	  the	  same	  si-­‐Kin1	  used	  in	  MDA-­‐MB-­‐231	  cells	  
(Fig.17.),	  and	  for	  Kin2	  depletion	  we	  applied	  a	  combination	  of	  two	  single	  siRNA	  
oligos	   targeted	   against	   FERMT2	   open	   reading	   frame,	   si-­‐Kin2ORF1	   and	   si-­‐
Kin2ORF2,	  hereinafter	  mentioned	  as	  si-­‐Kin2.	  Combination	  of	  si-­‐Kin1	  and	  si-­‐Kin2	  
(si-­‐Kin1+Kin2)	  was	  used	  for	  co-­‐depletion	  of	  Kin1	  and	  Kin2.	  Overall,	  we	  did	  not	  
notice	  any	  compensation	  in	  protein	  expression	  of	  Kin1	  upon	  depletion	  of	  Kin2	  






















Figure	  24:	   Individual	  depletion	  of	  Kin1	  and	  Kin2,	  and	  co-­‐depletion	  of	  Kin1+Kin2	   in	  HeLa	  cells.	   (A)	  
Western	   blot	   analysis	   of	   Kin1	   and	   Kin2	   expression	   in	   si-­‐NT,	   si-­‐Kin1,	   si-­‐Kin2	   and	   si-­‐Kin1+Kin2	   cells.	  
HeLa	   cells	  were	   lysed	  72	  hours	   following	   si-­‐RNA	   transfection.	  β-­‐actin	  was	  used	  as	   loading	   control.	  
B,C:	  Quantification	   of	   B:	   Kin1	   and	   C:	   Kin2	   expression	   levels	   was	   performed	   in	   relation	   to	   β-­‐actin	  
expression	   levels	   via	   band	   densitometric	   analysis	   with	   ImageJ	   software.	   For	   each	   graph,	   2	  
independent	  western	  blots	  were	  used	  to	  calculate	  protein	  expression.	  Results	  presented	  as	  mean	  ±	  
SEM.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test;	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐
value	  ≤	  0.01,	  ***	  p-­‐value	  ≤	  0.001.	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4.7.	  Assessment	  of	  morphology	  and	  viability	  of	  si-­‐Kin1,	  si-­‐Kin2	  
and	  si-­‐Kin1+Kin2	  in	  HeLa	  cells	  	  
We	  observed	  that	  72	  hours	  post-­‐transfection,	  cells	  transfected	  with	  si-­‐NT	  and	  
si-­‐Kin1	   had	   a	   cobblestone-­‐like,	   polygonal	   morphology	   (Fig.25.A.).	   However,	  
HeLa	   cells	   treated	   with	   si-­‐Kin2	   and	   si-­‐Kin1+Kin2	   had	   lost	   their	   cobblestone	  
morphology,	  with	  the	  majority	  of	  cells	  adopting	  a	  rounded	  shape	  (Fig.25.A.).	  	  
	  
Following,	  we	  assessed	  cell	  viability	  with	  the	  use	  of	  alamar	  blue	  assay,	  which	  
revealed	   that	   si-­‐Kin2	  and	  si-­‐Kin1+Kin2	   treated	  cells	  had	  a	  ~40%	  reduction	   in	  
viability	  compared	  to	  si-­‐NT	  treated	  cells	  (Fig.25.B.).	  No	  significant	  change	  was	  

























Figure	   25:	  Morphological	   and	   viability	   characterisation	  of	   si-­‐NT,	   si-­‐Kin1,	   si-­‐Kin2	   and	   si-­‐Kin1+Kin2	  
treated	  HeLa	  cells.	  A:	  Phase-­‐contrast	  images	  of	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  si-­‐Kin1+Kin2	  treated	  HeLa	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cells	  72	  hours	  post-­‐transfection.	  Yellow	  arrows	  indicate	  cells	  with	  a	  rounded	  morphology.	  Scale	  bar	  
represents	  125μm.	  B:	  Cell	  viability	  of	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  si-­‐Kin1+Kin2	  treated	  HeLa	  cells	  was	  
assessed	   72	   hours	   post-­‐transfection	   with	   the	   use	   of	   an	   alamar	   blue	   assay.	   one-­‐way	   ANOVA	  with	  
Tukey’s	  multiple	  comparison	  test;	  ns	  (non-­‐significant):	  p-­‐value	  >	  0.05,	  **	  p-­‐value	  ≤	  0.01.	  n=3.	  
	  
4.8.	  Assessment	  of	  duration	  of	  mitosis	  and	  mitotic	  spindle	  	  
phenotypes	  in	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  si-­‐Kin1+Kin2	  treated	  
HeLa	  cells	  
In	   a	   similar	   manner	   to	   MDA-­‐MB-­‐231	   cells	   (Fig.19.),	   we	   assessed	   mitosis	   in	  














Figure	  26:	  Assessment	  of	  mitosis	  in	  HeLa	  cells	  was	  performed	  from	  prophase	  to	  telophase	  with	  the	  
use	  of	  live	  cell	  imaging.	  Representative	  fluorescent	  image	  of	  a	  HeLa	  cell	  undergoing	  (i):	  prophase,	  (ii)	  
prometaphase,	   (iii)	  metaphase,	   (iv)	   anaphase	   and	   (v)	   telophase.	   Main	   chromosome	   and	   mitotic	  
spindle	   events	   that	   accompany	   each	   phase	   of	   mitosis	   are	   described	   below	   each	   representative	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Live	  cell	  imaging	  was	  initiated	  72	  hours	  following	  si-­‐RNA	  transfection.	  We	  first	  
assessed	  duration	  of	  mitosis,	  and	  observed	  that	  the	  majority	  of	  si-­‐NT	  treated	  
HeLa	   cells	   underwent	   mitosis	   within	   20-­‐40	   minutes	   (Fig.27.),	   which	   we	  
perceived	   as	   the	   normal	   time	   HeLa	   cells	   would	   spend	   to	   complete	   mitosis.	  
Cells	  undertaking	  longer	  to	  undergo	  mitosis	  (40-­‐80	  minutes)	  were	  marked	  as	  
having	  “mitotic	  exit	  delay”.	  	  
	  
We	  saw	  that	  majority	  of	  si-­‐NT	  (~75%)	  treated	  cells	  completed	  mitosis	  within	  
the	  normal	   time	   frame	  (20-­‐40	  minutes),	  which	  was	  significantly	  greater	   than	  
the	  amount	  of	  si-­‐Kin2	  (~37%)	  and	  si-­‐Kin1+Kin2	  (~45%)	  	  treated	  cells	  (Fig.27.).	  
Likewise,	   a	   significantly	   lower	   amount	   of	   si-­‐NT	   (~25%)	   treated	   cells	   had	  
mitotic	   exit	   delay,	  which	  was	   significantly	   lower	   than	   the	   amount	   of	   si-­‐Kin2	  
(63%)	   and	   si-­‐Kin1+Kin2	   (55%)	   treated	   cells	   (Fig.27.).	   We	   observed	   no	  
significant	   difference	   in	   the	   duration	   of	   mitosis	   between	   si-­‐NT	   and	   si-­‐Kin1	  








Figure	  27:	  Assessment	  of	  duration	  of	  mitosis	  in	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  si-­‐Kin1+Kin2	  treated	  HeLa	  
cells	  with	  the	  use	  of	  live	  cell	  imaging.	  Live	  cell	  imaging	  was	  performed	  in	  in	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  
si-­‐Kin1+Kin2	   treated	   HeLa	   cells	   that	   had	   been	   transfected	   with	   Histone	   H2B:GFP	   and	   β-­‐
tubulin:DsRed.	   Quantification	   of	   length	   of	   mitosis,	   from	   prophase	   to	   telophase	   was	   performed	  
manually.	  We	  categorised	  cells	  as	  spending	  20-­‐40	  min	  or	  40-­‐80	  minutes	  in	  mitosis.	  Results	  presented	  
as	  mean	  ±	  SEM.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test;	  ns	  (non-­‐significant):	  p-­‐value	  
>	  0.05,	  *	  p-­‐value	  ≤	  0.05.	  n=4.	  Thick	  gray	  line	  indicates	  that	  statistical	  testing	  was	  performed	  within	  
cells	  that	  received	  the	  same	  siRNA	  treatment,	  and	  compared	  the	  percentage	  of	  cells	  divided	  within	  
20-­‐40	  with	  percentage	  of	  cells	  divided	  within	  40-­‐80	  minutes.	  
	  
	  
Chapter	  4:	  exploring	  the	  role	  of	  Kin1	  and	  Kin2	  in	  mitosis	   98	  
Moreover,	  we	   assessed	   spindle	   orientation	   relative	   to	   the	   substratum	  during	  
metaphase	   (normal	   orientation	   parallel	   to	   underlying	   substratum	   vs	   spindle	  
misorientation	   off-­‐parallel/perpendicular	   to	   underlying	   substratum)	  
(Fig.28.A),	   chromosomal	   segregation	   fidelity	   during	   anaphase	   (normal,	  
complete	   segregation	   vs	   chromosome	   missegregation)	   (Fig.28.B.),	   and	  




















Figure	   28:	   Phenotypic	   analysis	   of	   spindle	   orientation,	   chromosome	   segregation	   and	   spindle	  
formation	   in	  HeLa	  cells	  with	   the	  use	  of	   live	   cell	   imaging.	  A:	  Representative	  fluorescent	   images	  of	  
chromosomes	  and	  mitotic	  spindle	  in	  metaphase	  in	  a	  cell	  with	  correctly	  orientated	  spindle	  positioned	  
parallel	  to	  the	  underlying	  substratum,	  and	  in	  a	  cell	  with	  incorrect,	  misorientated	  spindle	  positioned	  
perpendicularly	   (~90o)	   to	   substratum.	   B:	   Representative	   fluorescent	   images	   of	   complete	  
chromosome	  segregation,	  and	  chromosome	  missegregation	  during	  anaphase.	  Yellow	  arrow	  indicates	  
missegregated	   chromosome.	   C:	   Representative	   fluorescent	   images	   of	   metaphase	   chromosome	  
positioning	  in	  a	  cell	  with	  bipolar	  spindle	  or	  a	  cell	  with	  multipolar	  spindle.	  A-­‐C:	  Scale	  bar	  represents	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We	  proceeded	  to	  analyse	  phenotypes	  of	  mitotic	  spindles	  following	  transfection	  
of	  si-­‐NT,	  si-­‐Kin1,	  si-­‐Kin2	  and	  si-­‐Kin1+Kin2	  in	  HeLa	  cells.	  Similar	  to	  MDA-­‐MB-­‐
231	   cells,	   we	   considered	   normal	   mitosis,	   when	   HeLa	   cells	   formed	   bipolar	  
mitotic	  spindles	  orientated	  parallel	  to	  the	  underlying	  substrate	  and	  there	  was	  
complete	  chromosome	  segregation	  during	  anaphase.	  
	  
Compared	  to	  si-­‐NT	  treated	  cells	  (~75%),	  si-­‐Kin1	  (~42%),	  si-­‐Kin2	  (~48%)	  and	  si-­‐
Kin1+Kin2	   (~41%)	   treated	  cells	  had	   significantly	   lower	  percentages	  of	  normal	  
mitotic	   spindles	   (Fig.29.A).	   Percentage	   of	   misorientated	   spindles	   was	  
significantly	   lower	   in	   si-­‐NT	   treated	   cells	   (~8%)	   when	   compared	   to	   si-­‐Kin1	  
(~20%),	   si-­‐Kin2	   (~30%)	   and	   si-­‐Kin1+Kin2	   (~27%)	   treated	   cells	   (Fig.29.B).	  
Incidence	   of	   spindles	   with	   missegregated	   chromosomes	   was	   significantly	  
greater	  in	  si-­‐Kin1	  (~12%)	  and	  si-­‐Kin1+Kin2	  treated	  cells	  (~12%)	  compared	  to	  si-­‐
NT	   (~4%)	   treated	   cells	   (Fig.29.C).	   Finally,	   si-­‐Kin2	   (~6%)	   and	   si-­‐Kin1+Kin2	  
(~7%)	   treated	   cells	   had	   significantly	   greater	   incidence	  of	  multipolar	   spindles	  













































Figure	   29:	   Assessment	   of	   mitotic	   spindle	   phenotypes	   in	   si-­‐NT,	   si-­‐Kin1,	   si-­‐Kin2	   and	   si-­‐Kin1+Kin2	  
treated	   HeLa	   cells.	   Live	   cell	   imaging	   was	   performed	   in	   in	   si-­‐NT,	   si-­‐Kin1,	   si-­‐Kin2	   and	   si-­‐Kin1+Kin2	  
treated	   HeLa	   cells	   that	   had	   been	   transfected	   with	   Histone	   H2B:GFP	   and	   β-­‐tubulin:DsRed.	  
Quantification	   of	   percentage	   of	   A:	   normal	   spindles	   (bipolar,	   correct	   spindle	   orientation	   during	  
metaphase,	   complete	   chromosome	   segregation	   during	   anaphase),	   B:	   misorientated	   spindles,	   C:	  
spindles	  with	   lagging	  chromatids	  and	  D:	  multipolar	  spindles	  was	  performed	  manually.	  A-­‐D:	  Results	  
presented	   as	   mean	   ±	   SEM.	   one-­‐way	   ANOVA	   with	   Tukey’s	   multiple	   comparison	   test;	   ns	   (non-­‐
significant):	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	  ≤	  0.01.	  n=4.	  Total	  number	  of	  mitotic	   cells	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4.9.	  Discussion	  
The	  role	  of	  Kin1	  in	  mitosis	  emerged	  a	  few	  years	  ago,	  when	  in	  vitro	  depletion	  of	  
Kin1	   in	   MDA-­‐MB-­‐231	   breast	   cancer	   epithelial	   cells	   was	   shown	   to	   increase	  
incidence	  of	  mitotic	  spindle	  defects,	  as	  demonstrated	  by	  IF	  staining	  [53].	  This	  
prompted	  us	  to	  study	  the	  role	  of	  Kin1	  in	  mitosis	  in	  vivo,	  which	  we	  described	  in	  
Chapter	   3,	   and	   characterise	   the	   role	   of	   Kin1	   as	  well	   as	   Kin2	   in	  mitosis	   in	   a	  
more	  comprehensive	  manner,	  which	  was	  the	  aim	  of	  this	  chapter.	  We	  achieved	  
this	  with	  the	  use	  of	   live	  cell	   imaging	  that,	  contrary	  to	  the	  static	  nature	  of	   IF,	  
enabled	  us	  to	  analyse	  the	  dynamic	  and	  temporal	  nature	  of	  mitosis.	  	  
	  
4.9.1.	  Kin1	  regulates	  chromosome	  segregation	  in	  MDA-­‐MB-­‐231	  cells	  	  
Live	  cell	   imaging	  uncovered	  a	  novel	  role	  for	  Kin1	  in	  chromosome	  segregation	  
in	  MDA-­‐MB-­‐231	  cells.	  Erroneous	  chromosomal	  segregation	  is	  often	  a	  result	  of	  
hypostable	  spindles,	  as	  observed	  after	   in	   vitro	  depletion	  of	  spindle-­‐stabilising	  
proteins	  such	  as	  EB1	  [166]	  and	  csi2p	  [167].	  	  
	  
Notably,	   recent	   data	   showed	   that	   α-­‐tub	   acetyltransferase	   TgATAT	  promoted	  
α-­‐tub	   acetylation,	   which	   enhanced	   spindle	   stability	   and	   was	   required	   for	  
correct	   chromosome	   segregation	   in	   Toxoplasma	   [168].	   This	   finding	   linked	  
chromosomal	  segregation	  fidelity,	  microtubule	  stability	  and	  α-­‐tub	  acetylation,	  
a	  connection	  that	  was	  also	  highlighted	  in	  our	  data.	  	  
	  
Our	  in	  vivo	  observations	  (Chapter	  3)	  and	  recently	  published	  data	  from	  our	  lab	  
showed	   that	   loss	   or	   depletion	   of	  Kin1	   in	  mouse	   epidermis	   and	  MDA-­‐MB-­‐231	  
cells,	   respectively,	   significantly	   reduced	   levels	   of	   acetylated	   α-­‐tub	   (Fig.12.,	  
[156]),	  which	  is	   indicative	  of	  reduced	  microtubule	  stability	  [137]-­‐[140].	  One	  of	  
the	  main	   regulators	   of	   ac-­‐tub	   levels	   is	  HDAC6	   [161][162].	   Data	   from	   our	   lab	  
showed	  that	  application	  of	  tubacin,	  a	  selective	  HDAC6	  inhibitor	  [163],	  rescued	  
the	   reduction	   in	   ac-­‐tub	   levels,	   in	   mitotic	   and	   interphase	   cells,	   and	   spindle	  
instability	   in	  MDA-­‐MB-­‐231	   cells	   [156].	   Additionally,	   incubation	   with	   tubacin	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followed	   by	   gradual	   washout	   resulted	   in	   si-­‐NT	   and	   si-­‐Kin1	   treated	   cells	  
gradually	   reducing	   ac-­‐tub	   levels,	   which,	   however,	   did	   not	   occur	   in	  HDAC6-­‐
depleted	  cells	  [53].	  Overall,	  these	  data	  showed	  that	  Kin1	  regulated	  ac-­‐tub	  levels	  
and	  microtubule	   stability	   in	   an	  HDAC6-­‐dependent	  manner	   in	  MDA-­‐MB-­‐231	  
cells.	  By	  showing	  full	  rescue	  of	  chromosome	  missegregation	  defects	  in	  tubacin	  
treated,	   Kin1	   depleted	   cells	   (Fig.22.C.),	   our	   observations	   demonstrated	   that	  
Kin1	   controls	   chromosome	   segregation	   fidelity	   during	   mitosis	   via	   HDAC6	  
mediated	  regulation	  of	  ac-­‐tub	  levels	  and,	  hence,	  microtubule	  stability.	  	  
	  
Interestingly,	  our	  lab	  showed	  that	  ac-­‐tub	  levels	  were	  similar	  after	  expression	  of	  
wild-­‐type	  Kin1	  and	  Kin1-­‐W612A	  integrin-­‐binding	  mutant	  in	  Kin1-­‐depleted	  cells,	  
demonstrating	  that	  Kin1	  regulated	  ac-­‐tub	  in	  an	  integrin-­‐independent	  manner	  
[156].	   This	   suggests	   that	   in	   our	   findings	   Kin1	   may	   regulate	   chromosome	  
segregation	   fidelity	   and	   ac-­‐tub	   levels	   independent	   of	   its	   role	   in	   integrin	  
activation.	  
	  
4.9.2.	  Kin1	  regulates	  spindle	  orientation	  in	  MDA-­‐MB-­‐231	  cells	  	  
Live	   cell	   imaging	   also	   confirmed	   defects	   in	   mitotic	   spindle	   orientation	   in	  
MDA-­‐MB-­‐231	  cells	  upon	  depletion	  of	  Kin1	  (Fig.22.B.),	  which	  we	  also	  observed	  
in	   vivo	   following	   loss	   of	   Kin1	   in	  mouse	   epidermis	   (Fig.11.C.).	   These	   findings	  
mirrored	   previous	   IF	   data,	   showing	   increased	   spindle	   orientation	  
abnormalities	  in	  Kin1-­‐depleted	  MDA-­‐MB-­‐231	  cells	  [53].	  
	  	  
Our	  data	  showed	  that	  the	  role	  of	  Kin1	   in	  spindle	  orientation	  in	  MDA-­‐MB-­‐231	  
cells	   also	   occurs	   via	   regulation	   of	   HDAC6,	   as	   tubacin-­‐mediated	   HDAC6	  
inhibition	   partially	   rescued	   misorientation	   phenotype	   in	   Kin1	   depleted	   cells	  
(Fig.22.B.).	   Nevertheless,	   partial	   rescue	   of	   abnormal	   phenotype	   implies	   that	  
HDAC6-­‐mediated	   deacetylation	   of	   ac-­‐tub	   levels	   is	   not	   be	   the	   sole	   cause	   of	  
spindle	  misorientation	  in	  these	  cells.	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4.9.3.	  Kin1	  and	  Kin2	  display	  overlapping	  and	  distinct	  functions	  in	  
regulating	  mitotic	  homeostasis	  	  
As	   Kin1	   and	   Kin2	   have	   both	   overlapping	   and	   distinct	   functions	   in	   various	  
biological	   processes,	   we	   questioned	   whether	   in	   HeLa	   cells	   the	   two	   proteins	  
adopt	   the	   same	   or	   distinct	   roles	   to	   regulate	   mitotic	   homeostasis.	   After	  
examination	  of	   cell	  division	   in	  Kin1,	  Kin2	  and	  Kin1+Kin2	  depleted	  HeLa	  cells	  
with	   the	   use	   of	   live-­‐cell	   imaging,	   it	   became	   apparent	   that	   Kin1	   and	   Kin2	  
modulated	   various	  mitotic	   features	   in	   an	   overlapping	   or	   distinct	  manner.	   In	  
particular,	   we	   demonstrated	   that	   in	   HeLa	   cells,	   Kin1	   and	   Kin2	   were	   both	  
important	  for	  spindle	  orientation	  (Fig.29.B.)	  while	  Kin1	  regulated	  segregation	  
fidelity	   (Fig.29.C.),	  and	  Kin2	  was	  important	  for	  spindle	  formation	  (Fig.29.D.).	  
According	   to	   literature,	   these	   mitotic	   features	   can	   be	   regulated	   in	   integrin	  
dependent	  and/or	  independent	  ways.	  	  
	  
Although	  the	  mechanisms	  that	   lead	  to	  formation	  of	  multipolar	  spindles	  have	  
not	  been	  fully	  elucidated,	  perturbed	  β1	  integrin	  activation	  was	  shown	  as	  one	  of	  
the	  main	  causes	  of	  this	  phenotype	  [147][169],	  raising	  the	  possibility	  that	  Kin2	  
controls	  spindle	  formation	  via	  its	  role	  in	  β1	   integrin	  activation.	  If	  this	   is	  true,	  
then	   lack	   of	  multipolar	   spindles	   following	   Kin1	   depletion	   could	   also	   suggest	  
that	  Kin2	  may	  play	   a	   greater	   role	   in	   integrin	   activation	   compared	   to	  Kin1	   in	  
HeLa	  cells.	  	  
	  
As	   discussed	   earlier,	   chromosomal	   segregation	   fidelity	   depends	   on	  
microtubule	  stability	  mechanisms,	  such	  as	  acetylation	  of	  α-­‐tub	  [168],	  which	  we	  
detected	   in	   MDA-­‐MB-­‐231	   cells.	   As	   Kin1	   promoted	   α-­‐tub	   acetylation	  
independent	  of	   integrin	  activation	  in	  MDA-­‐MB-­‐231	  cells	  [156],	   it	   is	   likely	  that	  
Kin1	   could	   also	   exert	   its	   role	   in	   chromosome	   segregation	   in	   HeLa	   cells	   via	  
integrin-­‐independent	  microtubule	  stability.	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Finally,	   as	   reviewed	   extensively	   in	   Chapter	   3,	   Section	   3.6.1.,	   spindle	  
orientation	   can	   occur	   in	   various	   integrin-­‐dependent	   ways,	   such	   as	   cell-­‐
substrate	  adhesion,	  and	   integrin-­‐independent	  ways,	   such	  as	  via	   regulation	  of	  
microtubule	   stability	   [137].	   Kin1	   and	   Kin2	   play	   a	   critical	   role	   in	   β1	   integrin	  
activation,	  but	  not	  always	  to	  the	  same	  extent	  [88].	   It	   is,	   therefore,	   likely	  that	  
greater	  incidence	  of	  spindle	  misorientation	  in	  Kin2	  depleted	  cells	  compared	  to	  
Kin1	  depleted	  cells	  could	  reflect	  that	  in	  HeLa	  cells	  Kin2	  may	  play	  a	  greater	  role	  
in	   integrin	   activation	   compared	   to	   Kin1.	   Nevertheless,	   this	   could	   also	   result	  
from	  the	   fact	   that	  Kin1	  and	  Kin2	  may	  control	   spindle	  orientation	  via	  distinct	  
pathways.	   For	   example,	   Kin1	  may	   control	   spindle	   orientation	   in	   an	   integrin-­‐
independent	  pathway,	  via	  its	  role	  in	  microtubule	  stability	  [156],	  whereas	  Kin2	  
may	  function	  towards	  spindle	  orientation	  via	  its	  role	  in	  β1	  integrin	  activation.	  	  
	  
It	   is,	   therefore,	   important	   to	   analyse	   β1	   integrin	   activation	   after	   individual	  
depletion	  or	   co-­‐depletion	  of	  Kin1	   and	  Kin2	   in	  our	  model,	  which	  will	  help	  us	  
appreciate	  if	  and	  to	  which	  extent	  Kin1	  and	  Kin2	  activate	  β1	   integrins	  in	  HeLa	  
cells.	   Use	   of	  W612A	   and	  W615A	  Kin1	   and	   Kin2	   β1	   integrin-­‐binding	  mutants,	  
respectively	   [49][53][99][170],	   will	   help	   us	   define	   whether	   Kin1	   and	   Kin2	  
control	   features	   of	  mitosis,	   such	   as	   spindle	   formation	   and	   orientation,	   in	   an	  
integrin	  dependent	  manner.	  
	  
4.9.4.	  Kin1	  and	  Kin2	  display	  distinct	  functions	  in	  regulating	  cell	  
morphology	  	  
Besides	   differential	   regulation	   of	   mitotic	   features,	   our	   findings	   showed	   that	  
Kin1	  and	  Kin2	  do	  not	  exhibit	   the	  same	  role	   in	  control	  of	  cell	  morphology.	   In	  
HeLa	   cells,	   Kin2,	   but	   not	   Kin1	   depletion	   led	   to	   aberrant	   cell	   phenotype	  
(Fig.25.),	   implying	   that	   Kin2,	   contrary	   to	   Kin1,	   may	   exert	   a	   role	   in	   cell	  
morphology	   regulation	   in	   this	   mode.	   Interestingly,	   in	   MDA-­‐MB-­‐231	   cells,	  
where	   Kin1,	   but	   not	   Kin2	   is	   expressed,	   Kin1	   played	   a	   role	   in	   morphology	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(Fig.18.),	   indicating	  that	   in	  that	  model	  Kin1	  could	  adopt	  some	  functions	  that	  
in	  other	  cell	  lines,	  such	  as	  HeLa	  cells,	  would	  otherwise	  be	  carried	  out	  by	  Kin2.	  
	  
Rounded	   cell	   shape,	   similar	   to	   the	   one	   observed	   in	   Kin2	   and	   Kin1+Kin2	  
depleted	   HeLa	   cells,	   was	   observed	   in	   talin-­‐depleted	   fibroblasts	   and	   mouse	  
embryonic	   stem	   cells,	   along	   with	   compromised	   focal	   adhesion	   assembly	   as	  
well	   as	   reduced	   cell-­‐substrate	   adhesion	   and	   decreased	   expression	   of	   total	   or	  
active	  β1	   integrin	  [171][87].	   Individual	   loss	  of	  Kin1	  or	  Kin2	  in	  different	  models	  
impairs	  the	  formation	  of	  focal	  adhesions,	  as	  seen	  in	  KS	  keratinocytes	  and	  Kin2-­‐
deleted	   endoderm	   cells,	   respectively	   [94][99].	   However,	   when	   individual	  
depletion	   of	   Kin1	   and	   Kin2	   were	   compared	   concomitantly	   in	   immortalised	  
keratinocytes,	  effect	  of	  Kin2	  depletion	  in	  focal	  adhesion	  formation	  was	  much	  
more	   severe	   when	   compared	   to	   that	   of	   Kin1	   depletion,	   which	   only	   affected	  
focal	   adhesions	   to	   a	   negligible	   level	   [88].	  We	   have	   yet	   to	   examine	   whether	  
implications	  of	  Kin2	  depletion	   in	  HeLa	  cell	  morphology	  are	   accompanied	  by	  
defects	   in	   β1	   integrin-­‐mediated	   cell	   adhesion,	   and	   whether	   Kin1	   and	   Kin2	  
control	  this	  process	  in	  a	  differential	  manner	  as	  well.	  	  
	  
4.9.5.	  Summary	  and	  future	  work	  
Overall,	  our	  findings	  indicated	  overlapping	  and	  different	  roles	  of	  Kin1	  and	  Kin2	  
in	  mitotic	   homeostasis,	   as	   individual	   depletion	   of	   the	   two	   proteins	   affected	  
mitosis	   in	   similar	   and	   separate	   ways.	   Distinct	   Kin1	   and	   Kin2	   functions	   have	  
been	   reported	   previously	   in	   keratinocytes	   in	   cell-­‐cell	   contact	   and	   focal	  
adhesion	   formation	   [88].	   Examination	   of	   rescue	   of	   mitotic	   abnormalities	  
following	  endogenous	  depletion	  of	  Kin1	  and	  Kin2	  and	  concomitant	  expression	  
of	  si-­‐RNA-­‐resistant	  Kin1	  and	  Kin2,	  along	  with	  use	  of	  individual	  siRNA	  oligos	  to	  
deplete	  Kin1	  and	  Kin2	  in	  HeLa	  cells,	  will	  allow	  us	  to	  evade	  potential	  siRNA	  off-­‐
target	   effects.	   This,	   together	  with	   re-­‐expression	   of	   integrin-­‐binding	  Kin1	   and	  
Kin2	   mutants	   will	   help	   to	   further	   elucidate	   Kin1	   and	   Kin2	   roles	   in	   mitotic	  
homeostasis.
Chapter	  5:	  exploring	  the	  role	  of	  Kin1	  in	  SCC	   106	  
Chapter	  5:	  	  
exploring	  the	  roles	  of	  Kin1	  in	  SCC	  
	  
Kin1	   is	  documented	  to	  promote	  carcinogenesis,	   invasion	  and	  metastasis.	   It	   is	  
overexpressed	  in	  lung,	  colon	  and	  bladder	  cancer	  and	  promotes	  progression	  of	  
pancreatic	   cancer	   via	   enhancement	   of	   cell	   migration	   and	   invasion	   [110][111].	  
Kin1	   was	   also	   shown	   to	   promote	   breast	   cancer	   lung	  metastasis	   [115],	   and	   in	  
hepatocellular	  carcinoma	  its	  expression	  positively	  correlated	  with	  tumour	  size	  
and	  aggressiveness,	  status	  of	  metastasis	  and	  unfavourable	  overall	  survival	  [112].	  
	  
Paradoxically,	  absence	  of	  Kin1	  also	  promotes	  oncogenesis,	  as	  KS	  patients	  have	  
a	  propensity	  to	  develop	  aggressive,	  cutaneous	  SCC	  [9][10][13].	  A	  cohort	  study	  
of	  62	  patients	  revealed	  that	  70%	  of	  KS	  patients	  over	  45	  years	  old	  had	  developed	  
SCC	   [9],	   making	   it	   one	   of	   the	   biggest	   complications	   within	   the	   KS	   patient	  
population.	  Little	  is	  known	  about	  the	  mechanism	  that	  predisposes	  KS	  patients	  
to	  SCC.	  There	  is	  a	  single	  in	  vivo	  study	  that	  defines	  a	  tumour	  suppressor	  role	  for	  
Kin1	   in	  the	  skin	  via	  control	  of	  homeostasis	  of	  cutaneous	  epithelial	  stem	  cells,	  
by	   maintaining	   a	   balance	   between	   Wnt-­‐β-­‐catenin-­‐mediated	   growth-­‐
stimulating	  signals	  and	  TGF-­‐β-­‐mediated	  growth-­‐supressing	  signals	  [119].	  
	  
However,	  to	  date,	  no	  study	  has	  addressed	  the	  role	  of	  Kin1	  in	  development	  and	  
progression	   of	   this	   pathology.	   SCC	   that	   develops	   particularly	   in	   limbs	   of	   KS	  
patients	   is	   extremely	   aggressive	   and	   metastatic,	   and	   sometimes	   fatal,	   often	  
necessitating	   amputation	   and	   lymph	   node	   excision	   [2][13][14].	   Search	   for	   a	  
comprehensive	   explanation	   for	   the	   function	   of	   Kin1	   in	   KS-­‐developed	   SCC	  
tumours	   will	   provide	   a	   mechanistic	   aetiology	   for	   the	   tumour	   biology	   and	  
aggressiveness,	   and	   potentially	   improve	   patient	   treatment	   and	   overall	  
Chapter	  5:	  exploring	  the	  role	  of	  Kin1	  in	  SCC	   	  	   107	  
prognosis.	  Thus,	  here	  we	  sought	  to	  define	  a	  role	  for	  Kin1	  in	  cutaneous	  SCC	  in	  
vitro	  and	  in	  vivo.	  	  
	  
Specific	  aims	  of	  this	  chapter	  include:	  
1. Characterisation	  of	   in	  vitro	  SCC	  model	  of	  conditional	  Fermt1	  knockout	  
and	  re-­‐expression	  of	  wild	  type	  and	  integrin-­‐binding	  mutant	  Fermt1.	  	  
2. Development	   and	   characterisation	   of	   in	   vivo	   mouse	   model	   of	   SCC,	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5.1.	  Characterisation	  of	  mouse	  SCC	  cell	  lines	  	  
To	  address	   the	   role	  of	  Kin1	   in	  cutaneous	  SCC,	  we	  used	  mouse	  SCC	  cell	   lines	  
that	  had	  previously	  been	  generated	  in	  the	  lab	  in	  K14-­‐Cre-­‐Kin1fl/fl	  mice,	  via	  the	  
application	  of	   the	  well-­‐established	   two-­‐stage	  protocol	   of	   cutaneous	   chemical	  
carcinogenesis	   [126][127]	   (Fig.30.A.).	   In	   particular,	   application	   of	   chemical	  
initiator	   mutagen	   DMBA	   (Fig.30.A.1.)	   was	   followed	   by	   application	   of	   pro-­‐
inflammatory,	  pro-­‐proliferative	  TPA	  (Fig.30.A.2.),	  leading	  to	  the	  formation	  of	  
benign	   cutaneous	   papillomas,	   some	   of	   which	   progressed	   to	   form	   cutaneous	  
SCC	  tumours	  (Fig.30.A.3.)	  in	  3	  K14-­‐Cre-­‐Kin1fl/fl	  mice	  (mouse	  no.117,	  no.130	  and	  
no.145).	   Subsequent	   isolation	   (Fig.30.A.4.)	   and	   culture	   (Fig.30.A.5.)	   of	   SCC	  
cells	   generated	   3	  mouse	   SCC	   cell	   lines	   (117	   SCC	   cells,	   130	   SCC	   cells,	   145	   SCC	  
cells)	   (Dr	   Hitesh	   Patel)	   with	   variable	   expression	   levels	   of	   Kin1	   and	   Kin2	  
(Fig.30.B.).	  	  
	  
We	  observed	   that	  mouse	  SCC	  cells	  were	  characterised	  by	  an	  overall	   spindle-­‐
shaped	   morphology	   (Fig.30.C.).	   Similar	   spindle-­‐like	   morphology	   was	  
previously	   observed	   in	   mouse	   SCC	   cells	   isolated	   from	   DMBA-­‐TPA-­‐induced	  
tumours,	   and	   was	   accompanied	   by	   reduced	   expression	   of	   E-­‐cadherin	   when	  
compared	   to	  normal	  epidermis	   [172].	   In	  agreement	  with	   this	  observation,	  we	  
saw	  that	  E-­‐cadherin	  expression	  was	  virtually	  absent	  from	  mouse	  SCC	  cell	  lines,	  











































Figure	  30:	  Development	  and	  characterisation	  of	  mouse	  SCC	  cell	   lines.	  3	  mouse	  SCC	  cell	  lines	  (117	  
SCC	   cells,	   130	   SCC	   cells,	   145	   SCC	   cells)	   had	   been	   generated	   following	   application	   of	   a	   2-­‐stage	  
chemical	   carcinogenesis	   protocol	   in	   3	   K14-­‐Cre-­‐Kin1fl/fl	  mice	   (mouse	   no.117,	   no.130,	   no.145).	  A:	   As	  
instructed	   by	   the	   carcinogenesis	   protocol	   (1.)	   application	   of	   DMBA,	   a	   chemical	   initiator	  mutagen,	  
was	   followed	   by	   (2.)	   application	   of	   TPA,	   a	   pro-­‐inflammatory,	   pro-­‐proliferative	   compound.	   (3.)	   A	  
number	  of	  the	  resulting	  benign	  papillomas	  subsequently	  progressed	  to	  SCC	  tumours	  from	  which	  cells	  
were	   (4.)	   isolated	   and	   (5.)	   cultured	   (Dr	   Hitesh	   Patel).	   B:	  Western	   blot	   analysis	   of	   Kin1	   and	   Kin2	  
expression	   in	   117,	   130	   and	   145	   SCC	   cells.	   Each	   lane	   contains	   15μg	   of	   lysate.	   β-­‐actin	  was	   used	   as	  
loading	   control.	   C:	   Representative	   phase-­‐contrast	   images	   of	   117,	   130	   and	   145	   SCC	   cells	   in	   two-­‐
dimensional	   cell	   culture.	   Scale	   bar	   represents	   125μm.	   D:	   Western	   blot	   analysis	   of	   E-­‐cadherin	  
expression	  in	  mouse	  tail	  keratinocytes,	  and	  117,	  130	  and	  145	  SCC	  cells.	  Each	  lane	  contains	  10μg	  of	  
lysate.	  β-­‐actin	  was	  used	  as	  loading	  control.	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5.2.	  Cre-­‐Lox	  recombination	  system-­‐mediated	  conditional	  
knockout	  of	  Fermt1	  in	  mouse	  SCC	  cells	  	  
We	  next	  used	  a	  mouse	  SCC	  cell	  line,	  previously	  developed	  in	  the	  lab	  as	  follows	  
(Dr	   Hitesh	   Patel),	   in	   which	   Fermt1	   deletion	   recapitulated	   the	   Kin1-­‐null	  
background	  of	  SCC	  tumours	  developed	  in	  KS	  patients.	  
	  
To	  achieve	  Fertm1	  knockout,	  117	  SCC	  cells	  had	  been	  treated	  with	  4OHT	  for	  48	  
hours	   (117	   SCC+4OHT).	   This	   induced	   Cre-­‐mediated	   genetic	   deletion	   of	   the	  
Fermt1	   gene	   [125],	   as	   117	   SCC	   cells	   had	   been	   generated	   in	   a	   K14-­‐Cre-­‐Kin1fl/fl	  
mouse	   (Fig.30.A.).	   Heterogeneity	   within	   a	   tumour	   mass	   and,	   therefore,	   a	  
tumour-­‐derived	  cell	  line,	  as	  well	  as	  variability	  in	  the	  success	  rate	  of	  Cre-­‐loxP-­‐
mediated	   gene	   deletion,	   exposed	   the	   need	   for	   identification	   of	   individual	  
Kin1null	   cells	   within	   the	   117	   SCC+4OHT	   cell	   population.	   As	   a	   result,	   single-­‐cell	  
cloning	   had	   been	   employed	   and	   aimed	   to	   isolate	   multiple	   Kin1null	   SCC	   cell	  
clones	  that	  would,	  ultimately,	  be	  expanded	  into	  cell	   lines.	  This	  would	  enable	  
evaluation	  of	  the	  biological	  reproducibility	  and	  exclude	  the	  possibility	  that	  any	  
differences	  between	  Kin1null	  and	  Kin1wt	  SCC	  cells	  were	  due	  to	  clonal	  variation.	  
However,	  only	  a	  single	  Kin1null	  SCC	  clone	  had	  been	  detected,	  thus	  reflecting	  a	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5.3.	  Characterisation	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  mouse	  SCC	  
cell	  lines	  
Due	   to	   potential	   variation	   of	   individual	   clones	  within	   a	   cell	   line	   population,	  
comparison	  between	  the	  Kin1null	  clonal	  SCC	  cell	   line	  with	  a	  clonal	  cell	   line	  in	  
which	  Fermt1	  was	  still	  expressed	  was	  avoided.	  Instead,	  we	  sought	  to	  compare	  
how	  does	  re-­‐expression	  of	  wild	  type	  or	  mutant	  Fermt1	  on	  a	  Kin1null	  background	  
regulate	  SCC	  growth	  and	  behaviour,	  both	  in	  vitro	  and	  in	  vivo.	  	  
	  
For	   this,	  we	  used	  cell	   lines	   that	  had	  been	  previously	  prepared	   in	   the	   lab	   (Dr	  
Hitesh	  Patel)	  as	  follows.	  Kin1null	  clone	  obtained	  via	  Cre-­‐LoxP-­‐mediated	  Fermt1	  
deletion	  (Chapter	  5,	  Section	  5.2)	  was	  expanded	  into	  a	  Kin1null	  SCC	  cell	  line	  to	  
which	   wild	   type	   Fermt1	   (Fig.31.A.ii.)	   and	   QW611/612AA	   Fermt1	   mutant,	  
encoding	  Kin1	  unable	  to	  interact	  with	  integrins	  (Fig.31.A.iii.),	  were	  introduced	  
with	   the	   use	   of	   pWZL	   retroviral	   vector.	   Use	   of	   SCC	   cell	   line	   carrying	  
QW611/612AA	  Fermt1	  mutation	  (hereinafter	  referred	  to	  as	  Kin1AA	  SCC	  cell	  line)	  
allowed	  us	  to	  examine	  whether	  the	  role	  of	  Kin1	  in	  SCC	  is	  dependent	  upon	  the	  
protein’s	  ability	  to	  bind	  and	  activate	  integrins.	  
	  
We	   initially	   confirmed	   loss	   of	   Kin1	   in	   Kin1null	   SCC	   cell	   line	   (Fig.31.B-­‐C.).	  
Overall,	   there	   was	   differential	   expression	   of	   Kin1	   across	   Kin1null,	   Kin1wt	   and	  
Kin1AA	  SCC	  cells,	  and	  we	  observed	  that	  Kin1AA	  SCC	  cells	  expressed	  the	  highest	  
levels	   of	   Kin1	   amongst	   the	   three	   SCC	   cell	   lines	   (Fig.31.C.).	   A	   slight,	   non-­‐
significant	  difference	  was	  observed	  in	  expression	  of	  Kin2,	  according	  to	  which	  
Kin1AA	  SCC	  cells	  expressed	  the	  lowest	  levels	  of	  Kin2,	  whereas	  Kin1null	  SCC	  cells	  
the	   highest	   (Fig.31.D.).	   	   Finally,	   we	   saw	   that	   all	   cell	   lines	   displayed	   an	  
elongated,	   spindle-­‐shaped	   morphology,	   and	   there	   was	   no	   phenotypic	  
difference	  between	  them	  (Fig.31.E.).	  
	  
	  
























Figure	   31:	   Development	   and	   characterisation	   of	   in	   vitro	  mouse	   SCC	   model:	   Kin1null,	   Kin1wt	   and	  
Kin1AA	  SCC	   cell	   lines.	   A:	   Kin1null,	   Kin1wt	   and	   Kin1AA	  SCC	   cell	   lines	   had	  been	   generated	   by	  Dr	  Hitesh	  
Patel	  as	   follows.	  Kin1null	  clonal	  SCC	  cell	   line	   (Kin1null	  SCC	  cells)	  was	   infected	  with	   (i)	  an	  empty	  pWZL	  
retroviral	  vector	  (Kin1null),	  (ii)	  pWZL	  vector	  with	  a	  wild-­‐type	  Fermt1	  (Kin1wt)	  or	  (iii)	  pWZL	  vector	  with	  
a	  Fermt1QW611/612AA	   (Kin1AA).	  B:	  Western	  blot	  analysis	  of	  Kin1	  and	  Kin2	  expression	   in	  Kin1null,	   Kin1wt	  
and	  Kin1AA	  SCC	  cell	  lines.	  Each	  lane	  contains	  15μg	  of	  lysate.	  β-­‐actin	  was	  used	  as	  loading	  control.	  C-­‐D:	  
Quantification	   of	   C:	   Kin1	   and	   D:	   Kin2	   expression	   levels	   was	   performed	   in	   relation	   to	   β-­‐actin	  
expression	   levels	   via	   band	   densitometric	   analysis	   with	   ImageJ	   software.	   For	   each	   graph,	   3	  
independent	  western	  blots	  were	  used	  to	  calculate	  protein	  expression.	  Results	  presented	  as	  mean	  ±	  
SEM.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test;	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐
value	  ≤	  0.01.	  E:	  Representative	  phase-­‐contrast	   images	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	   lines	   in	  
two-­‐dimensional	  cell	  culture.	  Scale	  bar	  represents	  125μm.	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5.4.	  Subcellular	  localisation	  of	  Kin1	  and	  Kin2	  within	  Kin1null,	  
Kin1wt	  and	  Kin1AA	  mouse	  SCC	  cell	  lines	  
All	   members	   of	   the	   kindlin	   protein	   family	   are	   localised	   at	   focal	   adhesions	  
where	   they	   bind	   to	   and	   activate	   integrins	   and,	   ultimately,	   contribute	   to	   the	  
connection	   between	   actin	   cytoskeleton	   and	   extracellular	   matrix	  
[49][97][99][100][173].	   We,	   thus,	   inspected	   localisation	   of	   Kin1	   and	   Kin2	   in	  
subcellular	   compartments	   of	   Kin1null,	   Kin1wt	   and	   Kin1AA	   SCC	   cell	   lines,	  
including	  focal	  adhesions,	  with	  the	  use	  of	  IF.	  	  
	  
As	  expected,	  Kin1	  was	  absent	  from	  Kin1null	  SCC	  cells,	  and	  was	  enriched	  at	  focal	  
adhesions,	   where	   it	   colocalised	  with	   FAK,	   as	   well	   as	   in	   nuclei	   of	   Kin1wt	  SCC	  
cells	  (Fig.32.A.).	  Kin1	  also	  localised	  at	  focal	  adhesions	  and	  in	  nuclei	  of	  Kin1AA	  
SCC	  cells	  (Fig.32.A.).	  We	  detected	  localisation	  of	  Kin2	  at	  focal	  adhesions,	  but	  
not	   in	   nuclei,	   in	   all	   SCC	   cell	   lines	   (Fig.32.B.).	   Finally,	  we	   detected	   punctate	  





























































Figure	  32:	  Subcellular	  localisation	  of	  Kin1	  and	  Kin2	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	  lines.	  A-­‐B:	  
Representative	  IF	  images	  of	  A:	  Kin1	  and	  B:	  Kin2	  subcellular	  localisation	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
SCC	   cell	   lines.	   White	   arrows	   indicate	   nuclear	   localisation	   of	   Kin1.	   Yellow	   arrows	   indicate	  
colocalisation	  of	  Kin1	  or	  Kin2	  with	  FAK	  at	  focal	  adhesions.	  Scale	  bar	  represents	  50μm.	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5.5.	  In	  vitro	  assessment	  of	  proliferation	  and	  clonogenicity	  in	  
Kin1null,	  Kin1wt	  and	  Kin1AA	  mouse	  SCC	  cell	  lines	  	  
We	  next	  set	  out	  to	  explore	  the	  in	  vitro	  role	  of	  Kin1	  in	  proliferation	  of	  the	  three	  
mouse	   SCC	   cell	   lines.	   A	   growing	   body	   of	   evidence	   suggests	   that	   cellular	  
functions	  including	  proliferation	  [174][175],	  cell-­‐ECM	  interactions	  [176],	  as	  well	  
as	  gene	  and	  protein	  expression	  [177][178]	  vary	  between	  two-­‐dimensional	  (2D)	  
and	   three-­‐dimensional	   (3D)	   cultures,	   which	   prompted	   us	   to	   examine	   cell	  
proliferation	  in	  both	  systems.	  
	  
We	   initially	   assessed	   the	   proliferation	   of	   Kin1null,	   Kin1wt	   and	   Kin1AA	   SCC	   cell	  
lines	   in	   2D	   conditions.	   To	   achieve	   this,	   we	   seeded	   cells	   at	   low	   density	   on	  
artificial	  substrate,	  which	  enabled	  the	  formation	  of	  2D	  monolayers	  (Fig.33.A.).	  
We	   then	   monitored	   cell	   density	   as	   a	   marker	   for	   proliferation	   in	   a	   2D	  
environment,	   in	   real	   time	  over	   the	  course	  of	   four	  days	  with	   the	  use	  of	   time-­‐
lapse	  microscopy.	  We	  observed	  no	   significant	  difference	   in	   cell	  density,	   and,	  

















































Figure	  33:	  In	  vitro	  assessment	  of	  proliferation	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	  lines	  in	  2D	  cell	  
culture.	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cells	  were	  seeded	  at	  low	  density	  on	  artificial	  substrate	  where	  
they	  proceeded	  to	  proliferate	  and	  form	  2D	  monolayers.	  Post-­‐seeding,	  phase-­‐contrast	  images	  of	  cells	  
were	  captured	  every	  3	  hours	  by	  Incucyte	  live	  cell	  analysis	  system,	  and	  were,	  eventually,	  combined	  to	  
form	  time-­‐lapse	  microscopy	  movies.	  A:	  Representative	  phase-­‐contrast	  images	  captured	  on	  Day0	  and	  
Day3	   post-­‐seeding.	   Scale	   bar	   represents	   30μm.	   B:	   Quantification	   of	   cell	   density	   (%	   of	   well	   area	  
covered	  by	  cells)	  of	  Kin1null,	   Kin1wt	  and	  Kin1AA	  SCC	  cells	  was	  performed	  at	  Day0,	  Day1,	  Day2,	  Day3	  
and	   Day4	   post-­‐seeding,	   using	   data	   generated	   automatically	   by	   Incucyte	   control	   software.	   Results	  







Chapter	  5:	  exploring	  the	  role	  of	  Kin1	  in	  SCC	   	  	   117	  
We	   proceeded	   to	   evaluate	   proliferation	   of	   the	   three	   SCC	   cell	   lines	   in	   a	   3D	  
environment	  with	  the	  use	  of	  methylcellulose-­‐over-­‐agarose	  proliferation	  assay.	  
Single-­‐cell	  suspensions	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cells	  were	  seeded	  on	  
low-­‐adherent	  agarose	  plates	  with	  methylcellulose	  media,	  which	  facilitated	  the	  
gradual	  growth	  of	  single	  cells	  into	  3D	  spheroids	  (Fig.34.A.).	  Cell	  proliferation	  
was	  reflected	  by	  spheroid	  growth,	  monitored	  by	  measuring	  the	  average	  area	  of	  
individual	  3D	  spheroids	  from	  Day1,	  which	  is	  when	  spheroids	  started	  forming,	  
until	  Day6	  post-­‐seeding.	  	  
	  
We	   observed	   growth	   in	   all	   spheroids	   from	   Day1	   until	   Day3,	   after	   which	   it	  
proceeded	   to	   decline	   in	   Kin1wt	   and	   Kin1AA	   spheroids	   and	   arrest	   in	   Kin1null	  
spheroids	   (Fig.34.B.).	   We	   found	   that	   by	   Day3,	   Kin1null	   spheroids	   were	  
significantly	   larger	  when	  compared	  to	  Kin1wt	  and	  Kin1AA	  cell	   lines	  (Fig.34.B.).	  
Despite	   not	   reaching	   significance	   following	   statistical	   analysis,	   we	   observed	  
that	  Kin1wt	   spheroids	  were	   slightly	   larger	   than	  Kin1AA	   spheroids	   at	  Day3	   and	  
Day6	  (Fig.34.B.).	  	  
	  
By	   Day3	   there	   was	   still	   a	   number	   of	   Kin1null,	   Kin1wt	   and	   Kin1AA	   single	   cells,	  
which	  had	  not	  managed	  to	  grow	  into	  spheroids.	  We	  thus,	  proceeded	  to	  assess	  
the	   clonogenicity	   of	   each	   cell	   line,	   by	   measuring	   the	   percentage	   of	   Kin1null,	  
Kin1wt	  and	  Kin1AA	  3D	  spheroids	   that	  had	   formed	  by	  Day3.	  Following	  analysis,	  
we	   detected	   that	   Kin1null	   SCC	   cells	   had	   formed	   a	   significantly	   greater	  
percentage	   of	   3D	   spheroids	   and,	   thus,	   had	   the	   highest	   clonogenicity	   when	  








































Figure	  34:	   In	  vitro	  assessment	  of	  proliferation	  and	  clonogenicity	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  
cell	  lines	  in	  3D	  cell	  culture.	  Single-­‐cell	  suspension	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cells	  was	  seeded	  
in	  methylcellulose-­‐over-­‐agarose	  assay	  to	  enable	  the	  gradual	  growth	  of	  single	  cells	  into	  3D	  spheroids.	  
A:	   Representative	   phase-­‐contrast	   images	   captured	   on	   Day0	   and	   Day3	   post-­‐seeding.	   Scale	   bar	  
represents	   125μm.	  B:	   3D	   spheroid	   growth	   was	   determined	   by	  manual	   quantification	   of	   spheroid	  
area	  from	  Day1	  to	  Day6	  post-­‐seeding	  with	  ImageJ	  software.	  A	  collection	  of	  cells	  was	  considered	  as	  a	  
spheroid	   if	   it	   occupied	   an	   area	   ≥	   3	   times	   larger	   than	   the	   average	   area	   of	   a	   single	   cell.	   Manual	  
quantification	  of	   the	   single-­‐cell	   area	  was	  performed	  at	  Day0	  post-­‐seeding	  with	   ImageJ	   software.	  5	  
low-­‐power	  fields	  were	  analysed	  per	  cell	  line.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test.	  
C:	   Quantification	   of	   cell	   line	   clonogenicity	   was	   determined	   by	   measuring	   the	   percentage	   of	   3D	  
spheroids	  at	  Day3	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	  lines.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  
comparison	  test.	  B-­‐C:	  Results	  presented	  as	  mean	  ±	  SEM.	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	  
≤	  0.01	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5.6.	  In	  vivo	  assessment	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  mouse	  SCC	  
tumour	  growth	  
We	   next	   sought	   to	   determine	   whether	   growth	   of	   Kin1null,	   Kin1wt	   and	   Kin1AA	  
mouse	  SCC	  cell	  lines	  in	  vitro	  reflected	  in	  vivo	  tumour	  growth,	  by	  carrying	  out	  
bilateral	   subcutaneous	   implantations	   of	   SCC	   cells	   in	   7-­‐week	   old	   CD-­‐1	   nude	  
mice.	  	  
	  
We	   initially	   injected	   0.50x106	  Kin1null	   or	   Kin1wt	   SCC	   cells	   per	  mouse	   flank,	   in	  
order	   to	   assess	   differences	   between	   growth	   of	   Kin1null	   and	   Kin1wt	   tumours	  
(tumour	  growth	  study	  A)	  (Fig.35.A.).	  Subsequently,	  to	  compare	  the	  growth	  of	  
Kin1AA	  tumours	  against	  Kin1null	  and	  Kin1wt	  tumour	  growth,	  we	  also	  carried	  out	  
injections	  of	  1.00x106	  and	  0.25x106	  Kin1null,	  Kin1wt	  or	  Kin1AA	  SCC	  cells	  per	  mouse	  
flank,	   during	   tumour	   growth	   study	   B	   (Fig.35.B.)	   and	   C	   (Fig.35.C.),	  
respectively.	   Injections	   of	   different	   number	   of	   cells	   in	   every	   tumour	   growth	  
study	   allowed	   us	   to	   scrutinise	   if	   the	   number	   of	   SCC	   cells	   injected	   affected	  
tumour	  growth	  and,	  thus,	  reproducibility	  of	  results.	  Signs	  of	  tumour	  ulceration	  
led	  to	  termination	  of	  studies	  at	  Day	  24.	  	  
	  
Overall,	   we	   observed	   that	   differences	   in	   growth	   between	   Kin1null,	   Kin1wt	   and	  
Kin1AA	  tumours	  started	  to	  appear	  between	  Day10	  and	  Day17	  post-­‐implantation,	  
as	  prior	  to	  that	  all	  tumours	  had	  similar	  volume	  (Fig.35.A-­‐C.).	  Kin1null	  tumours	  
were	  significantly	  larger	  than	  Kin1wt	  tumours	  in	  every	  growth	  study	  (Fig.35.A-­‐
C.).	  According	  to	  tumour	  volume	  data	  from	  growth	  study	  B,	  Kin1null	   tumours	  
were	   significantly	   larger	   than	  Kin1wt	   and	  Kin1AA	   tumours,	   and	  Kin1wt	  tumours	  
were	   also	   significantly	   larger	   than	   Kin1AA	   tumours	   (Fig.35.B.).	   This	   growth	  
trend	   was	   reflected	   between	   tumours	   of	   growth	   study	   C,	   but	   difference	  
between	  Kin1wt	  and	  Kin1AA	  tumours	  was	  not	  statistically	  significant	  (Fig.35.C.).	  	  
Interestingly,	  despite	   injection	  of	  different	  SCC	  cell	  number,	  Kin1null	   tumours	  
had	  reached	  comparable	  size	  by	  Day24	  in	  growth	  studies	  B	  and	  C,	  which	  was	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also	   observed	   for	   Kin1AA	   tumours,	   whereas	   Kinwt	   tumours	   were	   significantly	  
smaller	  in	  study	  C	  compared	  to	  study	  B	  (Fig.35.D.).	  This	  accounts	  for	  the	  non-­‐
statistically	   significant	   difference	   between	   Kin1wt	   and	   Kin1AA	   tumours	   in	  
growth	   study	   C	   (Fig.35.C.).	   Combination	   of	   growth	   rate	   data	   from	   growth	  
studies	  B	  and	  C	  allowed	  us	  to	  examine	  statistical	  significance	  between	  Kin1null,	  
Kin1wt	  and	  Kin1AA	  tumour	  growth	  across	  both	  studies,	  whilst	  circumventing	  the	  
variability	   in	   tumour	   volume	   values.	  We	   found	   that	   overall,	  Kin1null	   tumours	  
had	   significantly	   greater	   growth	   rate	   than	   Kin1wt	   and	   Kin1AA	   tumours,	   and	  















































Figure	   35:	   In	   vivo	   assessment	   of	   Kin1null,	   Kin1wt	   and	   Kin1AA	   SCC	   tumour	   growth.	   Bilateral	  
subcutaneous	  implantations	  of	  A:	  0.50x106	  Kin1null	  and	  Kin1wt,	  B:	  1.00x106	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
and	   C:	   0.25x106	  Kin1null,	   Kin1wt	   and	   Kin1AA	   SCC	   cells	   were	   administrated	   in	   CD-­‐1	   nude	   mice.	   A-­‐C:	  
Tumour	   volume	   was	   quantified	   over	   the	   course	   of	   24	   days.	   Only	   statistical	   analysis	   using	   values	  
obtained	   at	   Day24	   is	   shown.	   A:	   Unpaired	   t-­‐test.	   B:	   one-­‐way	   ANOVA	   with	   Tukey’s	   multiple	  
comparison	  test.	  C:	  Kruskal-­‐Wallis	  ANOVA	  with	  Dunn’s	  multiple	  comparison	  test.	  D:	  Combination	  of	  
tumour	  growth	  rate	  values	  from	  studies	  B	  and	  C	  represents	  the	  percentage/100	  of	  change	  of	  tumour	  
measurements	  against	   initial	   tumour	  measurements	   that	  were	  considered	  as	  a	  baseline	  start	  of	  1.	  
one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test.	  A-­‐D:	  Results	  presented	  as	  mean	  ±	  SEM.	  p-­‐
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5.7.	  Morphological	  assessment	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
mouse	  SCC	  tumours	  
Initially,	   morphology	   and	   tumour	   structure	   were	   assessed	   by	   H&E	   staining,	  




















Figure	  36:	  Morphological	  assessment	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  tumours.	  Representative	  IHC	  
images	  of	  H&E	  staining	  that	  was	  performed	  on	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  tumours	  from	  growth	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We	   observed	   a	   spindle-­‐like	   nuclear	   morphology	   across	   Kin1null,	   Kin1wt	   and	  
Kin1AA	  tumours	  (Fig.37.A).	  Upon	  closer	  inspection	  we	  saw	  that	  Kin1null	  tumour	  
nuclei	   displayed	   a	   more	   elongated	   structure	   when	   compared	   to	   Kin1wt	   and	  
Kin1AA	   nuclei	   (Fig.37.A).	   Nuclear	   length	   analysis	   on	   tumours	   from	   growth	  
study	  C	   confirmed	   our	   observation,	   as	   it	   showed	   that	  Kin1null	   tumour	   nuclei	  
were	  significantly	  longer	  than	  Kin1wt	  nuclei	  (Fig.37.B.).	  We	  also	  observed	  that	  
quantification	  of	  Kin1null	   and	  Kin1AA	  nuclear	   length	  reflected	  our	  observation,	  
as	  Kin1null	  nuclei	   showed	  a	   tendency	   towards	  a	   longer	   structure	  compared	   to	  
Kin1AA	   nuclei,	   albeit	   not	   reaching	   statistical	   significance	   (Fig.37.B.).	   We	  
believe	   that	   the	   variability	   in	   average	   nuclear	   length	   measurements	   within	  
Kin1null	   and	   Kin1AA	   tumours	   prevented	   the	   difference	   between	   Kin1null	   and	  
Kin1AA	   tumours	   nuclear	   length	   reaching	   significance	   and	   analysis	   of	   further	  
tumours	  will	  be	  required	  to	  confirm	  this.	  There	  was	  no	  significant	  difference	  in	  
the	   average	   area	   occupied	   by	   each	   Kin1null,	   Kin1wt	   and	   Kin1AA	   nucleus	   in	  
tumours	  from	  growth	  study	  C	  (Fig.37.C).	  	  
	  
Furthermore,	   we	   observed	   that	   Kin1null	   tumours	   displayed	   higher	   nuclear	  
density	   and	   lower	   ECM	   deposition	   compared	   to	   Kin1wt	   and	   Kin1AA	   tumours	  
(Fig.37.A.).	   To	   assess	   our	   observation	   on	   nuclear	   density	   more	   closely,	   we	  
measured	  the	  percentage	  of	  tumour	  area	  covered	  by	  all	  nuclei	  within	  various	  
fields	   of	   tumours	   from	   growth	   study	   C.	   We	   found	   that	   Kin1null	   tumours	  
displayed	  a	  significantly	  higher	  nuclear	  density	  when	  compared	  to	  Kin1wt	  and	  













































Figure	  37:	  Analysis	  of	  nuclear	  length,	  nuclear	  area	  and	  nuclear	  density	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
SCC	   tumours.	  H&E	  staining	  was	  performed	  on	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  tumours	  from	  growth	  
study	  C.	  A:	  Representative	  IHC	  images	  of	  H&E	  staining	  that	  display	  features	  such	  as	  tumour	  nuclear	  
structure	  and	  density.	  Mag	  x40.	  The	  scale	  bar	  represents	  50μm.	  B:	  Quantification	  of	  nuclear	  length	  
was	   performed	  manually	   with	   ImageJ	   software.	   5	   nuclei	   from	   5	   representative	   high-­‐power	   fields	  	  
were	   analysed	   per	   Kin1null,	   Kin1wt	   and	   Kin1AA	   tumour	   (n=4).	   Results	   presented	   as	   mean	   ±	   SEM.	  
Kruskal-­‐Wallis	  ANOVA	  with	  Dunn’s	  multiple	  comparison	  test.	  C:	  Quantification	  of	  area	  occupied	  by	  
each	   nucleus	   was	   performed	   manually	   with	   ImageJ	   software.	   Area	   of	   5	   individual	   nuclei	   from	   5	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representative	  high-­‐power	   fields	  was	  analysed	  per	  Kin1null,	  Kin1wt	  and	  Kin1AA	   tumour	   (n=4).	  Results	  
presented	  as	  mean	  ±	  SEM.	  one-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  comparison	  test.	  D:	  Quantification	  
of	  nuclear	  density	  was	  performed	  automatically	  with	  ImageJ	  software	  by	  calculating	  the	  percentage	  
of	  tumour	  field	  area	  covered	  by	  nuclei.	  Segmentation	  of	  higher	   intensity	  nuclear	  pixels	   from	  lower	  
intensity	  background	  pixels	  was	  performed	  automatically	  with	  Threshold	  plugin	  of	   ImageJ.	  Nuclear	  
density	  from	  10	  low-­‐power	  fields	  was	  analysed	  per	  Kin1null,	  Kin1wt	  and	  Kin1AA	  tumour	  (n=4).	  one-­‐way	  
ANOVA	  with	   Tukey’s	  multiple	   comparison	   test.	  B-­‐D:	   Results	   presented	   as	  mean	   ±	   SEM.	   p-­‐value	   >	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To	   evaluate	   ECM	  deposition	   in	   tumours,	  we	  measured	   collagen-­‐I	   deposition	  
within	  Kin1null	  and	  Kin1wt	  tumours	  with	  the	  use	  of	  second	  harmonic	  microscopy	  
(Fig.38.A.).	  We	  found	  that	  Kin1null	  tumours	  from	  growth	  studies	  A	  and	  C	  had	  a	  

























Figure	  38:	  Analysis	  of	  collagen-­‐I	  deposition	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  Collagen-­‐I	  deposition	  
was	  measured	   in	   Kin1null	  and	   Kin1wt	   tumours	   from	   growth	   studies	   A	   and	   C	  with	   second	   harmonic	  
microscopy.	  A:	   Representative	   images	   of	   collagen-­‐I	   deposition	   in	   Kin1null	  and	   Kin1wt	   tumours	   from	  
growth	  study	  C.	  Tumour	  perimeter	   is	  defined	  with	  the	  dashed	  white	   line.	  The	  scale	  bar	  represents	  
10μm.	   B-­‐C:	   Quantification	   of	   collagen-­‐I	   deposition	   was	   performed	   automatically	   with	   ImageJ	   by	  
calculating	   the	   fraction	   of	   Integrated	   Density	   (sum	   of	   pixel	   value)	   of	   collagen-­‐I	   over	   tissue	  
autofluorescence,	   thus	   taking	   into	   account	   the	   size	   of	   each	   tumour.	  One	   image	  was	   analysed	   per	  
tumour,	  which	  was	   composed	  by	  25	   individual	   images,	   examples	  of	  which	   are	  pointed	  out	  by	   the	  
grid.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  each	  growth	  study’s	  tumour	  cohort	  
was	  normalised	  against	  the	  highest	  Kin1null	  tumour	  value.	  Unpaired	  t-­‐test;	  **	  p-­‐value	  ≤	  0.01,	  ***	  p-­‐
value	   ≤	   0.001.	  B:	   Squares	   represent	   values	   of	   individual	   tumours	   from	   growth	   study	   A.	  C:	   Circles	  
represent	  values	  of	  individual	  tumours	  from	  growth	  study	  C.	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5.8.	  Immunohistochemical	  assessment	  of	  proliferation,	  
apoptosis	  and	  vascularization	  in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  
tumours	  
Cellular	  proliferation	  and	  apoptosis,	  as	  well	  as	  tumour	  angiogenesis	  are	  potent	  
regulatory	   forces	   of	   tumour	   growth	   and	   development.	   Our	   objective	   was	   to	  
address	  whether	  Kin1	  regulates	  the	  above	  processes,	  which	  would,	  ultimately,	  
help	  us	  understand	  if	  this	  contributes	  to	  the	  significant	  differences	  in	  tumour	  
growth	  observed	  between	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  	  
	  
We	   initially	   scored	   cells	   within	   Kin1null	   and	   Kin1wt	   tumours	   from	   growth	  
studies	   A	   and	   C	   that	   were	   positive	   for	   cellular	   proliferation	   marker	   Ki67	  
(Fig.39.A.).	  Overall,	  we	  observed	  that	  cells	   from	  Kin1null	   tumours	  proliferated	  




















Figure	  39:	  Analysis	  of	  proliferation	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  IHC	  was	  performed	  with	  a	  Ki-­‐
67	  antibody	  on	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  studies	  A	  and	  C.	  A:	  Representative	  images	  of	  
Ki-­‐67	  staining	  in	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  A.	  Mag	  x40.	  The	  scale	  bar	  represents	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50μm.	  B-­‐C:	  Quantification	   of	   the	   percentage	  of	   Ki-­‐67-­‐positive	   nuclei	  was	   performed	   automatically	  
with	  Immunoratio	  plugin	  of	  ImageJ	  software	  [128].	  15	  or	  more	  high-­‐power	  fields	  were	  analysed	  per	  
Kin1null	  and	  Kin1wt	  tumour.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Unpaired	  t-­‐test;	  *	  p-­‐value	  ≤	  0.05.	  
B:	  Squares	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  A.	  C:	  Circles	  represent	  values	  of	  
individual	  tumours	  from	  growth	  study	  C.	  	  
	  
To	  define	  any	  differences	  in	  apoptosis	  between	  Kin1null	  and	  Kin1wt	  tumours	  we	  
scored	  nuclei	   that	  were	  positive	   for	   the	   apoptosis	  marker	   casp-­‐3	   (Fig.40.A.).	  
We	  overall	  observed	  a	  very	  low	  percentage	  of	  apoptotic	  cells	  and	  no	  statistical	  
difference	  in	  apoptosis	  between	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  





















Figure	  40:	  Analysis	  of	  apoptosis	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  IHC	  was	  performed	  with	  a	  casp-­‐3	  
antibody	   on	   Kin1null	  and	   Kin1wt	   tumours	   from	   growth	   study	   B.	  A:	   Representative	   images	   of	   casp-­‐3	  
staining	  in	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  B.	  Mag	  x40.	  The	  scale	  bar	  represents	  50μm.	  
B:	   Quantification	   of	   the	   percentage	   of	   casp-­‐3-­‐positive	   nuclei	   was	   performed	   automatically	   with	  
Immunoratio	  plugin	  of	   ImageJ	   software	   [128].	   15	  high-­‐power	   fields	  were	  analysed	  per	  Kin1null	   and	  
Kin1wt	   tumour.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Unpaired	  t-­‐test;	  p-­‐value	  >	  0.05.	  Diamonds	  
represent	  values	  of	  individual	  tumours	  from	  growth	  study	  B.	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Finally,	  to	  determine	  whether	  angiogenesis	  is	  linked	  to	  the	  growth	  differences	  
observed	   in	  our	   tumour	  models,	  we	  quantified	  vascularisation	  of	   tumours	  by	  
measuring	   tumour	   Vascular	   Surface	   Area	   (VSA).	   This	   was	   achieved	   by	  
calculating	  the	  percentage	  of	  tumour	  area	  covered	  by	  blood	  vessels	  positive	  for	  
endothelial	   marker	   CD31.	   VSA	   was	   evaluated	   by	   performing	   IF	   on	   tumours	  
from	  growth	  study	  A	  and	  IHC	  on	  tumours	  from	  growth	  study	  B	   (Fig.41.A-­‐B.).	  
Results	  from	  both	  immunostaining	  studies	  showed	  that	  Kin1null	  tumours	  had	  a	  





























Figure	  41:	  Analysis	  of	  VSA	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  Immunostaining	  was	  performed	  with	  a	  
CD31	   antibody	   on	   Kin1null	  and	   Kin1wt	   tumours	   from	   growth	   studies	   B	   and	   C.	  A:	   Representative	   IF	  
images	  of	  CD31	  staining	  in	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  A.	  Mag	  x20.	  The	  scale	  bar	  
represents	  50μm.	  B:	  Representative	  IHC	  images	  of	  CD31	  staining	  in	  Kin1null	  and	  Kin1wt	  tumours	  from	  
growth	  study	  B.	  Mag	  x40.	  The	  scale	  bar	  represents	  50μm.	  C-­‐D:	  Quantification	  of	  VSA	  was	  performed	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automatically	  with	   ImageJ	   software	  by	  calculating	   the	  percentage	  of	   tumour	   field	  area	  covered	  by	  
CD31-­‐positive	   vessels.	   Segmentation	   of	   higher	   intensity	   vessel	   pixels	   from	   lower	   intensity	  
background	   pixels	   was	   performed	   automatically	   with	   Threshold	   plugin	   of	   ImageJ.	   15	   low-­‐power	  
fields	  were	  analysed	  per	  Kin1null	  and	  Kin1wt	  tumour.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  
value	  within	  each	  growth’s	  study	  tumour	  cohort	  was	  normalised	  against	  the	  highest	  Kin1null	  tumour	  
value.	   C:	   Mann-­‐Whitney	   U	   Test.	  D:	   Unpaired	   t-­‐test.	   C-­‐D:	   *	   p-­‐value	   ≤	   0.05,	   **	   p-­‐value	   ≤	   0.01.	   C:	  
Squares	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  A.	  D:	  Diamonds	  represent	  values	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5.9.	  Comparative	  RNA-­‐Seq	  analysis	  of	  gene	  expression	  changes	  
in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  tumours	  
We	  next	  employed	  RNA-­‐Seq	   to	  characterise	   the	   transcriptome	  of	  Kin1null	  and	  
Kin1wt	   tumours	   and,	   thus,	   determine	   changes	   in	   signaling	   pathways,	   which	  
could	  account	   for	   the	  variations	   in	   tumour	  growth,	  cellular	  proliferation	  and	  
angiogenesis	  between	  the	  two	  tumour	  sets.	  RNA-­‐Seq	  was	  performed	  on	  three	  
Kin1null	  tumours	  (volumes:	  0.14cm3,	  0.21cm3,	  0.25cm3)	  and	  three	  Kin1wt	  tumours	  
(volumes:	  0.05cm3,	  0.07cm3,	  0.08cm3),	  which	  were	  collected	  from	  growth	  study	  
A	  24	  days	  following	  the	  injection	  of	  Kin1null	  and	  Kin1wt	  SCC	  cells	  in	  CD-­‐1	  nude	  
mice.	   As	   half	   of	   every	   tumour	   was	   fixed	   for	   immunohistochemical	   analysis,	  
RNA	   extraction	   was	   performed	   in	   the	   other	   tumour	   half,	   which	   was	   snap	  
frozen	  in	  liquid	  N2	  immediately	  following	  its	  extraction.	  
	  
Reads	   were	   mapped	   to	   the	   mouse	   mm9	   reference	   genome,	   as	   described	   in	  
Chapter	   2,	   Section	   2.7.2.	   Construction	   of	   Principal	   Component	   Analysis	  
(PCA)	  plot	  was	  performed	  by	  Dr	  Stuart	  Aitken	  and	  revealed	  a	  63%	  variance	  in	  
gene	  expression	  between	  Kin1null	  and	  Kin1wt	  tumours	  (Fig.42.).	  Genes	  with	  a	  q	  
value	  (p	  value	  adjusted	  for	  multiple	  testing)	  of	  less	  than	  0.05	  were	  considered	  
differentially	  expressed.	  Table	   4	   shows	   the	   10	  most	  highly	  enriched	  genes	   in	  










Figure	  42:	  PCA	  of	  RNA-­‐Seq	  results:	  PCA	  plot	  generated	  from	  the	  DESeq2	  analysis	  of	  gene	  count	  data	  
shows	  that	  Kin1null	  and	  Kin1wt	  samples	  are	  separated	  on	  the	  first	  principle	  component,	  as	  is	  desirable.	  	  




































Table	  4:	  Analysis	  of	  RNA-­‐Seq	  results	   from	  Kin1null	  and	  Kin1wt	  SCC	  tumours:	  Differential	  expression	  
was	  analysed	  by	  Cuffdiff275	  and	  by	  DESeq2276,	  which	  provided	  lists	  of	  differentially	  expressed	  genes	  
by	   two	   alternative	   statistical	   techniques,	   by	   Dr	   Stuart	   Aitken	   Table	   showcases	   examples	   from	  
differential	   expression	   of	   20	   genes	   with	   lo2	   fold	   change	   >4	   between	   Kin1null	   and	   Kin1wt	   tumours.	  
FPKM=Fragments	   Per	   Kilobase	   of	   Exon	   Per	   Million	   Fragments	   Mapped.	   (A)	   Most	   highly	   enriched	  
genes	  in	  Kin1null	  tumours.	  (B)	  Most	  highly	  enriched	  genes	  in	  Kin1wt	  tumours.	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5.10.	  Exploring	  gene	  expression	  changes	  identified	  through	  
RNA-­‐Seq	  in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  tumours,	  and	  in	  
Kin1null,	  Kin1wt	  and	  Kin1null	  and	  Kin1AA	  mouse	  SCC	  cell	  lines	  
Quantitative	   real-­‐time	   PCR	   (q-­‐PCR)	   assays	   were	   employed	   to	   validate	  
expression	  changes	  in	  genes	  selected	  from	  RNA-­‐Seq	  result	  analysis,	  principally	  
due	   to	   their	   biological	   function.	   We	   evaluated	   gene	   expression	   changes	  
between	  Kin1null	   and	  Kin1wt	   tumours	   from	  growth	  studies	  A,	  B	  and/or	  C,	  and	  
between	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	  lines	  grown	  as	  artificial	  monolayers	  
(2D	  cell	  culture)	  and	  as	  3D	  spheroids	  in	  low-­‐adherent	  plates	  (3D	  cell	  culture).	  	  
	  
Overall,	  we	  observed	  a	  strong	  correlation	  and	  a	  similar	  gene	  expression	  trend	  
between	  RNA-­‐Seq	  based	   transcript	  abundance	  estimation	   (FPKM:	  Fragments	  
Per	   Kilobase	   of	   Exon	   Per	   Million	   Fragments	   Mapped)	   and	   q-­‐PCR	   assays,	  
highlighting	  the	  accuracy	  of	  the	  latter	  analysis.	  	  
	  
We	  also	  explored	  correlation	  between	  expression	   levels	  of	   various	  genes	  and	  
tumour	   volume.	   For	   each	   correlation	   assessment,	   we	   calculated	   both	   the	  
Pearson	  product-­‐moment	  correlation	  coefficient,	  which	  measured	  the	  strength	  
and	  the	  direction	  of	  a	  linear	  relationship	  between	  two	  variables,	  as	  well	  as	  the	  
statistical	  significance	  of	  the	  correlation	  coefficient.	  Due	  to	  the	  small	  tumour	  
sample	  size	  of	  each	  growth	  study	  (n	   ≤	  8),	  as	  well	  as	  variability	  within	  Kin1null	  
and/or	   Kin1wt	   tumour	   values	   from	   each	   growth	   study,	   it	   was	   sometimes	  
difficult	  to	  reach	  significance	  following	  statistical	  analysis.	  Nevertheless,	  even	  
without	   statistical	   significance,	  we	   often	   observed	   a	   strong	   correlation	   trend	  
between	  gene	   expression	   and	   tumour	   volume,	  which	  would	  be	  misleading	   if	  
we	  did	  not	  take	  into	  account.	  Thus,	  for	  the	  purposes	  of	  this	  study	  we	  valued,	  
and	  therefore	  commented	  on,	  strength	  of	  correlation	  coefficient	  rather	  than	  p-­‐
value.	   Interpretation	   of	   degree	   of	   correlation	   is	   based	   on	   “Correlation	  
Coefficient	  Interpretation	  Guide”	  (Table	  5)	  [132][132].	  








Table	   5:	   Correlation	   Coefficient	   Interpretation	   Guide.	   Correlation	   coefficient	   ranges	   from	   -­‐1	   (a	  
perfect	  negative	  correlation)	  to	  1	  (a	  perfect	  positive	  correlation).	  
	  
5.10.1.	  Validation	  of	  genetic	  loss	  of	  Fermt1	  gene	  in	  Kin1null	  mouse	  SCC	  
tumours	  	  
We	   initially	   validated	   the	   genetic	   loss	   of	   Fermt1	   in	   Kin1null	   tumours	   and	  
successful	   re-­‐expression	   of	   wild-­‐type	   Fermt1	   in	   Kin1wt	   SCC	   tumours	   from	  
growth	   study	   A	   (Fig.43.i.).	   There	   was	   no	   correlation	   between	   Fermt1	  













Figure	  43:	  Analysis	  of	  Fermt1	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  tumours.	  q-­‐PCR	  assay	  was	  
performed	  using	  DNA	   from	  Kin1null	  and	  Kin1wt	   tumours	   from	  growth	   study	  A.	   (i):	  Quantification	  of	  
relative	   Fermt1	  mRNA	   expression	   in	   relation	   to	  Gapdh	   expression	   in	   Kin1null	   and	   Kin1wt	   tumours.	  
Results	   presented	   as	   scatter	   plot	   ±	   SEM.	   Every	   value	   was	   normalised	   against	   the	   highest	   Kin1wt	  
tumour	  value.	  Squares	   represent	  values	  of	   individual	   tumours	   from	  growth	  study	  A.	   (ii):	  Pearson’s	  
correlation	  between	  relative	  Fermt1	  expression	  and	  tumour	  volume	  in	  Kin1wt	  tumours.	  r=	  correlation	  
coefficient	  value.	  (i-­‐ii):	  Unpaired	  t-­‐test;	  p-­‐value	  >	  0.05,	  ***	  p-­‐value	  ≤	  0.001.	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5.10.2.	  Analysis	  of	  expression	  of	  Metalloproteinase	  genes	  in	  Kin1null	  
and	  Kin1wt	  mouse	  SCC	  tumours,	  and	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
mouse	  SCC	  cells	  	  	  
Kin1null	   and	   Kin1wt	   tumours	   presented	   variations	   in	   expression	   of	   genes	  
encoding	  enzymes	  that	  belong	  to	  the	  Metalloproteinase	  protein	  family,	  whose	  
members	   play	   a	   role	   in	   the	   metabolic	   degradation	   of	   ECM	   components	   in	  
physiological	  and	  pathological	  conditions.	  Metalloproteinases	  are	  categorized	  
in	   four	   distinct	   groups;	   “classical”	  Matrix	  Metalloproteinases	   (MMPs),	  which	  
are	   secreted	   as	   soluble	   enzymes,	   transmembrane	   proteins	   membrane-­‐type	  
MMPs	   (MT-­‐MMPs),	   ADAMs	   (a	   disintegrin	   and	   metalloproteinase),	   which	  
contain	   a	   unique	   integrin	   receptor-­‐binding	   domain	   (disintegrin),	   and	  
ADAMTS	   (a	   disintegrin	   and	  metalloproteinase	  with	   thrombospondin	  motif),	  
which	  are	  secreted	  MMPs	  and	  contain	  disintegrin	  as	  well	  as	  a	  thrombospondin	  
(TSP-­‐1)	  domain	  in	  their	  C-­‐terminal	  region	  [179].	  
	  
In	  the	   following	  sections,	  we	  explored	  expression	   levels	  of	  genes	  that	  encode	  
proteins	   from	   three	   of	   the	   four	   different	   Metalloproteinase	   sub-­‐families:	  
MMPs,	   MT-­‐MMPs	   and	   ADAMTSs	   in	   Kin1null	   and	   Kin1wt	   tumours.	   We	   also	  
explored	  expression	  levels	  of	  MMP	  genes	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	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5.10.2.1.	  Analysis	  of	  expression	  of	  “classical”	  Matrix	  Metalloproteinase	  
(MMP)	  genes	  Mmp3	  and	  MMP13	  in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  tumours,	  
and	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  mouse	  SCC	  cells	  	  	  
According	   to	   RNA-­‐Seq	   results,	  Mmp3	   mRNA	   expression	   in	   Kin1null	   tumours	  
was	  ~4-­‐fold	  higher	  in	  comparison	  to	  Kin1wt	  tumours	  (Table	  4).	  Q-­‐PCR	  assay	  in	  
tumour	   samples	   isolated	   from	  growth	   studies	  A	  and	  C	  validated	   that	  Kin1null	  
tumours	  had	  a	  significantly	  higher	  Mmp3	  expression	   in	  comparison	  to	  Kin1wt	  
tumours	   (Fig.44.A.i.,B.i.).	   We	   found	   a	   very	   strong,	   positive	   correlation	  
between	  Mmp3	   expression	  and	  volume	  of	  Kin1null	   tumours	   from	  both	  growth	  
studies	   (Fig.44.A.ii.,B.ii.).	   Moreover,	   we	   detected	   a	   strong	   and	   moderate,	  
negative	  correlation	  between	  Mmp3	  expression	  and	  volume	  of	  Kin1wt	  tumours	  
from	  growth	  studies	  A	  and	  C,	  respectively	  (Fig.44.A.iii.,B.iii).	  
	  
In	   vitro	   evaluation	  of	  gene	  expression	   showed	   that	  overall,	  Mmp3	   expression	  
was	   significantly	   higher	   in	   Kin1wt	   and	   Kin1AA	   cells	   grown	   in	   3D	   culture	   in	  
comparison	  to	  Kin1wt	  and	  Kin1AA	  cells	  in	  2D	  culture	  (Fig.44.C.i.).	  Although	  not	  
significant,	  Kin1null	  cells	  from	  3D	  culture	  followed	  the	  above	  trend,	  as	  they	  also	  
showed	  slightly	  higher	  Mmp3	  expression	  levels	  compared	  to	  2D	  culture	  Kin1null	  
cells	   (Fig.44.C.i.).	   In	   2D	   culture,	   Kin1null	   cells	   showed	   a	   higher	   Mmp3	  
expression	   compared	   to	   Kin1wt	   cells	   (Fig.44.C.ii.),	   which	   reflects	   the	  Mmp3	  
expression	   pattern	   between	   Kin1null	   and	   Kin1wt	   tumours	   (Fig.44.A.i.,B.i.).	  
Moreover,	   in	   2D	   culture	   Kin1AA	   cells	   expressed	   comparable	  Mmp3	   levels	   to	  
Kin1null	   SCC	   cells,	   and	   significantly	   higher	   Mmp3	   levels	   than	   Kin1wt	   cells	  
(Fig.44.C.ii.).	   In	   contrast	   to	   2D	   culture,	   Kin1null	   cells	   from	   3D	   culture	  
expressed	   significantly	   lower	  Mmp3	   levels	   compared	   to	   Kin1wt	   counterparts	  
(Fig.44.C.i.),	  which	   also	   contrasts	  Mmp3	   expression	  pattern	   between	  Kin1null	  
and	  Kin1wt	  tumours	  (Fig.44.A.i.,B.i.).	  Moreover,	  Mmp3	  levels	  in	  Kin1AA	  3D	  cell	  
culture	  were	  similar	   to	  Kin1wt,	  and	  significantly	  higher	   than	  Kin1null	  SCC	  cells	  
(Fig.44.C.i.).	  	  
	  




































Figure	  44:	  Analysis	  of	  Mmp3	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours	  and	  Kin1null,	  
Kin1wt	  and	   Kin1AA	  SCC	   cell	   lines.	   q-­‐PCR	   assay	   was	   performed	   using	   cDNA	   from	   Kin1null	  and	   Kin1wt	  
tumours	  from	  growth	  studies	  A	  and	  C.	  A(i),B(i):	  Quantification	  of	  relative	  Mmp3	  mRNA	  expression	  in	  
relation	  to	  Gapdh	  expression	  in	  Kin1null	  and	  Kin1wt	  tumours.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  
Every	   value	  within	   each	   growth’s	   study	   tumour	   cohort	  was	  normalised	  against	   the	  highest	   Kin1null	  
tumour	  value.	  A(ii-­‐iii),B(ii-­‐iii):	  Pearson’s	  correlation	  between	  relative	  Mmp3	  expression	  and	  tumour	  
volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  correlation	  coefficient	  value.	  A-­‐B:	  Unpaired	  t-­‐test;	  *	  p-­‐value	  
≤	  0.05,	  **	  p-­‐value	  ≤	  0.01.	  A:	  Squares	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  A.	  B:	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Circles	  represent	  values	  of	   individual	  tumours	  from	  growth	  study	  C.	  C(i)	   :	  Quantification	  of	  relative	  
Mmp3	  mRNA	  expression	  in	  relation	  to	  Gapdh	  expression	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	   lines	  
grown	  in	  2D	  and	  3D	  cell	  culture.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  each	  cell	  
line	   was	   normalised	   against	   the	   highest	   value	   from	   Kin1null	   3D	   culture	   cells.	   Three	   biological	  
replicates	  were	   analysed	   per	   cell	   line.	   one-­‐way	   ANOVA	  with	   Tukey’s	  multiple	   comparison	   test;	   p-­‐
value	   >	   0.05,	   *	   p-­‐value	   ≤	   0.05,	   **	   p-­‐value	   ≤	   0.01.	   Thick	   grey	   line	   indicates	   that	   statistical	   testing	  
compared	  Mmp3	   expression	   in	   Kin1wt	   and	   Kin1AA	   SCC	   cells	   grown	   in	   2D	   culture	   against	   their	   3D	  
counterparts.	  (ii):	  Magnification	  of	  C(i)	  graph	  of	  cell	  lines	  grown	  in	  2D	  cell	  culture.	  
	  
	  
IF	  results	  showed	  that	  Kin1null	  tumours	  expressed	  significantly	  higher	  levels	  of	  
MMP3	   protein	   compared	   to	   Kin1wt	   tumours	   (Fig.45.B.),	   thus	   reflecting	   our	  
findings	  on	  Mmp3	  gene	  expression	  in	  our	  tumour	  samples	  (Fig.45.A.i.,B.i.).	  In	  
both	  Kin1null	  and	  Kin1wt	  tumours	  MMP3	  was	  localised	  in	  the	  cytoplasm	  and	  the	  
extracellular	   space.	   (Fig.45.A.).	   Likewise,	   western	   blot	   analysis	   of	   MMP3	  
expression	   levels	   in	  Kin1null,	  Kin1wt	   and	  Kin1AA	   cell	   lines	   grown	   in	   2D	  and	   3D	  
cultures	   mirrored	   in	   vitro	  Mmp3	   gene	   expression	   trends	   (Fig.45.C.).	   In	   2D	  
culture,	  Kin1null	  and	  Kin1AA	  cells	   had	   similar	   levels	   between	   them,	   and	  higher	  
MMP3	   levels	  compared	  to	  Kin1wt	  cells	  (Fig.45.C.).	   In	  3D	  culture,	  Kin1null	   cells	  



















































Figure	   45:	  Analysis	   of	  MMP3	  protein	   expression	   levels	   in	   Kin1null	  and	  Kin1wt	   SCC	   tumours	   and	   in	  
Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cell	   lines.	   	   IF	  was	  performed	  with	  an	  MMP3	  antibody	  on	  Kin1null	  and	  
Kin1wt	   tumours	   from	  growth	  study	  A.	  A:	  Representative	   IF	   images	  of	  MMP3	  staining	   in	  Kin1null	  and	  
Kin1wt	   tumours	   from	   growth	   study	   A.	   The	   scale	   bar	   represents	   50μm.	  B:	  Quantification	   of	  MMP3	  
expression	   was	   performed	   automatically	   with	   ImageJ	   software	   by	   calculating	   the	   Raw	   Integrated	  
Density	  (sum	  of	  pixel	  value)	  of	  every	  image.	  10	  representative	  high-­‐power	  fields	  were	  analysed	  per	  
Kin1null	  and	  Kin1wt	  tumour.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  each	  growth’s	  
study	  tumour	  cohort	  was	  normalised	  against	  the	  highest	  Kin1null	  tumour	  value.	  Mann-­‐Whitney;	  **	  p-­‐
value	  ≤	  0.01.	  Squares	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  A.	  C:	  Western	  blot	  
analysis	   of	  MMP-­‐3	   expression	   in	   Kin1null,	   Kin1wt	   and	   Kin1AA	  	  SCC	   cell	   lines	   grown	   in	   2D	   and	   3D	   cell	  
culture.	   Arrows	   indicate	   MMP-­‐3	   bands.	   Each	   lane	   contains	   15	   μg	   of	   lysate.	   β-­‐actin	   was	   used	   as	  
loading	  control.	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RNA-­‐Seq	  data	  revealed	  a	  ~4-­‐fold	  higher	  Mmp13	  expression	  in	  Kin1null	  compared	  
to	   Kin1wt	   SCC	   tumours	   (Table	   4),	   which	   resembled	   our	   results	   on	   Mmp3	  
expression.	  q-­‐PCR	  analysis	  validated	  that	  Kin1null	  tumours	  from	  growth	  studies	  
A	  and	  C	  had	  greater	  Mmp13	   levels	  than	  Kin1wt	  SCC	  tumours	  (Fig.46.A.i.,B.i.).	  
Correlation	  analysis	  between	  Mmp13	  expression	  and	  tumour	  volume	  presented	  
a	   similar	   trend	   with	   the	   correlation	   between	  Mmp3	   expression	   and	   tumour	  
volume	   (Fig.46.A.ii-­‐iii.,B.ii-­‐iii.).	   Samples	   from	   growth	   study	   A	   showed	   a	  
strong,	   positive	   and	   a	   very	   strong,	   negative	   correlation	   between	   Mmp13	  
expression	   and	   Kin1null	   and	   Kin1wt	   tumour	   volume,	   respectively	   (Fig.46.A.ii-­‐
iii.).	  Similarly,	  in	  samples	  from	  growth	  study	  C,	  Mmp13	  expression	  had	  a	  weak,	  
positive	   and	   a	   strong,	   negative	   correlation	   with	   Kin1null	   and	   Kin1wt	   tumour	  
volume,	  respectively	  (Fig.46.B.ii-­‐iii.).	  	  
	  
Similarly	  to	  the	   in	  vitro	  Mmp3	  expression	  pattern	  (Fig.45.C.i.),	  Kin1null,	  Kin1wt	  
and	  Kin1AA	  cell	  lines	  grown	  in	  3D	  culture	  had	  significantly	  higher	  Mmp13	  levels	  
when	  compared	  to	  2D	  culture	  counterparts	  (Fig.46.C.i.).	  Overall,	  2D	  and	  3D	  
culture	   cells	   displayed	   similar	  Mmp13	   expression	   pattern	   (Fig.46.C.i-­‐ii.).	  We	  
noticed	  that	  Kin1null	  2D	  and	  3D	  culture	  cells	  had	  lower	  Mmp13	  levels	  compared	  
to	  Kin1wt	  equivalents,	  although	  the	  difference	  was	  significant	  only	  in	  cells	  from	  
2D	  culture	  (Fig.46.C.i-­‐ii.).	  Although	  not	  significant,	  we	  observed	  that	  in	  both	  
2D	   and	   3D	   culture	   cells,	  Mmp13	   expression	   in	   Kin1AA	   cells	   was,	   similarly	   to	  
















































Figure	  46:	  Analysis	  of	  Mmp13	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours	  and	  Kin1null,	  
Kin1wt	  and	   Kin1AA	  SCC	   cell	   lines.	   q-­‐PCR	   assay	   was	   performed	   using	   cDNA	   from	   Kin1null	  and	   Kin1wt	  
tumours	  from	  growth	  studies	  A	  and	  C.	  A(i),B(i):	  Quantification	  of	  relative	  Mmp13	  mRNA	  expression	  
in	   relation	   to	  Gapdh	   expression	   in	   Kin1null	  and	   Kin1wt	   tumours.	   Results	   presented	   as	   scatter	   plot	   ±	  
SEM.	   Every	   value	   within	   each	   growth’s	   study	   tumour	   cohort	   was	   normalised	   against	   the	   highest	  
Kin1null	  tumour	  value.	  A(ii-­‐iii),B(ii-­‐iii):	  Pearson’s	  correlation	  between	  relative	  Mmp13	  expression	  and	  
tumour	  volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  correlation	  coefficient	  value.	  A-­‐B:	  Unpaired	  t-­‐test;	  
p-­‐value	   >	   0.05,	   **	   p-­‐value	   ≤	   0.01,	   ***	   p-­‐value	   ≤	   0.001.	  A:	   Squares	   represent	   values	   of	   individual	  
tumours	  from	  growth	  study	  A.	  B:	  Circles	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  C.	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C(i):	  Quantification	  of	  relative	  Mmp13	  mRNA	  expression	  in	  relation	  to	  Gapdh	  expression	  in	  Kin1null,	  
Kin1wt	  and	  Kin1AA	  	  SCC	  cell	  lines	  grown	  in	  2D	  and	  3D	  cell	  culture.	  Results	  presented	  as	  scatter	  plot	  ±	  
SEM.	   Every	   value	   within	   each	   cell	   line	   was	   normalised	   against	   the	   highest	   value	   from	   Kin1null	  3D	  
culture	   cells.	   Three	  biological	   replicates	  were	  analysed	  per	   cell	   line.	   one-­‐way	  ANOVA	  with	  Tukey’s	  
multiple	   comparison	   test;	   p-­‐value	   >	   0.05,	   *	   p-­‐value	   ≤	   0.05,	   ***	   p-­‐value	   ≤	   0.001.	   Thick	   grey	   line	  
indicates	   that	   statistical	   testing	   compared	  Mmp3	   expression	   in	   Kin1null,	   Kin1wt	   and	  Kin1AA	  SCC	   cells	  
grown	  in	  2D	  culture	  against	  their	  3D	  counterparts	  (ii):	  Magnification	  of	  C(i)	  graph	  of	  cell	  lines	  grown	  
in	  2D	  cell	  culture.	  
	  
5.10.2.2.	  Analysis	  of	  expression	  of	  Membrane-­‐Type	  Matrix	  
Metalloproteinase	  (MT-­‐MMP)	  genes	  Mmp15	  in	  Kin1null	  and	  Kin1wt	  mouse	  
SCC	  tumours	  
According	  to	  RNA-­‐Seq	  (not	   included	   in	   Table	   4),	   expression	   levels	  of	  MT-­‐
MMP	   gene	   Mmp15	   did	   not	   vary	   significantly	   between	   Kin1null	   and	   Kin1wt	  
tumours.	  This	  was	   confirmed	  by	  q-­‐PCR	  assay,	  which	   revealed	  no	   changes	   in	  
Mmp15	  expression	  between	  Kin1null	  and	  Kn1wt	   tumours	   from	  growth	  studies	  B	  
and	   C	   (Fig.47.A.i.,B.i.).	   Correlation	   coefficient	   analysis	   between	   Mmp15	  
expression	  and	  tumour	  volume	  provided	  inconsistent	  results	  among	  different	  
growth	   study	   tumour	  cohorts.	   In	  particular,	   volume	  of	  Kin1null	   tumours	   from	  
growth	   study	   B	   had	  weak,	   positive	   correlation,	  whereas	   from	   study	   C	   had	   a	  
strong,	   negative	   correlation	   with	   Mmp15	   expression	   (Fig.47.A.ii.,B.ii.),.	  
Moreover,	  volume	  of	  Kin1wt	  tumours	  from	  growth	  study	  B	  had	  no	  correlation,	  
whereas	   from	   study	   C	   has	   moderate,	   positive	   correlation	   with	   Mmp15	  
































Figure	   47:	   Analysis	   of	  Mmp15	   gene	   expression	   levels	   in	   Kin1null	  and	   Kin1wt	   SCC	   tumours.	   q-­‐PCR	  
assay	  was	  performed	  cDNA	  from	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  studies	  B	  and	  C.	  A(i),B(i):	  
Quantification	  of	   relative	  Mmp15	  mRNA	  expression	   in	   relation	   to	  Gapdh	   expression	   in	   Kin1null	  and	  
Kin1wt	   tumours.	   Results	   presented	   as	   scatter	   plot	   ±	   SEM.	   Every	   value	   within	   each	   growth’s	   study	  
tumour	  cohort	  was	  normalised	  against	   the	  highest	  Kin1null	  tumour	  value.	  A(ii-­‐iii),B(ii-­‐iii):	   	  Pearson’s	  
correlation	  between	  relative	  Mmp15	  expression	  and	  tumour	  volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  
r=	  correlation	  coefficient	  value.	  A-­‐B:	  Unpaired	  t-­‐test;	  p-­‐value	  >	  0.05.	  A:	  Diamonds	  represent	  values	  
of	   individual	   tumours	   from	  growth	  study	  B.	  B:	  Circles	   represent	  values	  of	   individual	   tumours	   from	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5.10.2.3.	  Analysis	  of	  expression	  of	  “A	  Disintegrin	  and	  Metalloproteinase	  
with	  Thrombospondin	  motif”	  (ADAMTS)	  genes	  Adamts6,	  Adamts12	  and	  
Adamts17	  in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  tumours	  
Adamts17	   expressed	   ~5-­‐fold	   lower	   transcript	   levels	   in	   Kin1null	   SCC	   tumours	  
when	  compared	  to	  Kin1wt	   tumours,	  according	   to	  RNA-­‐Seq	  (Table	   4).	  On	  the	  
other	   hand,	   gene	   expression	   profiling	   revealed	   that	   various	   other	   Adamts	  
genes,	   such	   as	   Adamts6	   and	   Adamts12	   presented	   no	   significant	   changes	  
between	  Kin1null	  and	  Kin1wt	  tumours.	  	  
	  
Similarly	   to	   RNA-­‐Seq	   results	   (not	   included	   in	   Table	   4),	   we	   detected	   no	  
changes	  in	  the	  expression	  levels	  of	  Adamts6	  and	  Adamts12	  between	  Kin1null	  and	  
Kin1wt	   tumours	   from	  growth	   study	  B	   (Fig.48.A.i.,B.i.).	  Adamts6	   levels	   had	   a	  
strong	   and	   weak,	   negative	   correlation	   with	   volume	   of	   Kin1null	   and	   Kin1wt	  
tumours,	   respectively	  (Fig.48.A.ii-­‐iii.).	  Kin1null	   tumour	  volume	  showed	  weak,	  
negative	   correlation,	   whereas	   Kin1wt	   tumour	   volume	   showed	   a	   moderate,	  
positive	  correlation	  with	  Adamts12	  expression	  levels	  (Fig.48.B.ii-­‐iii.).	  
	  
Finally,	  we	   validated	   that	  Adamts17	   levels	  were	   significantly	   lower	   in	  Kin1null	  
compared	   to	  Kin1wt	  tumours	   from	  growth	  study	  B	   (Fig.48.C.i.).	  Furthermore,	  
we	  detected	  a	  moderate,	  negative,	  and	  a	  strong,	  positive	  correlation	  between	  















































Figure	   48:	   Analysis	   of	  Adamts6,	   Adamts12	   and	   Adamts17	   gene	   expression	   levels	   in	   Kin1null	  and	  
Kin1wt	  SCC	  tumours.	  q-­‐PCR	  assay	  was	  performed	  using	  cDNA	  from	  Kin1null	  and	  Kin1wt	  tumours	  from	  
growth	   study	   B.	  A(i),B(i),C(i):	  Quantification	   of	   relative	  Adamts6,	   Adamts12	   and	  Adamts17	  mRNA	  
expression	   in	   relation	   to	   Gapdh	   expression	   in	   Kin1null	   and	   Kin1wt	   tumours.	   Results	   presented	   as	  
scatter	  plot	  ±	  SEM.	  Every	  value	  within	  each	  growth’s	   study	   tumour	  cohort	  was	  normalised	  against	  
the	   highest	   Kin1null	   tumour	   value.	   A:	  Mann-­‐Whitney.	   B-­‐C:	   Unpaired	   t-­‐test.	   A(ii-­‐iii),B(ii-­‐iii),C(ii-­‐iii):	  
Pearson’s	   correlation	  between	   relative	  Adamts6,	  Adamts12	  and	  Adamts17	   expression	  and	   tumour	  
volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  correlation	  coefficient	  value.	  Unpaired	  t-­‐test.	  A-­‐C:	  p-­‐value	  >	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0.05,	   *	   p-­‐value	   ≤	   0.05,	   **	   p-­‐value	   ≤	   0.01.	   Diamonds	   represent	   values	   of	   individual	   tumours	   from	  
growth	  study	  B.	  	  
	  
5.10.3.	  Analysis	  of	  expression	  of	  angiogenesis	  factors	  in	  Kin1null	  and	  
Kin1wt	  mouse	  SCC	  tumours	  	  
RNA-­‐Seq	   revealed	   that	   various	   angiogenesis	   related	   genes	   were	   enriched	   in	  
Kin1null	  tumours	  compared	  to	  Kin1wt	  tumours.	   In	  particular,	  we	   identified	  that	  
Angiopoietin1,	  which	  encodes	  a	  promoter	  of	  angiogenesis	  [180][181],	  had	  a	  ~2-­‐
fold	   (q-­‐value=0.007,	   not	   shown	   in	   Table	   4)	   higher	   expression	   in	   Kin1null	  
compared	   to	   Kin1wt	   SCC	   tumours.	   Similarly,	  Vcam1	   (Vascular	   Cell	   Adhesion	  
Molecule-­‐1),	  which	  also	  encodes	  a	  pro-­‐angiogenic	  protein	  [182],	  had	  ~2-­‐fold	  (q-­‐
value=0.002,	  not	  shown	  in	  Table	  4)	  significantly	  higher	  expression	  levels	  in	  
Kin1null	   tumours	   when	   compared	   to	   Kin1wt	   tumours.	   Finally,	   Kin1null	   tumours	  
had	   ~2-­‐fold	   higher	   expression	   of	   Hif1α	   (Hypoxia-­‐inducible	   factor	   1α)	   (q-­‐
value=0.046,	  not	  shown	  in	  Table	  4)	  in	  comparison	  to	  Kin1wt	  tumours,	  which	  
encodes	   a	   protein	   heavily	   implicated	   in	   promotion	   of	   angiogenesis	   under	  
hypoxic	  conditions	  [183].	  
	  
Primers	   for	   a	   number	   of	   the	   above	   genes,	   such	   as	   Angpt1,	   resulted	   in	  
nonspecific	  annealing	  and	  primer	  elongation	  events,	  which	  prevented	  us	  from	  
validating	   RNA-­‐Seq	   variations	   in	   this	   gene.	   As	   a	   result,	   we	   used	   q-­‐PCR	   to	  
validate	  expression	  changes	  of	  Hif1a,	  for	  which	  we	  had	  a	  reliable	  set	  of	  primer,	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5.10.3.1.	  Analysis	  of	  expression	  of	  Hif1α	  gene	  in	  Kin1null	  and	  Kin1wt	  mouse	  
SCC	  tumours	  	  	  
Q-­‐PCR	   analysis	   confirmed	   significantly	   higher	   Hif1α	   expression	   levels	   in	  
Kin1null	  tumours	  compared	  to	  Kin1wt	  tumours	  from	  growth	  study	  C	  (Fig.49.i.).	  
No	   correlation	   was	   observed	   between	   Kin1null	   tumour	   volume	   and	   Hif1α	  
expression	   levels	   (Fig.49.ii.),	   whereas	   we	   found	   a	   moderate,	   negative	  














Figure	  49:	  Analysis	  of	  Hif1α	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  q-­‐PCR	  assay	  
was	  performed	  using	  cDNA	  from	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  C.	  (i):	  Quantification	  
of	   relative	  Hif1α	  mRNA	   expression	   in	   relation	   to	  Gapdh	   expression	   in	   Kin1null	  and	   Kin1wt	   tumours.	  
Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  each	  growth’s	  study	  tumour	  cohort	  was	  
normalised	  against	   the	  highest	  Kin1null	  tumour	  value.	   (ii-­‐iii):	  Pearson’s	   correlation	  between	   relative	  
Hif1α	  expression	  and	  tumour	  volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  correlation	  coefficient	  value.	  
(i-­‐iii):	  Unpaired	  t-­‐test;	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05.	  Circles	  represent	  values	  of	  individual	  tumours	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5.10.3.2.	  Analysis	  of	  expression	  of	  Vegfa	  (Vascular	  endothelial	  growth	  a),	  
Flt1	  (FMS-­‐like	  tyrosine	  kinase	  1)	  and	  Kdr	  (Kinase	  insert	  domain	  receptor)	  
gene	  in	  Kin1null	  and	  Kin1wt	  mouse	  SCC	  tumours	  	  	  
VEGFA	  is	  one	  of	  the	  primary	  factors	  driving	  expansion	  of	  the	  vascular	  bed	  in	  
physiological	   and	   pathological	   processes	   [184].	   Thus,	   despite	   not	   being	  
included	  in	  the	  array	  of	  differentially	  expressed	  genes	  identified	  through	  RNA-­‐
Seq,	  we	  examined	  expression	  of	  Vegfa	   as	  well	   as	  Flt1	   and	  Kdr,	  which	  encode	  
two	   of	   VEGFA’s	   main	   receptors	   VEGFR1	   (VEGF	   Receptor	   1)	   and	   VEGFR2,	  
respectively.	  	  
	  
We	  did	  not	  observe	  any	  statistically	  significant	  difference	  between	  Vegfa,	  Flt1	  
or	  Kdr	  between	  Kin1null	  and	  Kin1wt	  tumours	  (Fig.50.A.i.,B.i.,C.i.).	  However,	  the	  
volume	   of	   Kin1null	   tumours	   had	   a	   strong,	   weak	   and	   very	   strong,	   negative	  
correlation	   with	   levels	   of	   Vegfa,	   Flt1	   and	   Kdr,	   respectively	  
(Fig.50.A.ii.,B.ii.,C.ii.).	  Inversely,	  volume	  of	  Kin1wt	  tumours	  had	  a	  very	  strong,	  
moderate	  and	  very	  strong,	  positive	  correlation	  with	  Vegfa,	  Kdr	  and	  Flt1	  levels,	  



















































Figure	  50:	  Analysis	  of	  Vegfa,	  Flt1	  and	  Kdr	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  
q-­‐PCR	  assay	  was	  performed	  using	  cDNA	  from	  Kin1null	  and	  Kin1wt	  tumours	  from	  growth	  study	  C	  or	  A.	  
A(i),B(i),C(i):	  Quantification	   of	   relative	  Vegfa,	   Flt1	   and	   Kdr	  mRNA	   expression	   in	   relation	   to	  Gapdh	  
expression	  in	  Kin1null	  and	  Kin1wt	  tumours.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  
each	  growth’s	   study	   tumour	   cohort	  was	  normalised	  against	   the	  highest	  Kin1null	  tumour	   value.	  A(ii-­‐
iii),B(ii-­‐iii),C(ii-­‐iii):	  Pearson’s	  correlation	  between	  relative	  Vegfa,	  Flt1	  and	  Kdr	  expression	  and	  tumour	  
volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  correlation	  coefficient	  value.	  A-­‐C:	  Unpaired	  t-­‐test;	  p-­‐value	  >	  
0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	  ≤	  0.01.	  A-­‐B:	  Circles	   represent	  values	  of	   individual	   tumours	   from	  
growth	  study	  C.	  C:	  Squares	  represent	  values	  of	  individual	  tumours	  from	  growth	  study	  A.	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5.10.3.3.	  Analysis	  of	  expression	  of	  Thbs1	  gene	  in	  Kin1null	  and	  Kin1wt	  mouse	  
SCC	  tumours	  	  	  
Despite	  not	  being	  identified	  through	  RNA-­‐Seq,	  we	  also	  examined	  expression	  of	  
Thbs1	   gene,	   which	   encodes	   Thrombospondin	   1	   (TSP1),	   an	   adhesive	  
glycoprotein	   and	   a	   potent	   endogenous	   inhibitor	   of	   angiogenesis	   [185][186].	  
Following	  q-­‐PCR	  analysis	  in	  samples	  from	  growth	  studies	  A	  and	  B,	  we	  detected	  
significantly	   lower	   Thbs1	   expression	   in	   Kin1null	   compared	   to	   Kin1wt	   tumours	  
(Fig.51.A.i.,B.i.).	   Volume	   of	   Kin1null	   tumours	   from	   growth	   study	   A	   had	   no	  
correlation	   with	   Thbs1	   levels,	   whereas	   from	   growth	   study	   B	   had	   a	   weak,	  
positive	  correlation	  with	  Thbs1	  levels	  (Fig.51.A.ii.,B.ii.).	  Overall,	  Kin1wt	  tumour	  
volumes	   from	  studies	  A	  and	  B	  showed	  strong	  positive	  correlation	  with	  Thbs1	  







































Figure	  51:	  Analysis	  of	  Thbs1	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  q-­‐PCR	  assay	  
was	  performed	  using	   cDNA	   from	  Kin1null	  and	  Kin1wt	   tumours	   from	  growth	   study	  A	   and	  B.	  A(i),B(i):	  
Quantification	   of	   relative	   Thbs1	  mRNA	   expression	   in	   relation	   to	  Gapdh	   expression	   in	   Kin1null	   and	  
Kin1wt	   tumours.	   Results	   presented	   as	   scatter	   plot	   ±	   SEM.	   Every	   value	  within	   each	   growth’s	   study	  
tumour	   cohort	  was	   normalised	   against	   the	   highest	   Kin1null	  tumour	   value.	  A(ii-­‐iii),B(ii-­‐iii):	   Pearson’s	  
correlation	  between	  relative	  Thbs1	  expression	  and	  tumour	  volume	  in	  Kin1null	  and	  Kin1wt	  tumours.	  r=	  
correlation	   coefficient	   value.	   A-­‐B:	   Unpaired	   t-­‐test;	   p-­‐value	   >	   0.05,	   *	   p-­‐value	   ≤	   0.05.	   A:	   Squares	  
represent	   values	   of	   individual	   tumours	   from	   growth	   study	   A.	   B:	   Diamonds	   represent	   values	   of	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5.10.4.	  Analysis	  of	  expression	  of	  chemokines	  in	  Kin1null	  and	  Kin1wt	  
mouse	  SCC	  tumours	  	  
RNA-­‐Seq	   revealed	   that	   Kin1null	   SCC	   tumours	   had	   enrichment	   in	   genes	   that	  
encode	  chemokines.	  Chemokines,	  which	  are	  chemoattractants	  that	  play	  a	  role	  
in	  recruiting	  and,	  subsequently,	  directing	  migration	  of	  immune	  cells,	  and	  are	  
subdivided	   into	   four	   subfamilies	   based	   on	   their	   N-­‐terminus	   structure	   [187].	  
Compared	  to	  Kin1wt	  tumours,	  we	  found	  that	  Kin1null	  tumours	  had	  significantly	  
higher	   expression	   in	   genes	   encoding	   chemokines	   from	   the	  C-­‐X-­‐C	   subfamily,	  
whose	  N-­‐terminus	  contains	  two	  cysteines	  separated	  by	  a	  variable	  amino	  acid,	  
and	   the	   C-­‐C	   subfamily,	   characterised	   by	   an	   N-­‐terminus	   with	   two	   adjacent	  
cysteine	  residues	  [186].	  
	  
We	  saw	  that	  expression	  of	  Cxcl1	  (C-­‐X-­‐C	  motif	   ligand	   1)	  and	  Cxcl5	  chemokines	  
was	   ~3-­‐	   (q-­‐value=0.007,	   data	   not	   shown	   in	   Table	   4)	   and	   ~2-­‐fold	   (q-­‐
value=0.002,	   data	   not	   shown	   in	   Table	   4)	   higher	   in	   Kin1null	   compared	   to	  
Kin1wt	  tumours.	  We	  proceeded	  to	  confirm	  that	  Cxcl1	  levels	  in	  Kin1null	  tumours	  
were	   significantly	   higher	   compared	   to	   Kin1wt	   ones	   from	   growth	   study	   C	  
(Fig.521.A.i.).	  Moreover,	  we	  observed	   that	  Cxcl1	   levels	   had	   a	   strong,	   positive	  
correlation	   with	   Kin1null	   tumour	   volume,	   and,	   a	   very	   strong,	   negative	  
correlation	  with	  Kin1wt	  tumour	  volume	  (Fig.52.A.ii-­‐iii.).	  	  	  	  
	  
Moreover,	   we	   detected	   that	   levels	   of	   Ccl2	   (C-­‐C	   motif	   ligand	   2)	   and	   Ccl7	  
chemokine	   genes	   were	   ~2-­‐fold	   higher	   (q-­‐value=0.003,	   data	   not	   shown	   in	  
Table	  4),	  and	  levels	  of	  Ccl9	  were	  ~4-­‐fold	  (q-­‐value=0.004,	  Table	  4)	  higher	  in	  
Kin1null	   tumours	   compared	   to	   Kin1wt	   tumours.	   Q-­‐PCR	   assay	   confirmed	   that	  
Kin1null	   tumours	   from	   growth	   study	   C	   had	   significantly	   higher	   levels	   of	  Ccl2	  
and	   Ccl7	   compared	   to	   Kin1wt	   counterparts	   (Fig.52.B.i.,C.i.).	   Correlation	  
analysis	   indicated	   that	   levels	   of	  Ccl2	   and	  Ccl7	   had	   a	   strong	   and	   a	  moderate,	  
positive	   correlation	   with	   volume	   of	   Kin1null	   tumours	   (Fig.52.B.ii.,C.ii.).	   In	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contrast,	   Ccl2	   and	   Ccl7	   expression	   had	   a	   strong,	   negative	   correlation	   with	  






















Figure	  52:	  Analysis	  of	  Cxcl1,	  Ccl2	  and	  Ccl7	  gene	  expression	  levels	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  
q-­‐PCR	   assay	   was	   performed	   using	   cDNA	   from	   Kin1null	   and	   Kin1wt	   tumours	   from	   growth	   study	   C.	  
A(i),B(i),C(i):	  Quantification	   of	   relative	  Cxcl1,	   Ccl2	  and	   Ccl7	  mRNA	  expression	   in	   relation	   to	  Gapdh	  
expression	  in	  Kin1null	  and	  Kin1wt	  tumours.	  Results	  presented	  as	  scatter	  plot	  ±	  SEM.	  Every	  value	  within	  
each	  growth’s	   study	   tumour	   cohort	  was	  normalised	  against	   the	  highest	  Kin1null	  tumour	   value.	  A(ii-­‐
iii),B(ii-­‐iii),C(ii-­‐iii):	  Pearson’s	  correlation	  between	  relative	  Cxcl1,	  Ccl2	  and	  Ccl7	  expression	  and	  tumour	  
volume	   in	   Kin1null	   and	   Kin1wt	   tumours.	   r=	   correlation	   coefficient	   value.	   Unpaired	   t-­‐test;	   p-­‐value	   >	  
0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	  ≤	  0.01	  ***	  p-­‐value	  ≤	  0.001.	  Circles	  represent	  values	  of	   individual	  
tumours	  from	  growth	  study	  C.	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The	   most	   significant	   gene	   expression	   changes	   between	   Kin1null	   and	   Kin1wt	   SCC	   tumours	   are	  




















Table	  6:	  Summary	  of	  the	  most	   important	  gene	  expression	  alterations	  between	  Kin1null	  and	  Kin1wt	  
SCC	   tumours.	   Results	   were	   obtained	   by	   performing	   a	   q-­‐PCR	   assay	   and	   using	   cDNA	   from	   tumour	  
samples	   from	   growth	   experiment	   A,	   or/and	   B,	   or/and	   C.	   Dark	   grey	   colour	   indicates	   the	   growth	  
experiment	  from	  which	  tumour	  samples	  had	  been	  tested.	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05,	  **	  p-­‐value	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5.11.	  Discussion	  
Despite	   the	   array	   of	   data	   that	   showcase	   a	   role	   for	   Kin1	   as	   a	   promoter	   of	  
proliferation	   and	   clonogenicity	   in	   vitro	   [115],	   and	   tumour	   growth	   and	  
progression	  in	  vivo	  [111][112][115],	  absence	  of	  Kin1,	  paradoxically,	  predisposes	  KS	  
patients	  to	  the	  development	  of	  cutaneous	  SCC	  [2][10][11][12].	  In	  the	  majority	  of	  
non-­‐KS	   related	   cases,	   SCC	   is	   usually	   localised	   and	   typically	   treatable	   [188].	  
However,	   in	   KS	   patients	   who	   develop	   SCC,	   particularly	   in	   their	   extremities,	  
cancer	   is	   usually	   aggressive	   and	   metastatic,	   which	   can	   even	   result	   in	  
amputation	   of	   the	   affected	   limb,	   lymph	   node	   excision	   as	  well	   as	   death.	   The	  
reason	  behind	  the	  enigmatic,	  aggressive	  nature	  of	  KS-­‐related	  SCC	  has	  not	  been	  
addressed.	  The	  aim	  of	  this	  study	  was,	  therefore,	  to	  examine	  the	  role	  of	  Kin1	  in	  
cutaneous	   SCC,	   both	   in	   vitro	   and	   in	   vivo,	   and	   propose	   a	   mechanistic	  
explanation	  for	  the	  behaviour	  of	  KS-­‐related	  SCC.	  	  
	  
To	   achieve	   this,	   we	   used	   mouse	   SCC	   cell	   lines	   that	   had	   derived	   from	   SCC	  
tumours	  previously	  generated	  following	  the	  application	  of	  two-­‐stage	  chemical	  
carcinogenesis	   protocol	   [126][127]	  (Fig.30.A.).	   Use	   of	   Kin1-­‐knockout	   (Kin1null)	  
SCC	  cell	   line	   (Fig.31.A.i.),	   and	  Kin1wt	  SCC	  cell	   line	   in	  which	  wild-­‐type	  Fermt1	  
had	   been	   re-­‐expressed	   in	   Kin1null	   SCC	   cells	   (Fig.31.A.ii.)	   enabled	   us	   to	  
scrutinise	   various	   biological	   processes,	   such	   as	   cellular	   proliferation	   and	  
tumour	  growth,	  in	  the	  absence	  and	  presence	  of	  Kin1.	  We	  also	  inspected	  if	  the	  
role	  of	  Kin1	  in	  SCC	  cells	  and	  tumours	  relies	  upon	  one	  of	  its	  principal	  functions	  
as	  an	  integrin	  co-­‐activator,	  by	  using	  a	  mouse	  SCC	  cell	  line	  generated	  following	  
re-­‐expression	   of	   mutant	   Fermt1	   QW611/612AA	   in	   Kin1null	   SCC	   cells	   (Kin1AA)	  
(Fig.31.A.iii.).	   Kin1-­‐W611/612A	   is	   unable	   to	   β1-­‐	   or	   β3-­‐integrins,	   and	   its	  
expression	  was	  shown	  to	  lead	  to	  impaired	  integrin	  activation	  [49][53].	  
	  
5.11.1.	  Role	  of	  Kin1	  in	  in	  vitro	  proliferation	  	  
We	   were	   first	   interested	   in	   addressing	   the	   in	   vitro	   role	   of	   Kin1	   towards	  
proliferation	   of	  mouse	   SCC	   cells,	   which,	   prior	   to	   this	   study,	   has	   never	   been	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studied.	  The	   function	  of	  Kin1	   in	   cellular	  proliferation	   surfaced	   a	  decade	   ago,	  
when	   lack	   of	   Kin1	   was	   associated	   with	   strongly	   diminished	   keratinocyte	  
proliferation	  in	  KS	  epidermis	  and	  cultivated	  KS	  keratinocytes	  [8].	  Likewise,	  in	  
previous	   chapters	   we	   have	   shown	   that	   loss	   of	   Kin1	   reduced	   keratinocyte	  
proliferation	   in	  mouse	  epidermis	  (Fig.9.),	  which	  we	  hypothesise	   to	  occur	  via	  
defects	  in	  mitotic	  spindle.	  	  
	  
It	   is	   possible	   that	   if	   the	   role	   of	   Kin1	   in	  maintenance	   of	  mitotic	   homeostasis	  
applies	   to	   SCC	   cells	   as	  well,	   then	   enhanced	   spindle	   abnormalities	   in	   Kin1null	  
mouse	   SCC	   cells	   could	   contribute	   to	   cell	   proliferation	   and	   tumour	   growth.	  
Proper	   chromosome	   segregation	   ensures	   the	   maintenance	   of	   a	   diploid	  
karyotype,	  with	  missegregation	  defects	  often	  identified	  as	  a	  causal	  factor	  of	  an	  
aneuploid	   genome	   [189][190][191].	   Aneuploidy	   can	   act	   as	   a	   promoter	   of	  
tumourigenesis	  and	  tumour	  evolution,	  as	  the	  lost	  or	  gained	  chromosomes	  can	  
harbour	  loci	  of	  tumour	  suppressor	  or	  tumour	  promoting	  genes,	  respectively.	  In	  
vivo	   studies	   have	   correlated	   aneuploidy	  with	   enhanced	   tumour	   growth	   [192]	  
and	   increased	   tumour	   vascularisation	   [193].	   Future	   examination	   of	   mitotic	  
spindle	   fidelity	   in	   mouse	   SCC	   tumours	   will	   be	   important	   in	   determining	  
whether	  the	  potential	  role	  of	  Kin1	  in	  mitosis	  in	  SCC	  contributes	  to	  differences	  
between	  Kin1null	  and	  Kin1wt	  SCC	  tumour	  biology.	  	  	  
	  
Fermt1	   ablation	   in	   mice	   [54]	   and	   depletion	   of	   Kin1	   in	   HaCaT	   immortalised	  
keratinocytes	   [142]	   has	   also	   been	   shown	   to	   lower	   keratinocyte	   proliferation.	  
Finally,	   stable	   expression	   of	   Kin1	   in	   KS	   keratinocytes	   enhanced	   cell	  
proliferation	  [94],	  which,	  in	  line	  with	  the	  aforementioned	  findings,	  highlights	  
the	   requirement	   of	   Kin1	   for	   keratinocyte	   proliferation.	   A	   regulatory	   role	   for	  
Kin1	   in	   proliferation	   was	   also	   demonstrated	   in	  MCF7	   breast	   cancer	   cells,	   in	  
which	  overexpression	  of	  Kin1	  enhanced	  proliferation	  and	  clonogenicity	  [115].	  
	  	  
Despite	  detecting	  no	  proliferation	  changes	  amongst	  Kin1null,	  Kin1wt	  and	  Kin1AA	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SCC	   cell	   lines	   cultivated	   in	   2D	   conditions	   (Fig.33.),	   we	   detected	   significant	  
changes	  in	  proliferation	  and	  clonogenic	  potential	  between	  cell	  lines	  grown	  in	  
3D	  conditions	  (Fig.34.).	  In	  particular,	  Kin1null	  SCC	  cells	  had	  significantly	  higher	  
proliferation	  and	  clonogenic	  potential	  compared	  to	  Kin1wt	  and	  Kin1AA	  SCC	  cells	  
in	  a	  3D	  environment	   (Fig.34.B-­‐C.).	  This	   indicated	   that	   in	  our	  model,	   lack	  of	  
Kin1	   granted	   SCC	   cells	   with	   a	   proliferative	   advantage	   over	   cells	   expressing	  
wild-­‐type	  Kin1	  or	  the	  non-­‐integrin	  binding	  mutant	  Kin1-­‐QW611/612AA.	  To	  our	  
knowledge,	   this	   is	   the	   first	   time	   that	   expression	   of	   Kin1	   is	   shown	   to	   reduce	  
proliferation	   in	   vitro.	   This	   correlates	   with	   the	   effects	   that	   we	   see	   on	   in	   vivo	  
growth	  of	  the	  SCC	  tumors	  and	  could	  be	  appointed	  to	  the	  fact	  that,	  in	  contrast	  
to	  2D	  monolayers,	  3D	  cultures	  bare	  a	  greater	  physiological	  relevance	  to	  in	  vivo	  
tissue	  architecture	  and	  environment	  [194].	  
	  
5.11.2.	  Role	  of	  Kin1	  in	  tumour	  growth	  and	  progression	  
Kin1null	  tumours	  were	  significantly	  bigger	  and	  had	  a	  significantly	  higher	  growth	  
rate	  compared	  to	  Kin1wt	  and	  Kin1AA	  tumours	  (Fig.35.).	  Taken	  together	  with	  our	  
in	  vitro	  data	  this	  highlights	  that	  absence	  of	  Kin1	  elevates	  SCC	  tumour	  growth,	  
and	  denotes	  an	  in	  vitro	  and	  in	  vivo	  inhibitory	  role	  for	  Kin1	  in	  SCC	  proliferation	  
and	  growth.	  Differences	  between	  Kin1null	  and	  Kin1wt	  tumour	  growth	  reflect	  the	  
enhanced	   proliferation	   in	   Kin1null	   tumours,	   as	   evident	   by	   Ki-­‐67	   staining	  
(Fig.39.A-­‐C.),	   which	   is	   in	   line	   with	   our	   proposition	   for	   an	   anti-­‐proliferative	  
role	  for	  Kin1	  in	  SCC.	  To	  our	  knowledge,	  analogous	  function	  for	  Kin1	  in	  tumour	  
growth	  has	  only	  been	  remarked	  in	  one	  other	  study,	  where	  expression	  of	  Kin1	  
reduced	  non-­‐small-­‐cell	  lung	  cancer	  xenograft	  tumour	  growth	  and	  in	  vitro	  cell	  
migration	  [120].	  	  
	  
In	  sharp	  contrast,	  numerous	  studies	  demonstrated	  a	  pro-­‐tumourigenic	  part	  for	  
Kin1	   in	   various	   other	   types	   of	   cancer.	   Silencing	   of	   Kin1	   prevented	   tumour	  
growth	   in	   a	  mouse	  model	   of	   breast	   cancer	   [115],	   and	   expression	   of	   Kin1	  was	  
higher	   in	  hepatocellular	  carcinoma	  than	   in	  normal	   tissue,	  where	   it	  positively	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correlated	   with	   tumour	   volume	   [112].	   Kin1	   overexpression	   was	   also	   noted	   in	  
colon,	   lung	   and	   bladder	   cancer,	   and	   in	   pancreatic	   cancer	   cell	   lines,	   in	  
comparison	  to	  healthy	  tissue	  and	  cells	  [110][111][115].	  In	  a	  variety	  of	  cancers	  Kin1	  
expression	  also	  promoted	  key	   factors	  of	   tumour	  progression.	  Overexpression	  
of	   Kin1	   in	   hepatocellular	   carcinoma	   presented	   a	   positive	   correlation	   with	  
tumour	  metastatic	  status	  and	  unfavourable	  overall	  survival	  [112],	  and	  depletion	  
of	  Kin1	  inhibited	  breast	  tumour	  metastasis	  in	  an	  orthotopic	  mouse	  model	  [115].	  
Likewise,	   depletion	   of	   Kin1	   in	   vitro	   decreased	   migratory	   and	   invasive	  
properties	   of	   pancreatic	   cancer	   cells	  [111].	   Thus,	   our	   findings	   indicate	   for	   the	  
first	  time	  an	  in	  vitro	  and	  in	  vivo	  anti-­‐proliferative/anti-­‐growth	  role	  for	  Kin1	  in	  
mouse	  SCC	  model.	  	  
	  
5.11.3.	  Role	  of	  Kin1-­‐integrin	  interaction	  in	  tumour	  growth	  and	  
proliferation	  	  
Separate	  studies	  have	  reported	  impaired	  β1	  integrin	  activation	  in	  cells	  that	  lack	  
Kin1	   or	   express	   Kin1-­‐W611/612A	   mutant.	   Reduced	   β1	   integrin	   activation	   has	  
been	   reported	   in	  Kin1-­‐deficient	   immortal	  keratinocytes	   [88]	  and	   in	   intestinal	  
epithelial	  cells	  with	  complete	  loss	  of	  Kin1	  [54].	  Similarly,	  cells	  expressing	  Kin1-­‐
W611/612A	  mutant	  protein	  displayed	  significant	  decrease	  in	  β3-­‐	  and	  β1	  integrin	  
binding	  and	  activation	  [49][53][54].	  	  
	  
Our	  lab	  has	  simultaneously	  examined	  β1	  integrin	  activation	  in	  mouse	  SCC	  cells	  
that	   lack	   Kin1	   (Kin1null),	   express	   wild-­‐type	   Kin1	   (Kin1wt)	   or	   express	   Kin1-­‐
QW611/612AA	  mutant	  protein	  (Kin1AA).	  Both	  Kin1null	  and	  Kin1AA	  SCC	  cell	  lines,	  
which	  behaved	  in	  a	  diametrically	  contrasting	  manner	  in	  proliferation	  (Fig.34.)	  
and	   tumour	   growth	   (Fig.35.),	   displayed	   significant	   reduction	   in	   β1	   integrin	  
activation	  when	  compared	  to	  Kin1wt	  counterpart	  (Fig.53.	  by	  Dr	  Hila	  Emmert).	  
However,	   β1	   integrin	   activation	   was	   significantly	   higher	   in	   Kin1AA	   SCC	   cells	  
than	  Kin1null	  SCC	  cells	  (Fig.53.	  by	  Dr	  Hila	  Emmert).	  These	  observations	  imply	  
that	  role	  of	  Kin1	  in	  proliferation	  and	  tumour	  growth	  in	  our	  mouse	  SCC	  model	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is	  independent	  from	  its	  role	  in	  β1	  integrin	  activation.	  However,	  to	  examine	  this	  
theory	   additional	   studies	   have	   to	   be	   performed,	   such	   as	   proliferation	   and	  
tumour	  growth	  assays	  in	  the	  same	  mouse	  SCC	  model	  following	  depletion	  of	  β1	  
integrin.	  	  
	  
Activation	  of	   integrins	  at	   focal	  adhesions	   is	  not	  a	   function	  restricted	   to	  Kin1,	  
which	  also	  could	  explain	  the	  β1	  integrin	  activation	  observed	  even	  in	  complete	  
absence	   of	   Kin1	   (Fig.53.	   by	   Dr	   Hila	   Emmert).	   Kin2,	   which	   is	   expressed	   at	  
focal	  adhesions	  in	  all	  three	  mouse	  SCC	  cell	  lines	  (Fig.33.B.)	  is	  also	  capable	  of	  
integrin	   activation	   and	   was	   shown	   to	   partially	   compensate	   for	   Kin1	   loss	   in	  
integrin	   activation	   in	   keratinocytes	   [88][195].	   Moreover,	   as	   previously	  
mentioned	   (Chapter	   1,	   Section	   1.5.),	   while	   synergy	   between	   kindlins	   and	  
talins	   is	   essential	   for	   maximal	   integrin	   activation,	   mutations	   that	   inhibit	   -­‐
kindlin-­‐integrin	   binding	   still	   permit	   talin-­‐mediated	   integrin	   activation,	   but	  
block	  the	  kindlin	  enhancement	  effect	   in	   vitro	   [54][68].	  This	  offers	  a	  potential	  
explanation	  for	  integrin	  activation	  at	  Kin1null	  and	  Kin1AA	  SCC	  cells,	  where	  Kin1	  










Figure	  53:	  Analysis	  of	  β1	  integrin	  activation	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  SCC	  cells.	  Flow	  cytometry	  
was	  performed	  with	  a	  9EG7	  antibody,	  which	  reacts	  with	  active	  β1	  integrin307,	  on	  Kin1null,	  Kin1wt	  and	  
Kin1AA	  SCC	  cells.	  Quantification	  of	  active	  β1	   integrin	  was	  performed	   in	   relation	   to	   total	  β1	   integrin	  
levels.	   Results	   presented	   as	   mean	   ±	   SEM.	   Kin1null	   and	   Kin1AA	  values	   were	   normalised	   against	   the	  
highest	   Kin1wr	   value.	   one-­‐way	  ANOVA	  with	   Tukey’s	  multiple	   comparison	   test;	   p-­‐value	   >	   0.05,	   *	   p-­‐
value	  ≤	  0.05,	  **	  p-­‐value	  ≤	  0.01.	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Although	  we	  have	  not	  examined	   this,	  we	  hypothesise	   that	  higher	  β1	   integrin	  
activation	   in	   Kin1AA	  SCC	   cells	   could	   suggest	   that,	   additionally	   to	   QW611/612	  
Kin1-­‐integrin	  binding	  site,	  other	  β1	   integrin	  binding	  sites	  are	  mapped	  to	  Kin1	  
and	  are	  important	  for	  integrin	  activation	  and	  binding.	  Examples	  include	  K610	  
and	  I651,	  both	  of	  which	  were	  identified	  on	  human	  Kin1,	  and	  their	  mutagenesis	  
strongly	   inhibited	  binding	   to	  β1	   integrin	   tails	   [49].	   In	  support	  of	   this	  we	  saw	  
Kin1-­‐QW611/612AA	   localisation	   at	   focal	   adhesions	   (Fig.32.A.).	   However,	   in	  
other	   studies	   this	   integrin	   binding	   mutant	   failed	   to	   accumulate	   at	   focal	  
adhesions	   [49][170]	   and	   compromised	   activation	   of	   β1-­‐	   and	   β3-­‐integrins	  
[37][49]	   in	   NIH-­‐3T3	   and	   CHO	   cells,	   respectively.	   Kin1	   has	   various	   binding	  
partners	  that	  are	  part	  of	  focal	  adhesion	  macromolecular	  assemblies,	  including	  
Kin2,	  FAK	  and	  migfilin	  [142][196],	  which	  could	  potentially	  retain	  Kin1	  at	  focal	  
adhesions	  in	  SCC	  cells	  in	  the	  absence	  of	  integrin	  binding.	  	  
	  
5.11.4.	  Role	  of	  Kin1	  in	  regulating	  the	  tumour	  microenvironment	  	  
It	  has	  emerged	  that	   interactions	  of	  abnormal	  cells	  that	  encompass	  malignant	  
potential	   with	   their	   microenvironment	   can	   aid	   tumour	   development	   and	  
progression.	   Key	   constituents	   of	   the	  microenvironment	   include	   the	   tumours	  
surrounding	   supportive	   ECM	   and	   components	   of	   the	   immune	   system	   and	  
vasculature.	  Therefore,	  examining	  the	   interplay	  between	  mouse	  SCC	  tumours	  
and	   their	   microenvironment	   would	   provide	   us	   with	   a	   better	   understanding	  
regarding	   the	   differences	   in	   growth,	   proliferation	   and	   angiogenesis	   between	  
Kin1null	  and	  Kin1wt	  tumours.	  
	  
5.11.4.1.	  Role	  of	  Kin1	  in	  regulating	  angiogenesis	  
Tumour	   growth	   depends	   on	   adequate	   supply	   of	   nutrients	   and	   oxygen	   and	  
removal	   of	   catabolites	   via	   the	   tumour’s	   vascular	   network,	   which	   is	   formed	  
through	  angiogenesis,	   a	  well-­‐established	  hallmark	  of	   cancer	   [197].	  Compared	  
to	   Kin1wt	   tumours,	   Kin1null	  SCC	   tumours	   had	   higher	   vascularisation	   (Fig.41.),	  
which	   could	   stem	   from	   enhanced	   expression	   of	   angiogenic	   activators	   and	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supressed	   expression	   of	   angiogenic	   inhibitors	   in	   Kin1null	   tumours.	   A	   key	  
promoter	   of	   angiogenesis	   in	   hypoxic	   areas	   such	   as	   localised	   ischemia	   and	  
tumours	  [183]	  is	  HIF1A,	  and	  expression	  of	  Hif1a	  mRNA	  was	  significantly	  higher	  
in	  Kin1null	  tumours	  compared	  to	  Kin1wt	  tumours	  (Fig.49.i.).	  Higher	  expression	  
of	  Hif-­‐1a	  suggests	  a	  more	  hypoxic	  environment	  in	  Kin1null	  tumours,	  which	  has	  
been	  linked	  to	  a	  more	  clinically	  aggressive	  metastatic	  behaviour	  [198].	  Kin1null	  
SCC	  tumours	  also	  presented	  a	  lower	  expression	  of	  Thbs1	  (Fig.51.i.,B.i.),	  which	  
encodes	  TSP1,	  an	  anti-­‐angiogenic	  protein	  that	  exerts	  an	  inhibitory	  outcome	  on	  
tumour	  vascularity	  and	  positively	   correlates	  with	   lower	   tumour	   invasion	  and	  
better	  overall	  prognosis	  [199][200].	  	  
	  
Thus,	   we	   show	   for	   the	   first	   time	   an	   in	   vivo	   anti-­‐angiogenic	   role	   for	   Kin1	   in	  
mouse	   SCC	   model.	   This	   may	   offer	   an	   insight	   to	   the	   properties	   of	   SCC	  
developed	  in	  KS	  patients	  and	  a	  potential	  link	  between	  the	  aggressive	  nature	  of	  
KS	  SCC	  tumours	  and	  enhanced	  growth	  as	  well	  as	  angiogenesis.	  	  
	  
Induction	  of	  tumour	  vasculature,	  termed	  the	  “angiogenic	  switch”,	  can	  occur	  at	  
different	   points	   within	   tumour	   development/progression.	   For	   example,	  
neovascularisation	   can	   happen	   in	   premalignant	   or	   dormant	   lesions	   where	   it	  
aids	   progression	   to	   malignancy	   [201],	   as	   well	   as	   in	   malignant	   tumours	   to	  
sustain	   and	   enhance	   propagation	   following,	   for	   example,	   the	   induction	   of	  
hypoxia.	  We	  are	  not	  aware,	  yet,	  whether	  angiogenesis	   is	  the	  cause	  of	  tumour	  
growth	  in	  our	  model,	  or	  was	  consequentially	  induced	  by	  mouse	  SCC	  tumours	  
to	  support	  tumour	  gradual	  growth,	  or	  a	  combination	  of	  the	  two.	  Dissecting	  the	  
cause-­‐and-­‐effect	  relationship	  between	  angiogenesis	  and	  growth	  in	  our	  tumour	  
model	   will	   help	   us	   understand	   tumour	   evolution	   and	   maintenance	   in	   our	  
mouse	  SCC	  model	  and,	  ultimately,	  SCC	  patients	  in	  KS.	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5.11.4.2.	  Role	  of	  Kin1	  in	  regulating	  the	  ECM	  
5.11.4.2.1.	  Role	  of	  Kin1	  in	  regulating	  MMPs	  	  
MMP3	  and	  MMP13	  are	  members	  of	  the	  MMP	  subfamily	  of	  metalloproteinases,	  
which	   are	   potent	   enzymes	   that,	   once	   activated,	   degrade	   and,	   ultimately,	  
remodel	   ECM	   [202].	   Mmp3	   and	   Mmp13	   were	   significantly	   upregulated	   in	  
Kin1null	   SCC	   tumours	   (Table	   4)	   (Fig.44.A.i.,B.i.),	   (Fig.46.A.i.,B.i.).	   Changes	  
observed	  in	  Mmp3	  expression	  between	  tumours	  translated	  in	  the	  protein	  level	  
(Fig.45.B.).	  We	  detected	  cytoplasmic	  and	  extracellular	   localisation	  of	  MMP3,	  
as	  MMPs	  are	   synthesised	  and	   stored	   in	   the	  cytoplasm	  prior	   to	   secretion	  and	  
engage	  in	  proteolytic	  degradation	  of	  macromolecules	  in	  the	  ECM	  [203]. 
	  
Notably,	  Kin1null	   tumours	  had	  lower	  expression	  of	  collagen-­‐I,	  one	  of	  the	  most	  
abundant	  proteins	  in	  the	  ECM,	  compared	  to	  Kin1wt	  tumours	  (Fig.38),	  which	  we	  
believe	   may	   explain	   why	   morphological	   evaluation	   of	   tumour	   histology	  
indicated	  lower	  ECM	  deposition	  in	  Kin1null	  tumours	  (Fig.37.A.),	  and	  link	  to	  the	  
higher	   Mmp3	   and	   Mmp13	   expression	   in	   Kin1null	   tumours	   (Fig.44.A.i.,B.i.),	  
(Fig.45.A(i),B(i)).	   Gel	   zymography	   is	   an	   important	   experiment	   to	   be	  
performed	  in	  the	  future,	  as	  it	  will	  determine	  the	  proteolytic	  activity	  of	  MMP3	  
and	  MMP13	   in	   tumours,	   and	  provide	   a	  direct	   link	  between	   these	  MMPs	   and	  
degradation	  of	  ECM	  components.	  	  
	  
MMPs	   are	   able	   to	   degrade	   and	   structurally	   reform	   the	   ECM	   as	   well	   as	   the	  
vascular	  basement	  membrane,	  which	  allows	  migration	  of	  vascular	  endothelial	  
cells	  and	  potentiates	  formation	  of	  new	  blood	  vessels.	  Specific	  MMPs,	  including	  
MMP3,	   contribute	   to	   angiogenesis	   in	   more	   ways	   than	   ECM	   remodelling.	  
Examples	  include	  release	  of	  ECM-­‐tethered	  angiogenic	  growth	  factors,	  such	  as	  
basic	   fibroblast	   growth	   factor	   [204],	   and	   exposure	   of	   cryptic	   pro-­‐angiogenic	  
sites,	   such	   as	   α5β3	   integrin-­‐binding	   sites	   that	   are	   normally	   hidden	   within	  
matrix-­‐immobilised	  collagen	  type	  IV	  [205].	  Thus,	  increased	  Mmp3	  and	  Mmp13	  
expression	  in	  Kin1null	  tumours	  could	  connect	  to	  the	  enhanced	  vasculature,	  and	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enhanced	  Hif1a	  and	  suppressed	  Thbs1	  expression,	  observed	  in	  Kin1null	  tumours.	  	  
	  
As	  with	  various	  other	  MMPs,	  MMP3-­‐	  and	  MMP13-­‐mediated	  augmentation	  of	  
angiogenesis,	   which	   can	   occur	   at	   various	   stages	   of	   tumour	   development	  
and/or	  progression,	  contributes	  to	  tumour	  growth	  enhancement,	  as	  noted	  by	  
studies	   in	  glioblastoma,	  gastric	  cancer	  and	  melanoma	  [206]–[208].	  Moreover,	  
proteolytic	   processing	   by	   MMPs	   can	   regulate	   tumour	   growth	   by	   increasing	  
bioavailability	   of	   growth	   factors	   that	   are	   otherwise	   bound	   to	   ECM	  or	   to	   cell	  
membranes.	  Prominent	  examples	   include	  degradation	  of	   insulin-­‐like	  growth-­‐
factor-­‐binding	  proteins	  by	  MMP3	  and	  MMP7,	  which	   facilitates	  bioavailability	  
of	   insulin-­‐like	   growth	   factor	   (IGF),	   an	   anti-­‐apoptotic	   and	   mitogenic	   factor,	  
favouring	   cancer	   cell	   proliferation	   [209][210].	   MMP3	   and	   MMP7	   are	   also	  
capable	   of	   shedding	   of	   transmembrane	  HB-­‐EGF	   (heparin-­‐binding	   epidermal	  
growth	   factor-­‐like	   growth	   factor),	   another	   potent	   mitogenic	   factor	   that	  
promote	  proliferation	  [211][212].	  
	  
In	   line	  with	   these	   findings,	  our	   results	   showed	   that	  Mmp3	   and	  Mmp13	   levels	  
correlated	   positively	   with	   volume	   of	   Kin1null	   tumours	   and	   negatively	   with	  
volume	   of	   Kin1wt	   tumours	   (Fig.44.A.ii-­‐iii.,B.ii-­‐iii.),	   (Fig.46.A.ii-­‐iii.,B.ii-­‐iii.).	  
Overall,	  our	  data	  imply	  a	  potential	  link	  between	  Mmp3	  and	  Mmp13	  levels	  and	  
tumour	  growth	  in	  our	  model.	  Our	  data	  may	  also	  suggest	  a	  multifunctional	  role	  
for	   Mmp3	   and	   Mmp13,	   which	   could	   be	   context-­‐	   and	   expression	   level-­‐
dependent,	   in	  our	  mouse	  SCC	  tumour	  model.	   In	   vivo	   tumour	  growth	  studies	  
with	   MMP3	   or	   MMP13-­‐deficient	   mouse	   SCC	   cells,	   will	   offer	   an	   insight	   on	  
whether	  these	  MMPs	  play	  a	  role	  in	  tumour	  growth	  in	  our	  model,	  and	  whether	  
this	   role	   is	   regulated	  by	  Kin1.	  Future	  correlation	  analysis	  between	  Mmp3	  and	  
Mmp13	   levels	   and	   vascularisation	   in	   our	   samples,	   which	   we	   were	   unable	   to	  
perform	  as	  there	  was	  no	  overlap	  between	  the	  tumours	  in	  which	  we	  examined	  
CD31	   expression	   and	   Mmp3	   and	   Mmp13	   levels,	   will	   reveal	   if	   there	   is	   a	  
connection	  between	  Mmp3,	  Mmp13	  and	  angiogenesis	  in	  our	  mouse	  model.	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Collectively,	   our	   data	   on	  Mmp3	   and	  Mmp13	   expression	   in	   vitro	   (Fig.44.C.),	  
(Fig.46.C.)	  did	  not	  reflect	  Mmp3	  and	  Mmp13	  expression	   in	   vivo,	  nor	  did	  they	  
reflect	   a	  pattern	   that	   could	  underline	  proliferation	  and	  clonogenicity	  data	   in	  
2D	  and	  3D	  conditions.	  Dissimilarity	  between	  in	  vivo	  and	  in	  vitro	  data	  in	  Mmp3	  
and	  Mmp13	  expression	  suggests	  differences	  between	  the	  potential	  mechanism	  
that	  controls	  cell	  proliferation	  in	  vitro	  and	  in	  vivo.	  
	  
Interestingly,	  our	   report	   is	  not	   the	   first	   study	   to	   show	  a	  connection	  between	  
Kin1	   and	  MMPs.	  As	   aforementioned,	   only	   one	   other	   study	   shows	  Kin1	   as	   an	  
inhibitor	   of	   tumour	   growth,	   which	   also	   reported	   downregulation	   of	  Mmp7,	  
Mmp9	  and	  Mmp13	  following	  ectopic	  expression	  of	  Kin1	  in	  non-­‐small	  cell	  lung	  
cancer	   in	   vitro	   [120].	   Moreover,	   Kin1	   deficient	   immortalised	   HaCat	  
keratinocytes	   expressed	   higher	   levels	   of	   MMP2	   and	   MMP9	   [213].	   Thus,	   our	  
findings	   are	   in	   concert	  with	   literature,	  demonstrating	   that	  Kin1	   is	   a	  negative	  
regulator	  of	  various	  MMPs	  in	  more	  than	  one	  cell	  types.	  	  
	  
Finally,	   another	   important	   function	   of	   MMPs	   in	   cancer	   is	   promotion	   of	  
metastasis,	   which	   they	   achieve	   by	   removing	   physical	   barriers	   posed	   by	  
basement	   membranes	   within	   the	   ECM	   thus	   allowing	   cell	   invasion,	  
intravasation	  and	  extravasation.	  This	  is	  shown	  by	  the	  fact	  that	  depletion	  of	  loss	  
of	   MMP3	   reduced	   invasion	   in	   gastric	   cancer	   cells	   in	   vitro	   [214]	   and	  
spontaneous	   lung	   metastasis	   in	   mammary	   carcinoma	   in	   vivo	   [215],	  
respectively.	  Moreover,	   thyroid	  cancer	  cohort	   study	   found	   that	  expression	  of	  
MMP13	   was	   increased	   in	   metastatic	   versus	   primary	   tumours	   [216],	   and	  
silencing	  of	  MMP13	  in	  melanoma	  and	  thyroid	  cancer	  cells	  decreased	  metastasis	  
in	  vivo	  [215][217].	  	  
	  
Two	   critical	   steps	   of	   the	   metastatic	   process	   are	   intravasation	   and	  
extravasation.	   Intravasation	   involves	   movement	   of	   cancer	   cells	   in	   tumour	  
embedded	   or	   neighbouring	   blood	   vessels	   that	   allow	   them	   to	   travel	   via	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circulation,	  and	  they	  are	  termed	  as	  circulating	  tumour	  cells	  (CTCs).	  Following	  
arrest	   of	   CTCs	   in	   the	   capillary	   bed,	   cells	   then	   traverse	   the	   endothelial	   cell	  
lining	   of	   vascular	   wall	   in	   a	   process	   termed	   extravasation,	   and	   invade	   the	  
extravascular	   tissue	  where	   they	  establish	  metastasis. Inhibition	  of	  MMP3	  was	  
linked	   to	   inhibited	   intravasation	   in	   an	   orthotopic	   ovarian	   cancer	   model,	  
whereas	  MMP13	  was	  shown	  to	  promote	  extravasation	  of	  colorectal	  cancer	  cells	  
in	   the	   liver	   microenvironment	   [218].	   Thus,	   elevated	   Mmp3	   and	   Mmp13	  
expression	  may	   predict	   enhanced	  metastatic	   ability	   for	   Kin1null	  SCC	   tumours	  
compared	   to	   Kin1wt	   counterparts	   via	   augmented	   intravasation	   and	  
extravasation. 
	  
Histological	   examination	   indicated	   that	   all	   SCC	   tumours	   were	   invasive	   to	  
skeletal	  muscle	  (Fig.36.),	  but	  we	  have	  yet	  to	  examine	  any	  potential	  variation	  in	  
invasive	  and	  metastatic	  capacity	  between	  Kin1null	  and	  Kin1wt	  SCC	  tumours. To	  
scrutinise	  this,	  we	  will	  search	  for	  levels	  of	  CTC	  in	  the	  bloodstream,	  which	  is	  a	  
biomarker	   readily	   used	   in	   estimation	   of	   intravasation	   and	   metastatic	  
progression	   [219].	   	   Moreover,	   tail-­‐vein	   injections	   will	   result	   in	   intravessel	  
growth	  of	  Kin1null	   and	  Kin1wt	  SCC	   cells	   in	   the	   lung	  microenvironment,	  which	  
will	  help	   interrogate	  subsequent	  extravasation	  and	   lung	  colonisation.	  Finally,	  
examination	  of	  metastatic	  burden	  in	  lymph	  nodes,	  liver,	  lung	  and	  other	  organs	  
following	   termination	   of	   future	   tumour	   growth	   experiment,	   and	   tumour	  
extraction,	   will	   help	   us	   further	   define	   any	   differences	   in	   metastatic	   ability	  
amongst	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	   
	  
5.11.4.2.2.	  Role	  of	  Kin1	  in	  regulating	  ADAMTSs	  
Various	   genes	   from	   the	   ADAMTS	   subfamily	   of	   metalloproteinases,	   such	   as	  
Adamts17	   were	   identified	   through	  RNA-­‐Seq	   and	   validated	   through	   q-­‐PCR	   as	  
having	   significantly	   lower	   expression	   in	   Kin1null	   compared	   to	   Kin1wt	   tumours	  
(Table	   4),	   (Fig.48.C.i.),	  contrary	  to	  the	  expression	  pattern	  observed	  in	  MMP	  
genes.	   Our	   data	   parallel	   numerous	   literature	   findings	   that	   show	   that	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expression	   of	   ADAMTS	   genes	   is	   reduced	   in	   a	   variety	   of	   cancers,	   including	  
breast,	  lung	  and	  oesophageal	  SCC	  [220]–[223].	  
	  
Due	  to	  limited	  research	  in	  Adamts17,	  its	  specific	  roles	  in	  cancer	  are	  unknown.	  	  
However,	   research	   in	   various	   other	   ADAMTSs,	   such	   as	   ADAMTS1	   and	  
ADAMTS9,	   reveals	   an	   angiostatic	   role	   for	   these	   proteins	   [224][225].	   As	  
suggested	  by	  their	  nomenclature,	  ADAMTSs	  share	  a	  motif	  with	  TSP1,	  a	  protein	  
shown	   to	   prohibit	   angiogenesis	   [199].	   However,	   whereas	   not	   all	   peptides	   of	  
TSP1	   have	   shown	   to	   have	   anti-­‐angiogenic	   effects,	   fragments	   shared	   by	  
ADAMTSs	  and	  TSP1	  were	  shown	  to	  be	  anti-­‐angiogenic	  [226]–[228].	  Our	  data,	  
therefore,	  underline	  the	  link	  between	  ADAMTSs	  and	  TSP1,	  as,	  both	  Adamts17	  
and	   Thbs1	   levels	   were	   lower	   in	   Kin1null	   compared	   to	   Kin1wt	   tumours	  
(Fig.48.C.i.),	  (Fig.51.A.i.,B.i.).	  	  
	  
Finally,	   we	   observed	   that	  Adamts17	   levels	   correlated	  with	   Kin1null	   and	   Kin1wt	  
tumour	  volume	  in	  an	  opposing	  manner	  (Fig.48.C.ii-­‐iii.).	  This	  implies	  that	  via	  
its	   role	   in	   angiogenesis,	   Adamts17	   expression	   might	   also	   influence	   tumour	  
growth	   in	   a	   context-­‐specific	   way,	   which,	   in	   this	   case,	   is	   the	   presence	   or	  
absence	  of	  Kin1.	  	  
	  
5.11.4.3.	  Role	  of	  Kin1	  in	  regulating	  the	  immune	  system	  
Chemokines	   are	   chemoattractants	   that	   facilitate	   leukocyte	   directed	  motility,	  
and	   are	   induced	   by	   inflammatory	   cytokines,	   pathogenic	   stimuli	   and	   growth	  
factors	   [187].	   Various	   studies	   have	   implicated	   expression	   of	   chemokines	   to	  
malignancy,	  which	  occurs	  in	  a	  variety	  of	  ways.	  	  
	  
We	   identified	   that	   a	   variety	   of	   genes	   that	   encode	   chemokines,	   such	   as	  Cxcl1	  
(Fig.52.A.i.),	  Ccl2	   (Fig.52.B.i.)	   and	  Ccl7	   (Fig.52.C.i.)	   had	  significantly	  higher	  
expression	   in	  Kin1null	   compared	   to	  Kin1wt	  tumours.	   Interestingly,	  according	   to	  
the	  RNA-­‐Seq	  results	  Kin1null	  tumours	  also	  expressed	  significantly	  higher	  levels	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of	  Ccr1,	  which	  encodes	  a	  chemokine	  receptor	  for	  both	  CCL7	  and	  CCL9.	  
	  
Various	   chemokines	   are	   overexpressed	   in	   cancer	   and	   stimulate	   cancer	  
progression.	   In	   colorectal	   cancer	   expression	   of	   CXCL1,	   induced	   by	  
prostanglandin	  E2,	  promoted	  angiogenesis	  [229],	  and	  overexpression	  of	  CXCL1	  
in	   gastric	   cancer	   cells	   in	   vitro	   promoted	   invasion,	   potentially	   via	   elevated	  
activity	  of	  MMP2	  and	  MMP9	  [230].	  	  
	  
CCL2	   also	   plays	   an	   important	   role	   in	   tumourigenesis.	   	   It	   is	   upregulated	   in	  
prostate	   cancer	   cells	   in	   vitro	   and	   in	   human	   cancers	   [231],	   and	   its	   expression	  
correlated	   with	   advanced	   stage	   in	   prostate	   cancer	   patients	   [232].	   Moreover,	  
CCL2	   was	   produced	   by	   prostate	   cancer	   cells	   in	   vitro,	   which	   promoted	  
proliferation	  and	  invasion[231].	  The	  proliferative	  and	  migratory	  effect	  of	  CCL2	  
to	  prostate	  cancer	  cells	  were	  shown	  to	  occur	  directly	  on	  tumour	  cell	  growth	  in	  
vitro,	   via	   the	   PI3	   Kinase/AKT	   signalling	   pathway	   and	   activation	   of	   p70-­‐S6	  
kinase	   [233],	   and	   via	   indirect	   effect	   on	   tumour	   microenvironment	   by	  
regulation	   of	   tumour-­‐associated	   macrophage	   (TAM)	   infiltration	   into	   the	  
tumour	  bed	  in	  vivo	  [231].	  	  
	  
Immune	   cells	   such	   as	   TAMs	   and	   cancer-­‐associated	   fibroblasts	   (CAFs)	   are	  
known	   to	   contribute	   to	   malignant	   progression	   and	   have	   been	   previously	  
linked	   to	   expression	   level	   changes	   in	   key	   components	   of	   the	   tumour	  
microenvironment.	   TAMs	   can	   stimulate	   expression	   of	  mitogenic	   stimuli	   and	  
induce	   angiogenesis	   during	   tumour	   growth	   via	   the	   production	   of	   various	  
angiogenic	  factors,	  such	  as	  VEGF,	  PDGF	  and	  MMPs.	  Moreover,	  levels	  of	  CCL2	  
have	   previously	   correlated	   with	   accumulation	   of	   TAMs	   and	   microvessel	  
density	   in	   primary	   breast	   cancer	   [234].	   Finally,	   CCL2-­‐	   and	   CCL5-­‐	   mediated	  
TAM	   infiltration	   was	   documented	   to	   promote	   growth	   and	   cancer	   cell	  
dissemination	  in	  breast	  cancer	  in	  vivo	  [235].	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Similarly	   to	   TAMs,	   CAFs	   have	   also	   been	   associated	   with	   the	   presence	   of	  
chemokines,	   such	   as	   CCL2.	   In	   particular,	   fibroblast	   activation	   protein	   (FAP)	  
was	  shown	  to	  trigger	  induction	  of	  a	  subset	  of	  CAFs	  in	  a	  murine	  tumour	  model,	  
which	   were	   a	   key	   source	   of	   CCL2	   [236].	   In	   fact,	   FAP-­‐mediated	   CCL2	  
upregulation	  and	  STAT3	  activation	  in	  CAFs	  promoted	  tumour	  growth,	  which	  
was	   abrogated	   in	   mice	   deficient	   for	   CCR2,	   which	   is	   the	   receptor	   for	   CCL2	  
[236].	   Interestingly,	   similar	   results	   were	   noted	   clinically,	   where	   a	   positive	  
correlation	   between	   stromal	   expression	   of	   FAP,	   p-­‐STAT3	   and	   CCL2	   was	  
observed	  in	  human	  intrahepatic	  cholangiocarcinoma,	  a	  highly	  aggressive	  liver	  
cancer	  [236].	  It	  is,	  thus,	  possible,	  that	  observed	  differences	  in	  expression	  levels	  
of	  chemokines,	  such	  as	  Ccl2,	  as	  well	  as	  of	  various	  MMPs	  and	  angiogenic	  factors	  
between	   Kin1null	   and	   Kin1wt	   SCC	   tumours	   are	   associated	   with	   enhanced	  
infiltration	  of	  immune	  system	  components.	  
	  
Notably,	   a	   central	   function	   of	   TAMs	   is	   the	   production	   of	   pro-­‐inflammatory	  
cytokines	  such	  as	  IL-­‐6	  (Interleukin-­‐6)	  [237][238],	  which	  is	  normally	  expressed	  
by	   T	   cells	   and	   macrophages	   and	   whose	   expression	   is	   associated	   with	  
stimulation	   of	   tumour	   angiogenesis,	   enhanced	   cell	   invasiveness,	   advanced	  
tumour	   stage	   [239][240].	   Interestingly,	   KS	   keratinocytes	   from	   numerous	   KS	  
patients	   have	   exhibited	   characteristics	   of	   inflammatory	   response,	   such	   as	  
increased	   secretion	   of	   pro-­‐inflammatory	   cytokines,	   including	   IL-­‐6,	   and	  
infiltration	   of	   macrophages	   [54][213][241].	   It	   is	   possible	   that	   long-­‐term	  
blistering	   and	   continuous	   skin	   fragility	   in	   KS	   skin	   could	   provoke	   chronic	  
inflammation,	  which,	   can	  be	  a	  pathological	   trigger	   for	   tumour	   initiation	  and	  
progression.	  In	  the	  future	  we	  will	  explore	  this	  avenue	  via	  examining	  presence	  
of	  cytokines	  such	  as	  IL-­‐6	  in	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  
	  
CCL2	  was	  also	  shown	  to	  induce	  angiogenesis	  directly	  via	  upregulation	  of	  HIF1a	  
levels	   and,	   in	   turn,	   induced	   VEGFA	   expression	   [242].	   Interestingly,	   we	  
observed	   no	   significant	   changes	   in	   expression	   of	  Vegfa	   (Fig.50.A.i.),	   or	   Flt1	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(Fig.50.B.i.)	  and	  Kdr	  (Fig.50.C.i.)	  between	  Kin1null	  and	  Kin1wt	  tumours,	  which	  
suggests	  that	  VEGA,	  VEGFR1	  and	  VEGFR2	  do	  not	  participate	  in	  enhancement	  
of	  angiogenesis	  in	  our	  model.	  	  
	  
Furthermore,	   expression	   of	   CCL7	   and	   its	   receptor	   CCR2,	   and	   infiltration	   of	  
CCR2-­‐positive	   TAMs	   was	   higher	   in	   tumour	   cells	   of	   renal	   cell	   cancer	   brain	  
metastasis	   compared	   to	   primary	   tumours,	   indicating	   a	   connection	   between	  
CCL7	  and	  metastasis	  [243].	  CCL7	  overexpression	  enhanced	  tumour	  growth	  and	  
induced	   liver	   and	   lung	  metastasis	   in	   colorectal	   cancer	   via	   activation	  of	  ERK-­‐
JNK	  signalling	  pathway	  [244].	  	  	  	  
	  
Interestingly,	   we	   observed	   that	   Cxcl1	   (Fig.52.A.ii-­‐iii.),	   Ccl2	   (Fig.52.B.ii-­‐iii.)	  
and	  Ccl7	  (Fig.52.C.ii-­‐iii.)	  expression	  correlated	  positively	  with	  Kin1null	  tumour	  
volume	   and	   negatively	   with	   Kin1wt	   tumour	   volume,	   which	   mirrors	   the	  
correlation	  pattern	  between	  Mmp3	  and	  Mmp13	  between	  and	  Kin1null	  and	  Kin1wt	  
tumour	   volume.	   This	   suggests	   that	   in	   our	   mouse	   SCC	   model	   various	  
chemokines	   may	   influence	   tumour	   growth	   in	   a	   different	   manner	   in	   the	  
presence	  or	  absence	  of	  Kin1.	  	  	  
	  
5.11.5.	  Role	  of	  Kin1	  in	  tumour	  growth	  in	  Kin1null,	  Kin1wt	  and	  Kin1AA	  
Met-­‐1	  mammary	  tumours	  	  
Interestingly,	   data	   from	   our	   lab	   showed	   that	   in	   mouse	   Met-­‐1	   mammary	  
tumours	   Kin1	   depletion	   affected	   tumour	   growth,	   but	   in	   an	   overall	   different	  
manner	   than	   the	   mouse	   SCC	   tumour	   model.	   Met-­‐1	   tumour	   growth	   study	  
demonstrated	   that	  Kin1wt	   and	  Kin1AA	   tumours	  had	  a	  higher	  growth	   rate	   than	  
Kin1null	  tumours,	  but	  showed	  no	  variation	  in	  growth	  between	  them	  (Fig.54.	  by	  
Georgia	  Dodd).	  This	  resembles	  in	  vitro	  and	  in	  vivo	  data	  that	  show	  a	  role	  for	  
Kin1	   as	   a	   proliferation	   and	   growth	   promoter	   in	   breast	   cancer	   [115],	   but	  
contradicts	   growth	   of	   mouse	   SCC	   tumours	   in	   our	   study	   (Fig.35.D.).	   High	  
variability	   in	   growth	   rate	   of	   Kin1AA	   tumours	   could	   have	   prevented	   the	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difference	   between	   Kin1null	   and	   Kin1AA	   tumours	   reaching	   significance,	   but	  









Figure	  54:	  Assessment	  of	  Kin1null,	  Kin1wt	  and	  Kin1AA	  Met-­‐1	  tumour	  growth.	  Bilateral	  subcutaneous	  
implantations	  of	  4x106	  Kin1null,	  Kin1wt	  and	  Kin1AA	  Met-­‐1	  cells	  were	  administrated	  in	  CD-­‐1	  nude	  mice.	  
Tumour	   volume	   was	   quantified	   over	   the	   course	   of	   30	   days.	   Only	   statistical	   analysis	   using	   values	  
obtained	   at	   Day30	   is	   shown.	   Results	   presented	   as	   mean	   ±	   SEM.	   one-­‐way	   ANOVA	   with	   Tukey’s	  
multiple	  comparison	  test;	  p-­‐value	  >	  0.05,	  *	  p-­‐value	  ≤	  0.05.	  (Experiment	  performed	  by	  Georgia	  Dodd).	  
	  
5.11.6.	  Summary	  and	  future	  work	  
Overall,	   we	   found	   that	   in	   our	   mouse	   SCC	   model,	   Kin1	   inhibits	   cell	  
proliferation,	   tumour	   growth	   and	   angiogenesis,	   both	   in	   vitro	   and	   in	   vivo.	  
Although	  we	  do	  not	  yet	  know	  the	  mechanisms	  that	  regulate	  cell	  proliferation	  
in	   3D	   conditions	   in	   vitro,	  we	   have	   identified	   a	   variety	   of	   changes	   in	   tumour	  
microenvironment	   that	   may	   contribute	   to	   differences	   in	   tumour	   growth	  
between	  Kin1null	  and	  Kin1wt	  SCC	  tumours.	  Kin1	  expression	  supresses	  expression	  
of	   Mmp3,	   MMP3	   and	   Mmp13	   which	   are	   known	   to	   induce	   tumour	   growth,	  
angiogenesis	   and	   metastasis,	   and	   induces	   expression	   of	   Adamts17,	   which	  
belongs	  to	  a	  family	  of	  angiostatic	  factors.	  Moreover,	  presence	  of	  Kin1	  reduces	  
expression	  of	  various	  chemokines,	   including	  Ccl2	  and	  Cxcl1,	  which	  have	  been	  
shown	   to	   induce	  pro-­‐angiogenic	   and	  pro-­‐metastatic	   response,	   sometimes	  via	  
involvement	   of	   MMPs.	   Interestingly,	   expression	   of	   various	   MMPs	   and	  
chemokines	  correlates	   in	  a	  positive	  manner	  with	  Kin1null	   tumour	  volume	  and	  
in	  a	  negative	  manner	  with	  Kin1wt	  tumour	  volume	  in	  our	  mouse	  SCC	  model.	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It	   is,	   therefore,	   likely	   that	   a	   signalling	   axis	   exists	   between	   chemokines	   and	  
metalloproteinases	   in	   our	   model	   that	   exerts	   anti-­‐	   or	   pro-­‐tumourigenic	   and	  
angiogenic	   effects	   in	   the	   presence	   or	   absence	   of	   Kin1,	   respectively,	   in	   a	  
context-­‐specific	  manner.	  Silencing	  of	  chemokines	  and	  MMPs	  regulated	  by	  Kin1	  	  
will	  help	  us	   establish	  whether	  differences	   in	   tumour	  growth	  between	  Kin1null	  
and	  Kin1wt	   SCC	   tumours	   occur	   in	   a	   chemokine-­‐metalloproteinase-­‐dependent	  
manner,	   and	   further	   define	   the	   interrelationship	   between	   Kin1	   and	   tumour	  
microenvironment.	  	  
	  
SCC	   tumours	  developed	  by	  KS	  patients	  are	  highly	  aggressive	  and	  metastatic,	  
but	   the	   mechanism	   accountable	   for	   this	   feature	   remains	   elusive.	   Here	   we	  
identify	   important	  roles	  for	  Kin1	   in	  SCC,	  which	  offer	  a	  mechanistic	   insight	  to	  
the	   development	   of	   aggressive	   SCC	   in	   KS,	   and	   may	   ultimately	   provide	  
therapeutic	  targets	  for	  SCC’s	  management.	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Chapter	  6:	  discussion	  	  
Kindler	  syndrome	  is	  an	  extremely	  rare	  genetic	  disorder,	  characterised	  by	  skin	  
blistering,	   epidermal	   atrophy	   and	   predisposition	   to	   aggressive	   SCC.	   As	   with	  
other	   variants	   of	   EB,	   treatment	   of	   the	  disease	   is	  mainly	   symptomatic	   and	  of	  
preventative	  nature,	  such	  as	  avoidance	  of	  physical	  trauma	  and	  management	  of	  
skin	  wounds.	  	  
	  
6.1.	  Therapeutic	  avenues	  for	  KS	  and	  other	  types	  of	  EB	  	  
Despite	   the	  potential	   benefits	   of	   therapies	   aimed	   at	   symptom	   relief,	   there	   is	  
still	  a	  need	  for	  a	  systemic	  therapeutic	  approach	  for	  KS	  and	  other	  subtypes	  of	  
EB,	   and	   research	   has	   shown	   promise	   towards	   the	   development	   of	   effective	  
treatments	  and	  therapies.	  
	  
6.1.1.	  Allogeneic	  bone	  marrow	  transplantation	  	  	  
Plasticity	  in	  bone	  marrow	  (BM)	  stem	  cells	  enables	  them	  to	  not	  only	  regenerate	  
the	   haematopoietic	   system,	   but	   differentiate	   into	   other	   organs	   such	   as	   skin	  
and	   aid	   cutaneous	   tissue	   repair	   [245]–[247].	   BM	   transplantation	   has	   also	  
shown	   promise	   in	   ameliorating	   RDEB,	   which	   is	   caused	   by	   loss-­‐of-­‐function	  
mutations	   in	  COLVIIA1	   gene.	   BM	   cells	   from	  healthy	   donors	  were	   capable	   of	  
migrating	  to	  affected	  skin	   lesions,	   restore	  production	  of	  Collagen	  VII	  protein	  
and	  skin	  structure,	  and	  mediate	  wound	  healing	  in	  animals	  and	  in	  clinical	  trial	  
[248]–[250].	  
	  
However,	   BM	   transplantation	   relies	   on	   a	   suitable	   human	   leukocyte	   antigen-­‐
matched	   donor,	   which	   not	   every	   patient	   has,	   and,	   despite	   the	   potential	  
benefits,	   remains	   a	   high-­‐risk	   therapeutic	   approach.	   This	   is	   due	   to	  
complications	   such	   as	   profound	   immunodeficiency,	   which	   is	   common	   after	  
allogeneic	  transplantation,	  and	  graft	  versus	  host	  disease.	  Thus,	  this	  presents	  a	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key	  limitation	  to	  clinical	  application	  of	  allogeneic	  transplant	  therapy	  to	  RDEB	  
and	  other	  genodermatoses,	  such	  as	  KS.	  	  
	  
6.1.2.	  Autologous	  gene	  therapy	  	  
Autologous	   cell	   transplantation	   should	   evade	   these	   complications,	   but	  
requires	  correction	  of	  defective	  genes.	  Gene	  therapy	  can	  be	  delivered	  via	  viral	  
or	   non-­‐viral	   gene	   systems,	   and	   this	   approach	   has	   shown	   promise	   for	   RDEB.	  
Codon-­‐optimised	   Collagen	   VII	   was	   delivered	   in	   cultured	   RDEB	   patient	  
fibroblasts	   via	   a	   lentiviral-­‐engineered	   platform,	   which	   restored	   protein	  
expression	   levels	   [251].	   Collagen	   VII-­‐expressing	   RDEB	   fibroblasts	   were	  
subsequently	   incorporated	  on	  a	  bioengineered	  human	  skin	  graft	   that	  was,	   in	  
turn,	   grafted	   on	  mouse	   skin,	  which	   resulted	   in	   functional	   recovery	   of	   RDEB	  
fibroblasts	   and	   morphological	   correction	   of	   the	   epidermis	   in	   RDEB	  
human:murine	  skin	  graft	  model	  [249].	  	  	  
	  
Ex	   vivo	   FERMT1	   gene	   delivery	   in	   KS	   patient	   keratinocytes	   and	   autologous	  
transplantation	   of	   corrected	   patient	   keratinocytes	   on	   affected	   areas	   of	   KS	  
patient	  skin	  holds	  potential	  for	  repair	  of	  affected	  KS	  epidermis.	  Nevertheless,	  
both	   viral-­‐	   and	   nonviral-­‐mediated	   gene	   therapy	   have	   been	   reported	   to	  
sometimes	   lead	   to	   undesirable	   off-­‐target	   side	   effects	   such	   as	   toxicity,	  
presenting	  a	  limitation	  to	  this	  approach	  [252][253].	  	  
	  
6.1.3.	  Revertant	  mosaicism	  
Interestingly	  various	  patients	  that	  suffer	  from	  genetic	  diseases	  that	  affect	  self-­‐
generating	   organs,	   such	   as	   blood	   and	   skin,	   have	   exhibited	   Revertant	  
mosaicism	   (RM),	   a	   naturally	   occurring	   phenomenon	   that	   involves	  
spontaneous	   reversion	   of	   inherited	   pathogenic	   mutations	   in	   somatic	   cells	  
[254][255].	  RM	  has	  also	  been	  reported	  in	  a	  variety	  of	  skin	  disorders,	  including	  
EB	   subtypes	   RDEB	   [256]	   and	   KS	   [257][258],	   where	   patients	   exhibit	   multiple	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revertant,	   normal-­‐appearing	   skin	   patches	   that	   contrast	   their	   otherwise	  
atrophic	  skin.	  	  
	  
In	   KS	   patients	   with	   revertant	   patches	   are	   positive	   for	   restoration	   of	   the	  
FERMT1	   reading	   frame,	   and	   FERMT1	   mRNA	   and	   Kin1	   expression	   over	   the	  
entire	   length	   of	   the	   biopsy,	   similar	   to	   normal	   skin	   [255][256].	   Signs	   of	   KS	  
epidermal	   atrophy,	   such	   as	   low	   epidermal	   thickness,	   decreased	   keratinocyte	  
proliferation	   and	   cleaved	   dermoepidermal	   junction	   are	   restored	   in	   revertant	  
skin	  patches	  [255][256].	  Notably,	  higher	  β1	  integrin	  activation	  is	  found	  at	  focal	  
adhesion	   of	   revertant	   keratinocytes,	   compared	   to	   non-­‐revertant	   KS	  
counterparts	  [258].	  	  
	  
Corrected	   revertant	   keratinocytes	   offer	   a	   unique	   opportunity	   for	   autologous	  
cell	  therapy	  in	  genodermatoses	  such	  as	  KS,	  as	  in	  vivo	  restoration	  obviates	  the	  
need	  for	  further	  genetic	  repair	  of	  the	  diseased	  skin,	  and	  the	  development	  of	  an	  
immune	  response.	  Punch	  graft	  transplantation	  of	  autologous	  revertant	  skin	  in	  
affected	   areas	   of	   the	   epidermis	   of	   a	   JEB	   patient	   resulted	   in	   revertant	   skin	  
expansion	   and	   phenotypical	   and	   genotypical	   cutaneous	   correction	   [259].	  
However,	   although	   beneficial,	   such	   approach	   cannot	   treat	   the	   entire	   body	  
surface,	   and,	   thus,	   does	   not	   accommodate	   the	   need	   for	   desired	   universal	  
therapy	  in	  KS	  and	  EB	  patients.	  	  
	  
In	   vitro	   cultivation	   and	   expansion	   of	   autologous	   keratinocyte	   stem	   cells,	   an	  
approach	  routinely	  used	  to	  form	  transplantable	  epidermal	  sheets	  to	  treat	  burn	  
victims	   [260],	   also	   presents	   limitations	   in	   EB	   diseases,	   as	   chronic	   wounding	  
and	   non-­‐healing	   tissue	   repair	   can	   lead	   to	   exhaustion	   and	   paucity	   of	  
keratinocyte	  stem	  cell	  population	  [261].	  To	  circumvent	  that,	  researchers	  have	  
shown	  that	   induced	  pluripotent	   stem	  cells	  can	  be	  derived	   from	  both	  mutant	  
and	   revertant	   skin	   of	   an	   affected	   individual,	   which	   can	   differentiate	   into	  
stratified	   skin	   epithelium	   [256].	   Such	   approach	   not	   only	   supports	   the	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likelihood	  of	  generating	   life-­‐long	  supply	  of	  patient-­‐specific	  keratinocytes,	  but	  
abolishes	   the	   need	   for	   RM,	   which	   is	   unknown	   if	   it	   occurs	   on	   every	   KS/EB	  
individual.	  
	  
6.2.	  A	  role	  for	  Kin1	  in	  skin	  homeostasis	  	  
Epidermal	  atrophy,	  which	  results	  in	  thin	  and	  fragile	  skin,	  is	  often	  characterised	  
by	  progressive	  deterioration,	  making	  it	  one	  of	  the	  major	  clinical	  features	  of	  KS	  
and	  other	  subtypes	  of	  EB.	  Our	  research	  has	  shown	  a	  novel	  role	  for	  Kin1	  in	  skin	  
homeostasis	  and	  may,	  ultimately,	  open	  up	  new	  therapeutic	  approaches,	  which	  
could	  help	  to	  relieve	  the	  epidermal	  atrophy	  and	  fragility	  symptoms	  of	  KS.	  
	  
We	  demonstrated	  for	  the	  first	  time	  that	  short-­‐term	  loss	  of	  Kin1	  in	  adult	  mouse	  
epidermis	  reduces	  keratinocyte	  proliferation,	  a	  feature	  that	  has	  been	  linked	  to	  
epidermal	  atrophy	  in	  KS	  patients	  and	  mice	  with	  congenital	  loss	  of	  Kin1	  [8][54].	  
We	   have	   also	   shown	   that	   adult	   mice	   with	   short-­‐term	   loss	   of	   Kin1	   had	  
decreased	  mitotic	   index,	   and	   abnormalities	   in	   important	   features	   of	  mitotic	  
spindles,	   such	   as	   spindle	   orientation	   and	   tubulin	   acetylation	   that	   is	   a	   well-­‐
established	  readout	  of	  microtubule	  stability	  [137]-­‐[140].	  This	  implies	  that	  skin	  
atrophy	  and	  reduced	  keratinocyte	  proliferation	  in	  KS	  patients	  may	  be	  linked	  to	  
faulty	  mitosis.	  	  
	  
Our	   in	   vitro	   data	   complemented	   our	   in	   vivo	   findings,	   showing	   that	   Kin1	  
depletion	  in	  human	  epithelial	  cell	  lines	  increased	  spindle	  abnormalities,	  which	  
were	  rescued	  via	  chemical	  inhibition	  of	  tubulin	  deacetylase	  HDAC6.	  Together	  
these	  data	   led	  us	   to	  conclude	   that	   in	   vitro,	  depletion	  of	  Kin1	   reduces	   tubulin	  
acetylation,	  weakens	  spindle	  stability	  and,	  ultimately,	   impairs	  proper	  mitosis,	  
potentially	  via	  enhancement	  of	  HDAC6	  expression.	  	  
	  
If	  our	  in	  vitro	  findings	  translate	  in	  vivo,	  a	  potential	  therapeutic	  avenue	  for	  skin	  
atrophy	  in	  KS	  patients	  would	  be	  pharmacological	  inhibition	  of	  HDAC6,	  which	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could	   restore	   correct	   mitotic	   function	   and,	   ultimately,	   keratinocyte	  
proliferation	   and	   skin	   homeostasis.	   For	   this	   to	   be	   implemented,	   additional	  
studies	   must	   be	   performed	   to	   examine	   in	   greater	   detail	   the	   role	   of	   Kin1	   in	  
mitosis	  in	  vivo,	  and	  the	  protein’s	  relationship	  with	  HDAC6.	  
	  
Translation	   of	   scientific	   discoveries	   into	  novel	   therapies	   for	   human	  diseases,	  
such	   as	   KS,	   necessitates	   development	   of	   suitable	   animal	   models	   that	   can	  
ultimately	   replicate	   the	   pathophysiology	   of	   human	   disease.	   Short-­‐term	   or	  
long-­‐term	   loss	  of	  Kin1	   in	  epidermis	  of	  adult	  K14Cre-­‐Kin1fl/fl	  FVB	  mice	  did	  not	  
replicate	   skin	   atrophy	   phenotype	   observed	   in	   KS	   patients,	   as	   revealed	   by	  
histological	  examination.	  In	  contrast,	  long-­‐term	  loss	  of	  Kin1	  in	  C57BL/6	  mouse	  
epidermis,	   which	   occurred	   during	   embryonic	   development,	   provoked	  
exhaustion	   of	   keratinocyte	   stem	   cell	   compartments	   and	   resulted	   in	   KS-­‐like	  
phenotypes,	  including	  skin	  atrophy	  and	  poikiloderma	  [119].	  Lack	  of	  epidermal	  
abnormalities	   in	   our	   model	   could	   stem	   from	   various	   factors,	   including	  
inability	  of	  Kin1	  to	  regulate	  an	  already	  established	  adult	  stem	  cell	  population	  
and/or	   from	  the	   fact	   that	  epidermal	  stem	  cell	  population	  of	  C57BL/6	  mice	   is	  
more	  susceptible	  to	  Kin1	  loss	  compared	  to	  that	  in	  FVB	  mice.	  As	  elaborated	  in	  
Chapter	   3,	   Section	   3.6.2,	   taking	   into	   consideration	   such	   factors	   is	   key	   for	  
developing	  a	  mouse	  model	  that	  would	  appropriately	  allow	  us	  to	  study	  if	  loss	  of	  
Kin1	  causes	  skin	  atrophy	  via	  regulation	  of	  mitosis.	  	  
	  
An	   attractive	   alternative	   to	   genetically	   modified	   animals	   would	   be	   the	  
development	  of	  a	  humanised	  mouse	  model	  via	  xenotransplantation	  of	  human	  
KS	  skin	  onto	  mice.	  This	  technique	  was	  first	  achieved	  in	  1973,	  and	  human	  grafts	  
were	   capable	   of	   preserving	   skin	   phenotype	   and	   accompanying	   genetic	   and	  
molecular	  characteristics	  of	  diseases	  such	  as	  RDEB	  in	  mice	  [262].	  By	  examining	  
if	   defective	   mitosis	   underlines	   skin	   atrophy	   in	   KS	   skin,	   and	   the	   molecular	  
mechanisms	   behind	   it,	   we	   will	   be	   able	   to	   identify	   molecular	   targets	   whose	  
clinical	  inhibition	  could	  relieve	  KS-­‐related	  skin	  atrophy,	  such	  as	  HDAC6.	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Over	   the	   past	   few	   years,	   clinical	   HDAC6	   inhibition	   has	   gained	   substantial	  
interest,	   as	   besides	   its	   role	   α-­‐tubulin	   deacetylation,	   HDAC6	   also	   promotes	  
deacetylation	  of	  cortactin	  and	  heat	  shock	  protein	  90,	  a	  process	  that	  promotes	  
endothelial	   cell	  migration,	   angiogenesis	   and	   stabilises	   survival/anti-­‐apoptotic	  
factors	  [263][264].	  A	  variety	  of	  HDAC6	  inhibitors	  have	  been	  identified,	  some	  of	  
which	   have	   been	   approved	   for	   cutaneous	   treatment	   of	   cutaneous	   T-­‐cell	  
lymphoma	  [265].	  If	  we	  confirm	  that	  in	  vivo	  Kin1	  regulates	  mitosis	  in	  an	  HDAC6	  
dependent	   manner,	   then	   application	   of	   HDAC6	   inhibitors	   on	   mouse	   and	  
humanised	  mouse	  model	  of	  KS	  will	  help	  us	  assess	  whether	  this	  could	  restore	  
mitosis	  and,	  ultimately,	  skin	  homeostasis	  in	  KS	  patients.	  	  
	  
6.3.	  A	  role	  for	  Kin1	  in	  the	  development	  of	  SCC	  	  
Patients	  of	  KS	  and	  of	  other	  EB	  subtypes	  are	  predisposed	  to	  the	  development	  of	  
aggressive	  SCC,	  which	  increases	  morbidity	  and	  mortality	  amongst	  KS	  patients.	  
To	   our	   knowledge,	   the	   mechanism	   that	   underlines	   EB	   patients	   to	   SCC	  
predisposition	  remains	  unknown.	  	  
	  
A	  single	  in	  vivo	  study	  recapitulated	  tumour	  susceptibility	  in	  Kin1-­‐null	  C57BL/6	  
mice,	   and	   defined	   a	   tumour	   suppressor	   role	   for	   Kin1,	   which	   controls	  
homeostasis	   of	   cutaneous	   epithelial	   stem	   cells	   by	   maintaining	   a	   balance	  
between	   Wnt-­‐β-­‐catenin-­‐mediated	   growth-­‐promoting	   signals	   and	   TGF-­‐β-­‐
mediated	   growth-­‐inhibiting	   signals	   [119].	  As	   a	   staggering	   70%	  of	  KS	   patients	  
over	  45	  years	  old	  develop	  SCC	  [9],	  targeting	  Wnt	  signalling	  could	  represent	  a	  
chemo	   preventative	   option.	   However,	   this	   will	   require	   a	   fine	   balancing	   act,	  
wherein	   the	   tumour-­‐promoting	   functions	   of	   Wnt	   signalling	   in	   SCC	   are	  
abolished	   without	   interfering	   with	   other	   key	   roles	   of	   Wnt	   signalling	   in	  
functions	  such	  as	  insulin	  sensitivity	  and	  bone	  development.	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Nevertheless,	   many	   tumours	   developed	   by	   C57BL/6	   animals	   were	   benign,	  
including	  trichofolluculoma-­‐like	  lesions	  and	  papillomas,	  and	  were	  only	  slightly	  
larger	  in	  mice	  with	  Kin1	  loss,	  which	  does	  not	  recapitulate	  the	  malignancy	  and	  
aggressiveness	  of	  SCC	  tumours	  observed	  in	  KS	  patients	  [119].	  This	  could	  be	  due	  
to	   the	   fact	   that	   C57CL/6	   mouse	   is	   less	   susceptible	   to	   development	   of	   SCC	  
tumours	   compared	   to	   other	  mouse	   strains,	   such	   as	   FVB,	   or	   that	   the	   cell	   of	  
origin	  in	  the	  mouse	  does	  not	  reflect	  that	  seen	  in	  the	  human	  disease.	  
	  
In	   this	   thesis	   we	   explored	   molecular	   mechanisms	   that	   underline	  
aggressiveness	  of	  SCC	  tumours	  developed	  in	  KS,	  and	  overall	  showed	  that	  Kin1	  
plays	  a	  role	  in	  SCC	  development	  and	  that	  this	  may	  be	  via	  regulation	  of	  tumour	  
microenvironment.	   We	   demonstrated	   that,	   compared	   to	   Kin1wt	   SCC	   cells,	  
injection	   of	   Kin1null	  SCC	   cells	   in	   CD-­‐1	   nude	  mice	   resulted	   in	   greater	   tumour	  
growth,	   enhanced	   vascularisation	   and	   increased	   expression	   of	   tumour	  
microenvironment	   factors	   known	   to	   promote	   tumour	   growth,	   angiogenesis	  
and	  metastasis,	  such	  as	  MMPs	  and	  chemokines.	  	  
	  
It	   is	   important	   to	   validate	   our	   findings	   in	   an	   in	   vivo	   model	   with	   genetic	  
resemblance	   to	   KS.	   Loss	   of	   Kin1	   during	   embryonic	   development	   via	  
establishment	  of	  K5-­‐Cre/Kin1fl/fl	  mice	  will	  allow	  us	  to	  recapitulate	   the	  genetic	  
background	   of	   KS.	   Subsequently	   assessment	   of	   growth,	   vascularisation,	  
histopathology	   and	   gene	   expression	   profile	   in	   SCC	   tumours	   that	   develop	  
spontaneously	  or	  following	  DMBA	  treatment	  will	  reveal	  if	  Kin1	  has	  a	  function	  
in	  SCC	  tumour	  development	  in	  this	  model.	  Finally,	  choice	  of	  FVB	  mice	  will	  aid	  
SCC	   tumour	   development	   due	   to	   their	   susceptibility	   to	   carcinogenesis	   in	  
several	  organ	  sites,	   including	  skin	   [155].	  Moreover,	  FVB	  mice	  will	  allow	  us	   to	  
scrutinise	   the	   role	   of	   Kin1	   in	   regulation	   of	   immune	   system	   factors,	   such	   as	  
chemokines,	  in	  a	  more	  representative	  manner,	  as,	  contrary	  to	  CD-­‐1	  nude	  mice,	  
FVB	  strains	  have	  an	  intact	  immune	  system.	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If	   we	   eventually	   define	   a	   causal	   relationship	   between	   enhanced	   MMP	   and	  
chemokine	  expression,	  and	  tumour	  growth	  and	  progression	  in	  our	  model,	  use	  
of	   MMP	   and	   chemokine	   inhibitors	   could	   be	   an	   important	   step	   towards	  
defining	  therapeutic	  points	  of	  clinical	  intervention	  for	  SCC	  in	  KS.	  	  
	  
Thus,	  by	  exploring	  the	  mechanism	  via	  which	  Kin1	  regulates	  skin	  homeostasis	  
and	   the	   development	   and	   nature	   of	   SCC	   in	   KS,	   we	   have	   defined	   potential	  
molecular	   targets	   for	   clinical	  management	  of	  prominent	   and	   life-­‐threatening	  
KS	  pathologies,	  such	  as	  skin	  atrophy	  and	  aggressive	  SCC.	  
	  
6.4.	  Concluding	  Remarks	  
In	   this	   study	  we	   explored	  molecular	  mechanisms	   that	   underline	  KS	   features	  
such	  as	  reduced	  keratinocyte	  proliferation	  and	  aggressive	  nature	  of	  SCC.	  	  We	  
show	   that	   Kin1	   is	   important	   for	   keratinocyte	   proliferation	   and	   mitosis	   and,	  
ultimately,	   epidermal	   homeostasis	   in	   vivo,	   and,	   for	   the	   first	   time,	   that	   Kin1	  
plays	   a	   key	   role	   in	   orientation	   and	   tubulin	   acetylation	  of	  mitotic	   spindles	   in	  
mouse	  epidermis	  (Figure	  55.A.).	  We	  also	  demonstrate	  a	  novel	  role	  for	  Kin1	  in	  
chromosome	   segregation	   in	   vitro,	   which,	   along	   with	   spindle	   orientation,	   is	  
regulated	  by	  Kin1	  in	  an	  HDAC6	  dependent	  manner	  (Figure	  55.A.).	  We	  further	  
characterise	  the	   in	   vitro	  roles	  of	  Kin1	  and	  Kin2	  in	  mitosis	  with	  the	  use	  of	   live	  
cell	  imaging.	  We	  define	  an	  overlapping	  function	  of	  the	  two	  protein	  isoforms	  in	  
spindle	  orientation,	  and	  a	  distinct	  function	  of	  Kin1	  in	  chromosome	  segregation	  
and	   of	   Kin2	   in	   mitotic	   spindle	   formation.	   Finally,	   we	   examine	   the	   tumour	  
suppressor	   role	  of	  Kin1	   in	  SCC	  and	  reveal	  a	   role	   for	  Kin1	   in	   inhibition	  of	  cell	  
proliferation	   and	   tumour	   growth	   (Figure	   55.B.).	   We	   provide	   evidence	   that	  
Kin1	  also	  plays	  a	  central	   role	   in	   regulation	  of	   tumour	  microenvironment	  and	  
represses	   vascularisation	   and	   expression	   of	   angiogenesis	  markers,	   as	   well	   as	  
expression	   of	   factors	   known	   to	   promote	   tumour	   progression,	   such	   as	  MMPs	  
and	   chemokines.	   In	   conclusion,	   this	   study	   reveals	   important	   roles	   and	   an	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insight	  to	  molecular	  mechanisms	  via	  which	  Kin1	  controls	  skin	  homeostasis	  and	  































Figure	  55:	  The	   role	  of	  Kin1	   in	   skin	  homeostasis	  and	   the	  development	  of	   SCC.	  A.	  We	  believe	  that	  
Kin1	  contributes	  to	  skin	  homeostasis	  by	  safeguarding	  the	  fidelity	  of	  mitosis	  in	  mouse	  keratinocytes.	  
According	  to	  our	   in	  vivo	  and	   in	  vitro	  findings,	   loss	  of	  Kin1	   in	  mouse	  epidermis	  or	  depletion	  of	  Kin1	  
from	  epithelial	   cell	   lines	  elevates	   the	   incidence	  of	  unstable	  mitotic	   spindles,	   resulting	   in	   increased	  
presence	   of	   spindle	   misorientation	   and	   lagging	   sister	   chromatids.	   Notably,	   we	   also	   show	   that	  
enhanced	  spindle	  misorientation	  in	  Kin1-­‐null	  mouse	  epidermis	  elevates	  the	  incident	  of	  asymmetrical	  
cell	   division,	   which	   reduces	   keratinocyte	   proliferation,	   thus,	   highlighting	   the	   role	   of	   Kin1	   in	   skin	  
homeostasis.	  Finally,	  data	  from	  this	  study,	  as	  well	  as	  data	  from	  our	   lab	  conclude	  that	  Kin1	  ensures	  
normal	   mitosis	   via	   inhibition	   of	   HDAC6,	   a	   key	   a-­‐tub	   deacetylase,	   which	   preserves	   the	   levels	   of	  
acetylated	  tubulin	  across	  mitotic	  spindles	  and,	  thus,	  the	  stability	  of	  the	  mitotic	  spindle	  apparatus.	  B.	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In	   this	   study	  we	  show	  that	  presence	  of	  Kin1	  has	  a	   regulatory	   role	  within	   the	  microenvironment	  of	  
SCC	  tumours,	  which	  hinders	  the	  development	  of	  SCC.	  As	  a	  result,	  loss	  of	  Kin1	  results	  in	  deregulation	  
of	   key	   components	   of	   the	   tumour	   microenvironment,	   including	   MMPs,	   chemokines	   and	  
angiogenesis	   factors,	   which	   likely	   underlines	   the	   development	   of	   favorable	   conditions	   for	  
upregulated	   SCC	   tumour	   growth,	   such	   as	   the	   enhancement	   of	   vasculature	   and	   the	   reduction	   of	  
collagen-­‐I,	  a	  key	  component	  of	  the	  ECM,	  that	  we	  observe	  in	  Kin1null	  SCC	  tumours.	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